{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "mount_file_id": "15DL5TZ8KCnka9QwcFaEux50ceq_nlu9x",
      "authorship_tag": "ABX9TyMkEVBIBmWz8u41VJlJBMHX"
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "source": [
        "# **Parse PHEE Data**\n",
        "\n",
        "PHEE data is stored in .txt files and .ann files, which are parsed and then stored in a dataframe.\n",
        "\n",
        "The dataframe with the data is exported as a '.pkl'\n",
        "file.\n",
        "\n",
        "**Important Notes for Running Notebook:**\n",
        "\n",
        "\n",
        "*   Need Clean Data to be saved in a directory, 'Input'\n",
        "*   Need to have a directory, 'Output'\n",
        "\n"
      ],
      "metadata": {
        "id": "qmQ0dLFwmTle"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "import pickle\n",
        "import os\n",
        "import glob\n",
        "import pandas as pd"
      ],
      "metadata": {
        "id": "n-n_U3cymUOL"
      },
      "execution_count": 3,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "# **Define Functions**\n",
        "\n",
        "\n",
        "\n",
        "1.   **parse_txt_file**: Parse '.txt' files\n",
        "2.   **parse_ann_file**: Parse '.txt' files\n",
        "3.   **Merge**: Helper function to merge two \n",
        "dictionaries\n",
        "4.   **pkl_load_dict**: Helper function to load dictionaries from pkl file\n",
        "5.   **df_creation**: Create df of raw data and save for future analysis\n",
        "\n",
        "\n"
      ],
      "metadata": {
        "id": "GXvXZtKUs6qr"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def parse_txt_file(input_path,output_path):\n",
        "  \"\"\"\n",
        "    Parse the text files and save the data to .pkl file\n",
        "\n",
        "    @p:\n",
        "    input_path (str): Path of the directory with input data\n",
        "    output_path (str): Path of the directory to save pkl file\n",
        "\n",
        "  \"\"\"\n",
        "  \n",
        "  temp_dict={}\n",
        "\n",
        "  for file_name in glob.glob(input_path + \"/*.txt\"):\n",
        "    id=file_name.split('.')[0].split('/')[-1]\n",
        "\n",
        "    with open(file_name) as f:\n",
        "      lines=f.readlines()[0]\n",
        "    \n",
        "    temp_dict[id]=lines\n",
        "\n",
        "    with open(output_path, 'wb') as handle:\n",
        "      pickle.dump(temp_dict, handle, protocol=pickle.HIGHEST_PROTOCOL)\n",
        "\n",
        "def parse_ann_file(input_path,output_path):\n",
        "  \"\"\"\n",
        "    Parse the ann files and save the specific key to .pkl file\n",
        "\n",
        "    @p:\n",
        "    input_path (str): Path of the directory with input data\n",
        "    output_path (str): Path of the directory to save pkl file\n",
        "\n",
        "  \"\"\"\n",
        "\n",
        "  label_lst=['Subject','Treatment',\n",
        "              'Potential_therapeutic_event',\n",
        "              'Drug','Effect','Adverse_event',\n",
        "              'Race','Age','Gender',\n",
        "              'Population','Disorder','Duration',\n",
        "              'Time_elapsed','Route','Freq',\n",
        "              'Dosage','Combination.Drug','Treat-Disorder']\n",
        "\n",
        "  for l in label_lst:\n",
        "    temp_dict={}\n",
        "\n",
        "    for file_name in glob.glob(input_path + \"/*.ann\")[:10]:\n",
        "      id=file_name.split('.')[0].split('/')[-1]\n",
        "\n",
        "      with open(file_name, 'r') as document_anno_file:\n",
        "        lines = document_anno_file.readlines()\n",
        "        print(lines)\n",
        "\n",
        "        temp_lst=[]\n",
        "\n",
        "        for line in lines:\n",
        "          standoff_line=line.split(\"\\t\")\n",
        "          standoff_line.pop(0)\n",
        "\n",
        "          identifier=standoff_line[0].split()[0].strip()\n",
        "          \n",
        "          if identifier==l: temp_lst.append(standoff_line[1].strip())\n",
        "        \n",
        "        temp_lst_str='||'.join(temp_lst)\n",
        "        temp_dict[id]=temp_lst_str\n",
        "\n",
        "    with open(output_path+'_{}.pickle'.format(l), 'wb') as handle:\n",
        "      pickle.dump(temp_dict, handle, protocol=pickle.HIGHEST_PROTOCOL)\n",
        "\n",
        "def Merge(dict1, dict2):\n",
        "  \"\"\"\n",
        "    Add the contents of dict2 to dict1\n",
        "\n",
        "    @P:\n",
        "    dict1 (dict): Dictionary that has info added to it\n",
        "    dict2 (dict): Dictionary that has the contents to add to dict 1\n",
        "  \"\"\"\n",
        "  dict2.update(dict1)\n",
        "  return dict2\n",
        "\n",
        "def pkl_load_dict(filename):\n",
        "  \"\"\"\n",
        "    Load the dictionary data from a pickle file into a variable\n",
        "\n",
        "    @P:\n",
        "    filename (str): Name of the pkl file\n",
        "    varname : Name of the df to save the pkl data\n",
        "\n",
        "    @R:\n",
        "    varname : Containing the pkl data\n",
        "  \"\"\"\n",
        "\n",
        "  with open(filename, 'rb') as handle:\n",
        "      df = pickle.load(handle)\n",
        "\n",
        "  return df\n",
        "\n",
        "def df_creation(df_data,Merge,output_path):\n",
        "  \"\"\"\n",
        "    Add the data from the ann to the dataframe with the text\n",
        "\n",
        "    @P:\n",
        "    Merge: function that merges dictionaries\n",
        "    df_data (df): Dataframe to hold the information\n",
        "    output_path (str): Path to save final dataframe\n",
        "\n",
        "  \"\"\"\n",
        "  \n",
        "  label_lst=['Subject',\n",
        "              'Potential_therapeutic_event',\n",
        "              'Drug','Effect','Adverse_event',\n",
        "              'Race','Age','Gender',\n",
        "              'Population','Disorder','Duration',\n",
        "              'Time_elapsed','Route','Freq',\n",
        "              'Dosage','Combination.Drug','Treat-Disorder']\n",
        "\n",
        "  train_path='/content/drive/MyDrive/PHEE/output/train_ann'\n",
        "  dev_path='/content/drive/MyDrive/PHEE/output/dev_ann'\n",
        "  test_path='/content/drive/MyDrive/PHEE/output/test_ann'\n",
        "\n",
        "  for l in label_lst:\n",
        "\n",
        "    with open(train_path+'_{}.pickle'.format(l), 'rb') as handle:\n",
        "        train_d=pickle.load(handle)\n",
        "\n",
        "    with open(dev_path+'_{}.pickle'.format(l), 'rb') as handle:\n",
        "        dev_d=pickle.load(handle)\n",
        "\n",
        "    with open(test_path+'_{}.pickle'.format(l), 'rb') as handle:\n",
        "        test_d=pickle.load(handle)\n",
        "\n",
        "    train_dev_dict=Merge(train_d, dev_d)\n",
        "    final_dict=Merge(train_dev_dict, test_d)\n",
        "\n",
        "    df=pd.DataFrame.from_dict(final_dict,orient='index',columns=[l])\n",
        "    df.reset_index(inplace=True)\n",
        "\n",
        "    df_data=df_data.merge(df,how='left',on='index')\n",
        "\n",
        "  df_data.to_pickle(output_path)\n",
        "\n",
        "  print('The shape of the final data set is: {}'.format(df_data.shape))\n"
      ],
      "metadata": {
        "id": "9kcu4QJzH_L_"
      },
      "execution_count": 6,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "**Parse the Text and Ann Files**"
      ],
      "metadata": {
        "id": "oRcRWu9ZurUk"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "path_train='/content/drive/MyDrive/PHEE/input/clean/train'\n",
        "path_dev='/content/drive/MyDrive/PHEE/input/clean/dev'\n",
        "path_test='/content/drive/MyDrive/PHEE/input/clean/test'\n",
        "\n",
        "#parse_txt_file(path_train,'/content/drive/MyDrive/PHEE/output/train_txt.pickle')\n",
        "#parse_txt_file(path_dev,'/content/drive/MyDrive/PHEE/output/dev_txt.pickle')\n",
        "#parse_txt_file(path_test,'/content/drive/MyDrive/PHEE/output/test_txt.pickle')\n",
        "\n",
        "\n",
        "parse_ann_file(path_train,'/content/drive/MyDrive/PHEE/output/train_ann')\n",
        "parse_ann_file(path_dev,'/content/drive/MyDrive/PHEE/output/dev_ann')\n",
        "parse_ann_file(path_test,'/content/drive/MyDrive/PHEE/output/test_ann')"
      ],
      "metadata": {
        "id": "5uqHFlq3wYBn",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "32775d89-628c-4676-fc23-337c40171c50"
      },
      "execution_count": 7,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "['T5\\tSubject 48 55\\tpatient\\n', 'T6\\tEffect 102 142\\tsevere agitation and aggressive behavior\\n', 'T7\\tTreatment 0 42\\tAfter three weeks of carbamazepine therapy\\n', 'T9\\tSeverity_cue 102 108\\tsevere\\n', 'T10\\tDuration 6 17\\tthree weeks\\n', 'T11\\tDrug 21 34\\tcarbamazepine\\n', 'T8\\tAdverse_event 0 5\\tAfter\\n', 'E1\\tAdverse_event:T8']\n",
            "['T3\\tEffect 0 11\\tOtotoxicity\\n', 'T4\\tTreatment 27 54\\tcis-platinum administration\\n', 'T6\\tDrug 27 39\\tcis-platinum\\n', 'T5\\tAdverse_event 17 23\\tresult\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tTreatment 55 66\\tpropranolol\\n', 'T4\\tEffect 101 114\\t2/1 S-A block\\n', 'T6\\tDrug 55 66\\tpropranolol\\n', 'T5\\tAdverse_event 119 123\\tseen\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 53 107\\ta 69-year-old male with severe chronic tophaceous gout\\n', 'T4\\tEffect 0 39\\tTelescoped digits of the hands and feet\\n', 'T6\\tTreatment 115 136\\tallopurinol treatment\\n', 'T7\\tAge 55 66\\t69-year-old\\n', 'T8\\tGender 67 71\\tmale\\n', 'T10\\tTreat-Disorder 77 107\\tsevere chronic tophaceous gout\\n', 'T11\\tDrug 115 126\\tallopurinol\\n', 'T5\\tAdverse_event 40 49\\tdeveloped\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 10 21\\tthree cases\\n', 'T4\\tEffect 25 46\\tsevere hepatotoxicity\\n', 'T6\\tTreatment 58 67\\tbenzarone\\n', 'T7\\tPopulation 10 15\\tthree\\n', 'T8\\tDrug 58 67\\tbenzarone\\n', 'T5\\tAdverse_event 47 54\\trelated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 0 133\\tA woman with a 20-year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T5\\tEffect 145 173\\ta B-cell lymphoma of the lip\\n', 'T6\\tTreatment 184 222\\t4 1/2 years of treatment with razoxane\\n', 'T7\\tGender 2 7\\twoman\\n', 'T9\\tDuration 174 195\\tfollowing 4 1/2 years\\n', 'T10\\tDrug 214 222\\trazoxane\\n', 'T11\\tTreat-Disorder 34 133\\tacral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T4\\tAdverse_event 135 144\\tdeveloped\\n', 'E1\\tAdverse_event:T4']\n",
            "['T3\\tEffect 0 34\\tInappropriate antidiuretic hormone\\n', 'T5\\tTreatment 45 64\\tadenine arabinoside\\n', 'T6\\tDrug 45 64\\tadenine arabinoside\\n', 'T4\\tAdverse_event 35 44\\tfollowing\\n', 'E1\\tAdverse_event:T4']\n",
            "['T6\\tEffect 143 170\\tdisseminated cryptococcosis\\n', 'T7\\tSpeculation_cue 109 123\\tmay facilitate\\n', 'T8\\tTreatment 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T9\\tDrug 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T5\\tAdverse_event 128 139\\tdevelopment\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tSubject 81 86\\ta man\\n', 'T4\\tTreatment 67 77\\tdisulfiram\\n', 'T6\\tEffect 20 45\\tfatal fulminant hepatitis\\n', 'T7\\tGender 83 86\\tman\\n', 'T8\\tSeverity_cue 20 25\\tfatal\\n', 'T9\\tDrug 67 77\\tdisulfiram\\n', 'T5\\tAdverse_event 46 52\\tcaused\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSeverity E1 High']\n",
            "['T3\\tTreatment 32 48\\t6-mercaptopurine\\n', 'T4\\tEffect 49 86\\tmyelotoxicity and therapeutic failure\\n', 'T5\\tSubject 90 132\\tchildren with acute lymphoblastic leukemia\\n', 'T7\\tAge 90 98\\tchildren\\n', 'T9\\tDrug 32 48\\t6-mercaptopurine\\n', 'T10\\tTreat-Disorder 104 132\\tacute lymphoblastic leukemia\\n', 'T6\\tAdverse_event 87 89\\tin\\n', 'E1\\tAdverse_event:T6 \\n']\n",
            "['T5\\tSubject 48 55\\tpatient\\n', 'T6\\tEffect 102 142\\tsevere agitation and aggressive behavior\\n', 'T7\\tTreatment 0 42\\tAfter three weeks of carbamazepine therapy\\n', 'T9\\tSeverity_cue 102 108\\tsevere\\n', 'T10\\tDuration 6 17\\tthree weeks\\n', 'T11\\tDrug 21 34\\tcarbamazepine\\n', 'T8\\tAdverse_event 0 5\\tAfter\\n', 'E1\\tAdverse_event:T8']\n",
            "['T3\\tEffect 0 11\\tOtotoxicity\\n', 'T4\\tTreatment 27 54\\tcis-platinum administration\\n', 'T6\\tDrug 27 39\\tcis-platinum\\n', 'T5\\tAdverse_event 17 23\\tresult\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tTreatment 55 66\\tpropranolol\\n', 'T4\\tEffect 101 114\\t2/1 S-A block\\n', 'T6\\tDrug 55 66\\tpropranolol\\n', 'T5\\tAdverse_event 119 123\\tseen\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 53 107\\ta 69-year-old male with severe chronic tophaceous gout\\n', 'T4\\tEffect 0 39\\tTelescoped digits of the hands and feet\\n', 'T6\\tTreatment 115 136\\tallopurinol treatment\\n', 'T7\\tAge 55 66\\t69-year-old\\n', 'T8\\tGender 67 71\\tmale\\n', 'T10\\tTreat-Disorder 77 107\\tsevere chronic tophaceous gout\\n', 'T11\\tDrug 115 126\\tallopurinol\\n', 'T5\\tAdverse_event 40 49\\tdeveloped\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 10 21\\tthree cases\\n', 'T4\\tEffect 25 46\\tsevere hepatotoxicity\\n', 'T6\\tTreatment 58 67\\tbenzarone\\n', 'T7\\tPopulation 10 15\\tthree\\n', 'T8\\tDrug 58 67\\tbenzarone\\n', 'T5\\tAdverse_event 47 54\\trelated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 0 133\\tA woman with a 20-year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T5\\tEffect 145 173\\ta B-cell lymphoma of the lip\\n', 'T6\\tTreatment 184 222\\t4 1/2 years of treatment with razoxane\\n', 'T7\\tGender 2 7\\twoman\\n', 'T9\\tDuration 174 195\\tfollowing 4 1/2 years\\n', 'T10\\tDrug 214 222\\trazoxane\\n', 'T11\\tTreat-Disorder 34 133\\tacral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T4\\tAdverse_event 135 144\\tdeveloped\\n', 'E1\\tAdverse_event:T4']\n",
            "['T3\\tEffect 0 34\\tInappropriate antidiuretic hormone\\n', 'T5\\tTreatment 45 64\\tadenine arabinoside\\n', 'T6\\tDrug 45 64\\tadenine arabinoside\\n', 'T4\\tAdverse_event 35 44\\tfollowing\\n', 'E1\\tAdverse_event:T4']\n",
            "['T6\\tEffect 143 170\\tdisseminated cryptococcosis\\n', 'T7\\tSpeculation_cue 109 123\\tmay facilitate\\n', 'T8\\tTreatment 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T9\\tDrug 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T5\\tAdverse_event 128 139\\tdevelopment\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tSubject 81 86\\ta man\\n', 'T4\\tTreatment 67 77\\tdisulfiram\\n', 'T6\\tEffect 20 45\\tfatal fulminant hepatitis\\n', 'T7\\tGender 83 86\\tman\\n', 'T8\\tSeverity_cue 20 25\\tfatal\\n', 'T9\\tDrug 67 77\\tdisulfiram\\n', 'T5\\tAdverse_event 46 52\\tcaused\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSeverity E1 High']\n",
            "['T3\\tTreatment 32 48\\t6-mercaptopurine\\n', 'T4\\tEffect 49 86\\tmyelotoxicity and therapeutic failure\\n', 'T5\\tSubject 90 132\\tchildren with acute lymphoblastic leukemia\\n', 'T7\\tAge 90 98\\tchildren\\n', 'T9\\tDrug 32 48\\t6-mercaptopurine\\n', 'T10\\tTreat-Disorder 104 132\\tacute lymphoblastic leukemia\\n', 'T6\\tAdverse_event 87 89\\tin\\n', 'E1\\tAdverse_event:T6 \\n']\n",
            "['T5\\tSubject 48 55\\tpatient\\n', 'T6\\tEffect 102 142\\tsevere agitation and aggressive behavior\\n', 'T7\\tTreatment 0 42\\tAfter three weeks of carbamazepine therapy\\n', 'T9\\tSeverity_cue 102 108\\tsevere\\n', 'T10\\tDuration 6 17\\tthree weeks\\n', 'T11\\tDrug 21 34\\tcarbamazepine\\n', 'T8\\tAdverse_event 0 5\\tAfter\\n', 'E1\\tAdverse_event:T8']\n",
            "['T3\\tEffect 0 11\\tOtotoxicity\\n', 'T4\\tTreatment 27 54\\tcis-platinum administration\\n', 'T6\\tDrug 27 39\\tcis-platinum\\n', 'T5\\tAdverse_event 17 23\\tresult\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tTreatment 55 66\\tpropranolol\\n', 'T4\\tEffect 101 114\\t2/1 S-A block\\n', 'T6\\tDrug 55 66\\tpropranolol\\n', 'T5\\tAdverse_event 119 123\\tseen\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 53 107\\ta 69-year-old male with severe chronic tophaceous gout\\n', 'T4\\tEffect 0 39\\tTelescoped digits of the hands and feet\\n', 'T6\\tTreatment 115 136\\tallopurinol treatment\\n', 'T7\\tAge 55 66\\t69-year-old\\n', 'T8\\tGender 67 71\\tmale\\n', 'T10\\tTreat-Disorder 77 107\\tsevere chronic tophaceous gout\\n', 'T11\\tDrug 115 126\\tallopurinol\\n', 'T5\\tAdverse_event 40 49\\tdeveloped\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 10 21\\tthree cases\\n', 'T4\\tEffect 25 46\\tsevere hepatotoxicity\\n', 'T6\\tTreatment 58 67\\tbenzarone\\n', 'T7\\tPopulation 10 15\\tthree\\n', 'T8\\tDrug 58 67\\tbenzarone\\n', 'T5\\tAdverse_event 47 54\\trelated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 0 133\\tA woman with a 20-year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T5\\tEffect 145 173\\ta B-cell lymphoma of the lip\\n', 'T6\\tTreatment 184 222\\t4 1/2 years of treatment with razoxane\\n', 'T7\\tGender 2 7\\twoman\\n', 'T9\\tDuration 174 195\\tfollowing 4 1/2 years\\n', 'T10\\tDrug 214 222\\trazoxane\\n', 'T11\\tTreat-Disorder 34 133\\tacral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T4\\tAdverse_event 135 144\\tdeveloped\\n', 'E1\\tAdverse_event:T4']\n",
            "['T3\\tEffect 0 34\\tInappropriate antidiuretic hormone\\n', 'T5\\tTreatment 45 64\\tadenine arabinoside\\n', 'T6\\tDrug 45 64\\tadenine arabinoside\\n', 'T4\\tAdverse_event 35 44\\tfollowing\\n', 'E1\\tAdverse_event:T4']\n",
            "['T6\\tEffect 143 170\\tdisseminated cryptococcosis\\n', 'T7\\tSpeculation_cue 109 123\\tmay facilitate\\n', 'T8\\tTreatment 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T9\\tDrug 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T5\\tAdverse_event 128 139\\tdevelopment\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tSubject 81 86\\ta man\\n', 'T4\\tTreatment 67 77\\tdisulfiram\\n', 'T6\\tEffect 20 45\\tfatal fulminant hepatitis\\n', 'T7\\tGender 83 86\\tman\\n', 'T8\\tSeverity_cue 20 25\\tfatal\\n', 'T9\\tDrug 67 77\\tdisulfiram\\n', 'T5\\tAdverse_event 46 52\\tcaused\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSeverity E1 High']\n",
            "['T3\\tTreatment 32 48\\t6-mercaptopurine\\n', 'T4\\tEffect 49 86\\tmyelotoxicity and therapeutic failure\\n', 'T5\\tSubject 90 132\\tchildren with acute lymphoblastic leukemia\\n', 'T7\\tAge 90 98\\tchildren\\n', 'T9\\tDrug 32 48\\t6-mercaptopurine\\n', 'T10\\tTreat-Disorder 104 132\\tacute lymphoblastic leukemia\\n', 'T6\\tAdverse_event 87 89\\tin\\n', 'E1\\tAdverse_event:T6 \\n']\n",
            "['T5\\tSubject 48 55\\tpatient\\n', 'T6\\tEffect 102 142\\tsevere agitation and aggressive behavior\\n', 'T7\\tTreatment 0 42\\tAfter three weeks of carbamazepine therapy\\n', 'T9\\tSeverity_cue 102 108\\tsevere\\n', 'T10\\tDuration 6 17\\tthree weeks\\n', 'T11\\tDrug 21 34\\tcarbamazepine\\n', 'T8\\tAdverse_event 0 5\\tAfter\\n', 'E1\\tAdverse_event:T8']\n",
            "['T3\\tEffect 0 11\\tOtotoxicity\\n', 'T4\\tTreatment 27 54\\tcis-platinum administration\\n', 'T6\\tDrug 27 39\\tcis-platinum\\n', 'T5\\tAdverse_event 17 23\\tresult\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tTreatment 55 66\\tpropranolol\\n', 'T4\\tEffect 101 114\\t2/1 S-A block\\n', 'T6\\tDrug 55 66\\tpropranolol\\n', 'T5\\tAdverse_event 119 123\\tseen\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 53 107\\ta 69-year-old male with severe chronic tophaceous gout\\n', 'T4\\tEffect 0 39\\tTelescoped digits of the hands and feet\\n', 'T6\\tTreatment 115 136\\tallopurinol treatment\\n', 'T7\\tAge 55 66\\t69-year-old\\n', 'T8\\tGender 67 71\\tmale\\n', 'T10\\tTreat-Disorder 77 107\\tsevere chronic tophaceous gout\\n', 'T11\\tDrug 115 126\\tallopurinol\\n', 'T5\\tAdverse_event 40 49\\tdeveloped\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 10 21\\tthree cases\\n', 'T4\\tEffect 25 46\\tsevere hepatotoxicity\\n', 'T6\\tTreatment 58 67\\tbenzarone\\n', 'T7\\tPopulation 10 15\\tthree\\n', 'T8\\tDrug 58 67\\tbenzarone\\n', 'T5\\tAdverse_event 47 54\\trelated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 0 133\\tA woman with a 20-year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T5\\tEffect 145 173\\ta B-cell lymphoma of the lip\\n', 'T6\\tTreatment 184 222\\t4 1/2 years of treatment with razoxane\\n', 'T7\\tGender 2 7\\twoman\\n', 'T9\\tDuration 174 195\\tfollowing 4 1/2 years\\n', 'T10\\tDrug 214 222\\trazoxane\\n', 'T11\\tTreat-Disorder 34 133\\tacral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T4\\tAdverse_event 135 144\\tdeveloped\\n', 'E1\\tAdverse_event:T4']\n",
            "['T3\\tEffect 0 34\\tInappropriate antidiuretic hormone\\n', 'T5\\tTreatment 45 64\\tadenine arabinoside\\n', 'T6\\tDrug 45 64\\tadenine arabinoside\\n', 'T4\\tAdverse_event 35 44\\tfollowing\\n', 'E1\\tAdverse_event:T4']\n",
            "['T6\\tEffect 143 170\\tdisseminated cryptococcosis\\n', 'T7\\tSpeculation_cue 109 123\\tmay facilitate\\n', 'T8\\tTreatment 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T9\\tDrug 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T5\\tAdverse_event 128 139\\tdevelopment\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tSubject 81 86\\ta man\\n', 'T4\\tTreatment 67 77\\tdisulfiram\\n', 'T6\\tEffect 20 45\\tfatal fulminant hepatitis\\n', 'T7\\tGender 83 86\\tman\\n', 'T8\\tSeverity_cue 20 25\\tfatal\\n', 'T9\\tDrug 67 77\\tdisulfiram\\n', 'T5\\tAdverse_event 46 52\\tcaused\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSeverity E1 High']\n",
            "['T3\\tTreatment 32 48\\t6-mercaptopurine\\n', 'T4\\tEffect 49 86\\tmyelotoxicity and therapeutic failure\\n', 'T5\\tSubject 90 132\\tchildren with acute lymphoblastic leukemia\\n', 'T7\\tAge 90 98\\tchildren\\n', 'T9\\tDrug 32 48\\t6-mercaptopurine\\n', 'T10\\tTreat-Disorder 104 132\\tacute lymphoblastic leukemia\\n', 'T6\\tAdverse_event 87 89\\tin\\n', 'E1\\tAdverse_event:T6 \\n']\n",
            "['T5\\tSubject 48 55\\tpatient\\n', 'T6\\tEffect 102 142\\tsevere agitation and aggressive behavior\\n', 'T7\\tTreatment 0 42\\tAfter three weeks of carbamazepine therapy\\n', 'T9\\tSeverity_cue 102 108\\tsevere\\n', 'T10\\tDuration 6 17\\tthree weeks\\n', 'T11\\tDrug 21 34\\tcarbamazepine\\n', 'T8\\tAdverse_event 0 5\\tAfter\\n', 'E1\\tAdverse_event:T8']\n",
            "['T3\\tEffect 0 11\\tOtotoxicity\\n', 'T4\\tTreatment 27 54\\tcis-platinum administration\\n', 'T6\\tDrug 27 39\\tcis-platinum\\n', 'T5\\tAdverse_event 17 23\\tresult\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tTreatment 55 66\\tpropranolol\\n', 'T4\\tEffect 101 114\\t2/1 S-A block\\n', 'T6\\tDrug 55 66\\tpropranolol\\n', 'T5\\tAdverse_event 119 123\\tseen\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 53 107\\ta 69-year-old male with severe chronic tophaceous gout\\n', 'T4\\tEffect 0 39\\tTelescoped digits of the hands and feet\\n', 'T6\\tTreatment 115 136\\tallopurinol treatment\\n', 'T7\\tAge 55 66\\t69-year-old\\n', 'T8\\tGender 67 71\\tmale\\n', 'T10\\tTreat-Disorder 77 107\\tsevere chronic tophaceous gout\\n', 'T11\\tDrug 115 126\\tallopurinol\\n', 'T5\\tAdverse_event 40 49\\tdeveloped\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 10 21\\tthree cases\\n', 'T4\\tEffect 25 46\\tsevere hepatotoxicity\\n', 'T6\\tTreatment 58 67\\tbenzarone\\n', 'T7\\tPopulation 10 15\\tthree\\n', 'T8\\tDrug 58 67\\tbenzarone\\n', 'T5\\tAdverse_event 47 54\\trelated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 0 133\\tA woman with a 20-year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T5\\tEffect 145 173\\ta B-cell lymphoma of the lip\\n', 'T6\\tTreatment 184 222\\t4 1/2 years of treatment with razoxane\\n', 'T7\\tGender 2 7\\twoman\\n', 'T9\\tDuration 174 195\\tfollowing 4 1/2 years\\n', 'T10\\tDrug 214 222\\trazoxane\\n', 'T11\\tTreat-Disorder 34 133\\tacral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T4\\tAdverse_event 135 144\\tdeveloped\\n', 'E1\\tAdverse_event:T4']\n",
            "['T3\\tEffect 0 34\\tInappropriate antidiuretic hormone\\n', 'T5\\tTreatment 45 64\\tadenine arabinoside\\n', 'T6\\tDrug 45 64\\tadenine arabinoside\\n', 'T4\\tAdverse_event 35 44\\tfollowing\\n', 'E1\\tAdverse_event:T4']\n",
            "['T6\\tEffect 143 170\\tdisseminated cryptococcosis\\n', 'T7\\tSpeculation_cue 109 123\\tmay facilitate\\n', 'T8\\tTreatment 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T9\\tDrug 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T5\\tAdverse_event 128 139\\tdevelopment\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tSubject 81 86\\ta man\\n', 'T4\\tTreatment 67 77\\tdisulfiram\\n', 'T6\\tEffect 20 45\\tfatal fulminant hepatitis\\n', 'T7\\tGender 83 86\\tman\\n', 'T8\\tSeverity_cue 20 25\\tfatal\\n', 'T9\\tDrug 67 77\\tdisulfiram\\n', 'T5\\tAdverse_event 46 52\\tcaused\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSeverity E1 High']\n",
            "['T3\\tTreatment 32 48\\t6-mercaptopurine\\n', 'T4\\tEffect 49 86\\tmyelotoxicity and therapeutic failure\\n', 'T5\\tSubject 90 132\\tchildren with acute lymphoblastic leukemia\\n', 'T7\\tAge 90 98\\tchildren\\n', 'T9\\tDrug 32 48\\t6-mercaptopurine\\n', 'T10\\tTreat-Disorder 104 132\\tacute lymphoblastic leukemia\\n', 'T6\\tAdverse_event 87 89\\tin\\n', 'E1\\tAdverse_event:T6 \\n']\n",
            "['T5\\tSubject 48 55\\tpatient\\n', 'T6\\tEffect 102 142\\tsevere agitation and aggressive behavior\\n', 'T7\\tTreatment 0 42\\tAfter three weeks of carbamazepine therapy\\n', 'T9\\tSeverity_cue 102 108\\tsevere\\n', 'T10\\tDuration 6 17\\tthree weeks\\n', 'T11\\tDrug 21 34\\tcarbamazepine\\n', 'T8\\tAdverse_event 0 5\\tAfter\\n', 'E1\\tAdverse_event:T8']\n",
            "['T3\\tEffect 0 11\\tOtotoxicity\\n', 'T4\\tTreatment 27 54\\tcis-platinum administration\\n', 'T6\\tDrug 27 39\\tcis-platinum\\n', 'T5\\tAdverse_event 17 23\\tresult\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tTreatment 55 66\\tpropranolol\\n', 'T4\\tEffect 101 114\\t2/1 S-A block\\n', 'T6\\tDrug 55 66\\tpropranolol\\n', 'T5\\tAdverse_event 119 123\\tseen\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 53 107\\ta 69-year-old male with severe chronic tophaceous gout\\n', 'T4\\tEffect 0 39\\tTelescoped digits of the hands and feet\\n', 'T6\\tTreatment 115 136\\tallopurinol treatment\\n', 'T7\\tAge 55 66\\t69-year-old\\n', 'T8\\tGender 67 71\\tmale\\n', 'T10\\tTreat-Disorder 77 107\\tsevere chronic tophaceous gout\\n', 'T11\\tDrug 115 126\\tallopurinol\\n', 'T5\\tAdverse_event 40 49\\tdeveloped\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 10 21\\tthree cases\\n', 'T4\\tEffect 25 46\\tsevere hepatotoxicity\\n', 'T6\\tTreatment 58 67\\tbenzarone\\n', 'T7\\tPopulation 10 15\\tthree\\n', 'T8\\tDrug 58 67\\tbenzarone\\n', 'T5\\tAdverse_event 47 54\\trelated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 0 133\\tA woman with a 20-year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T5\\tEffect 145 173\\ta B-cell lymphoma of the lip\\n', 'T6\\tTreatment 184 222\\t4 1/2 years of treatment with razoxane\\n', 'T7\\tGender 2 7\\twoman\\n', 'T9\\tDuration 174 195\\tfollowing 4 1/2 years\\n', 'T10\\tDrug 214 222\\trazoxane\\n', 'T11\\tTreat-Disorder 34 133\\tacral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T4\\tAdverse_event 135 144\\tdeveloped\\n', 'E1\\tAdverse_event:T4']\n",
            "['T3\\tEffect 0 34\\tInappropriate antidiuretic hormone\\n', 'T5\\tTreatment 45 64\\tadenine arabinoside\\n', 'T6\\tDrug 45 64\\tadenine arabinoside\\n', 'T4\\tAdverse_event 35 44\\tfollowing\\n', 'E1\\tAdverse_event:T4']\n",
            "['T6\\tEffect 143 170\\tdisseminated cryptococcosis\\n', 'T7\\tSpeculation_cue 109 123\\tmay facilitate\\n', 'T8\\tTreatment 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T9\\tDrug 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T5\\tAdverse_event 128 139\\tdevelopment\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tSubject 81 86\\ta man\\n', 'T4\\tTreatment 67 77\\tdisulfiram\\n', 'T6\\tEffect 20 45\\tfatal fulminant hepatitis\\n', 'T7\\tGender 83 86\\tman\\n', 'T8\\tSeverity_cue 20 25\\tfatal\\n', 'T9\\tDrug 67 77\\tdisulfiram\\n', 'T5\\tAdverse_event 46 52\\tcaused\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSeverity E1 High']\n",
            "['T3\\tTreatment 32 48\\t6-mercaptopurine\\n', 'T4\\tEffect 49 86\\tmyelotoxicity and therapeutic failure\\n', 'T5\\tSubject 90 132\\tchildren with acute lymphoblastic leukemia\\n', 'T7\\tAge 90 98\\tchildren\\n', 'T9\\tDrug 32 48\\t6-mercaptopurine\\n', 'T10\\tTreat-Disorder 104 132\\tacute lymphoblastic leukemia\\n', 'T6\\tAdverse_event 87 89\\tin\\n', 'E1\\tAdverse_event:T6 \\n']\n",
            "['T5\\tSubject 48 55\\tpatient\\n', 'T6\\tEffect 102 142\\tsevere agitation and aggressive behavior\\n', 'T7\\tTreatment 0 42\\tAfter three weeks of carbamazepine therapy\\n', 'T9\\tSeverity_cue 102 108\\tsevere\\n', 'T10\\tDuration 6 17\\tthree weeks\\n', 'T11\\tDrug 21 34\\tcarbamazepine\\n', 'T8\\tAdverse_event 0 5\\tAfter\\n', 'E1\\tAdverse_event:T8']\n",
            "['T3\\tEffect 0 11\\tOtotoxicity\\n', 'T4\\tTreatment 27 54\\tcis-platinum administration\\n', 'T6\\tDrug 27 39\\tcis-platinum\\n', 'T5\\tAdverse_event 17 23\\tresult\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tTreatment 55 66\\tpropranolol\\n', 'T4\\tEffect 101 114\\t2/1 S-A block\\n', 'T6\\tDrug 55 66\\tpropranolol\\n', 'T5\\tAdverse_event 119 123\\tseen\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 53 107\\ta 69-year-old male with severe chronic tophaceous gout\\n', 'T4\\tEffect 0 39\\tTelescoped digits of the hands and feet\\n', 'T6\\tTreatment 115 136\\tallopurinol treatment\\n', 'T7\\tAge 55 66\\t69-year-old\\n', 'T8\\tGender 67 71\\tmale\\n', 'T10\\tTreat-Disorder 77 107\\tsevere chronic tophaceous gout\\n', 'T11\\tDrug 115 126\\tallopurinol\\n', 'T5\\tAdverse_event 40 49\\tdeveloped\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 10 21\\tthree cases\\n', 'T4\\tEffect 25 46\\tsevere hepatotoxicity\\n', 'T6\\tTreatment 58 67\\tbenzarone\\n', 'T7\\tPopulation 10 15\\tthree\\n', 'T8\\tDrug 58 67\\tbenzarone\\n', 'T5\\tAdverse_event 47 54\\trelated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 0 133\\tA woman with a 20-year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T5\\tEffect 145 173\\ta B-cell lymphoma of the lip\\n', 'T6\\tTreatment 184 222\\t4 1/2 years of treatment with razoxane\\n', 'T7\\tGender 2 7\\twoman\\n', 'T9\\tDuration 174 195\\tfollowing 4 1/2 years\\n', 'T10\\tDrug 214 222\\trazoxane\\n', 'T11\\tTreat-Disorder 34 133\\tacral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T4\\tAdverse_event 135 144\\tdeveloped\\n', 'E1\\tAdverse_event:T4']\n",
            "['T3\\tEffect 0 34\\tInappropriate antidiuretic hormone\\n', 'T5\\tTreatment 45 64\\tadenine arabinoside\\n', 'T6\\tDrug 45 64\\tadenine arabinoside\\n', 'T4\\tAdverse_event 35 44\\tfollowing\\n', 'E1\\tAdverse_event:T4']\n",
            "['T6\\tEffect 143 170\\tdisseminated cryptococcosis\\n', 'T7\\tSpeculation_cue 109 123\\tmay facilitate\\n', 'T8\\tTreatment 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T9\\tDrug 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T5\\tAdverse_event 128 139\\tdevelopment\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tSubject 81 86\\ta man\\n', 'T4\\tTreatment 67 77\\tdisulfiram\\n', 'T6\\tEffect 20 45\\tfatal fulminant hepatitis\\n', 'T7\\tGender 83 86\\tman\\n', 'T8\\tSeverity_cue 20 25\\tfatal\\n', 'T9\\tDrug 67 77\\tdisulfiram\\n', 'T5\\tAdverse_event 46 52\\tcaused\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSeverity E1 High']\n",
            "['T3\\tTreatment 32 48\\t6-mercaptopurine\\n', 'T4\\tEffect 49 86\\tmyelotoxicity and therapeutic failure\\n', 'T5\\tSubject 90 132\\tchildren with acute lymphoblastic leukemia\\n', 'T7\\tAge 90 98\\tchildren\\n', 'T9\\tDrug 32 48\\t6-mercaptopurine\\n', 'T10\\tTreat-Disorder 104 132\\tacute lymphoblastic leukemia\\n', 'T6\\tAdverse_event 87 89\\tin\\n', 'E1\\tAdverse_event:T6 \\n']\n",
            "['T5\\tSubject 48 55\\tpatient\\n', 'T6\\tEffect 102 142\\tsevere agitation and aggressive behavior\\n', 'T7\\tTreatment 0 42\\tAfter three weeks of carbamazepine therapy\\n', 'T9\\tSeverity_cue 102 108\\tsevere\\n', 'T10\\tDuration 6 17\\tthree weeks\\n', 'T11\\tDrug 21 34\\tcarbamazepine\\n', 'T8\\tAdverse_event 0 5\\tAfter\\n', 'E1\\tAdverse_event:T8']\n",
            "['T3\\tEffect 0 11\\tOtotoxicity\\n', 'T4\\tTreatment 27 54\\tcis-platinum administration\\n', 'T6\\tDrug 27 39\\tcis-platinum\\n', 'T5\\tAdverse_event 17 23\\tresult\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tTreatment 55 66\\tpropranolol\\n', 'T4\\tEffect 101 114\\t2/1 S-A block\\n', 'T6\\tDrug 55 66\\tpropranolol\\n', 'T5\\tAdverse_event 119 123\\tseen\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 53 107\\ta 69-year-old male with severe chronic tophaceous gout\\n', 'T4\\tEffect 0 39\\tTelescoped digits of the hands and feet\\n', 'T6\\tTreatment 115 136\\tallopurinol treatment\\n', 'T7\\tAge 55 66\\t69-year-old\\n', 'T8\\tGender 67 71\\tmale\\n', 'T10\\tTreat-Disorder 77 107\\tsevere chronic tophaceous gout\\n', 'T11\\tDrug 115 126\\tallopurinol\\n', 'T5\\tAdverse_event 40 49\\tdeveloped\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 10 21\\tthree cases\\n', 'T4\\tEffect 25 46\\tsevere hepatotoxicity\\n', 'T6\\tTreatment 58 67\\tbenzarone\\n', 'T7\\tPopulation 10 15\\tthree\\n', 'T8\\tDrug 58 67\\tbenzarone\\n', 'T5\\tAdverse_event 47 54\\trelated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 0 133\\tA woman with a 20-year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T5\\tEffect 145 173\\ta B-cell lymphoma of the lip\\n', 'T6\\tTreatment 184 222\\t4 1/2 years of treatment with razoxane\\n', 'T7\\tGender 2 7\\twoman\\n', 'T9\\tDuration 174 195\\tfollowing 4 1/2 years\\n', 'T10\\tDrug 214 222\\trazoxane\\n', 'T11\\tTreat-Disorder 34 133\\tacral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T4\\tAdverse_event 135 144\\tdeveloped\\n', 'E1\\tAdverse_event:T4']\n",
            "['T3\\tEffect 0 34\\tInappropriate antidiuretic hormone\\n', 'T5\\tTreatment 45 64\\tadenine arabinoside\\n', 'T6\\tDrug 45 64\\tadenine arabinoside\\n', 'T4\\tAdverse_event 35 44\\tfollowing\\n', 'E1\\tAdverse_event:T4']\n",
            "['T6\\tEffect 143 170\\tdisseminated cryptococcosis\\n', 'T7\\tSpeculation_cue 109 123\\tmay facilitate\\n', 'T8\\tTreatment 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T9\\tDrug 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T5\\tAdverse_event 128 139\\tdevelopment\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tSubject 81 86\\ta man\\n', 'T4\\tTreatment 67 77\\tdisulfiram\\n', 'T6\\tEffect 20 45\\tfatal fulminant hepatitis\\n', 'T7\\tGender 83 86\\tman\\n', 'T8\\tSeverity_cue 20 25\\tfatal\\n', 'T9\\tDrug 67 77\\tdisulfiram\\n', 'T5\\tAdverse_event 46 52\\tcaused\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSeverity E1 High']\n",
            "['T3\\tTreatment 32 48\\t6-mercaptopurine\\n', 'T4\\tEffect 49 86\\tmyelotoxicity and therapeutic failure\\n', 'T5\\tSubject 90 132\\tchildren with acute lymphoblastic leukemia\\n', 'T7\\tAge 90 98\\tchildren\\n', 'T9\\tDrug 32 48\\t6-mercaptopurine\\n', 'T10\\tTreat-Disorder 104 132\\tacute lymphoblastic leukemia\\n', 'T6\\tAdverse_event 87 89\\tin\\n', 'E1\\tAdverse_event:T6 \\n']\n",
            "['T5\\tSubject 48 55\\tpatient\\n', 'T6\\tEffect 102 142\\tsevere agitation and aggressive behavior\\n', 'T7\\tTreatment 0 42\\tAfter three weeks of carbamazepine therapy\\n', 'T9\\tSeverity_cue 102 108\\tsevere\\n', 'T10\\tDuration 6 17\\tthree weeks\\n', 'T11\\tDrug 21 34\\tcarbamazepine\\n', 'T8\\tAdverse_event 0 5\\tAfter\\n', 'E1\\tAdverse_event:T8']\n",
            "['T3\\tEffect 0 11\\tOtotoxicity\\n', 'T4\\tTreatment 27 54\\tcis-platinum administration\\n', 'T6\\tDrug 27 39\\tcis-platinum\\n', 'T5\\tAdverse_event 17 23\\tresult\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tTreatment 55 66\\tpropranolol\\n', 'T4\\tEffect 101 114\\t2/1 S-A block\\n', 'T6\\tDrug 55 66\\tpropranolol\\n', 'T5\\tAdverse_event 119 123\\tseen\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 53 107\\ta 69-year-old male with severe chronic tophaceous gout\\n', 'T4\\tEffect 0 39\\tTelescoped digits of the hands and feet\\n', 'T6\\tTreatment 115 136\\tallopurinol treatment\\n', 'T7\\tAge 55 66\\t69-year-old\\n', 'T8\\tGender 67 71\\tmale\\n', 'T10\\tTreat-Disorder 77 107\\tsevere chronic tophaceous gout\\n', 'T11\\tDrug 115 126\\tallopurinol\\n', 'T5\\tAdverse_event 40 49\\tdeveloped\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 10 21\\tthree cases\\n', 'T4\\tEffect 25 46\\tsevere hepatotoxicity\\n', 'T6\\tTreatment 58 67\\tbenzarone\\n', 'T7\\tPopulation 10 15\\tthree\\n', 'T8\\tDrug 58 67\\tbenzarone\\n', 'T5\\tAdverse_event 47 54\\trelated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 0 133\\tA woman with a 20-year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T5\\tEffect 145 173\\ta B-cell lymphoma of the lip\\n', 'T6\\tTreatment 184 222\\t4 1/2 years of treatment with razoxane\\n', 'T7\\tGender 2 7\\twoman\\n', 'T9\\tDuration 174 195\\tfollowing 4 1/2 years\\n', 'T10\\tDrug 214 222\\trazoxane\\n', 'T11\\tTreat-Disorder 34 133\\tacral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T4\\tAdverse_event 135 144\\tdeveloped\\n', 'E1\\tAdverse_event:T4']\n",
            "['T3\\tEffect 0 34\\tInappropriate antidiuretic hormone\\n', 'T5\\tTreatment 45 64\\tadenine arabinoside\\n', 'T6\\tDrug 45 64\\tadenine arabinoside\\n', 'T4\\tAdverse_event 35 44\\tfollowing\\n', 'E1\\tAdverse_event:T4']\n",
            "['T6\\tEffect 143 170\\tdisseminated cryptococcosis\\n', 'T7\\tSpeculation_cue 109 123\\tmay facilitate\\n', 'T8\\tTreatment 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T9\\tDrug 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T5\\tAdverse_event 128 139\\tdevelopment\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tSubject 81 86\\ta man\\n', 'T4\\tTreatment 67 77\\tdisulfiram\\n', 'T6\\tEffect 20 45\\tfatal fulminant hepatitis\\n', 'T7\\tGender 83 86\\tman\\n', 'T8\\tSeverity_cue 20 25\\tfatal\\n', 'T9\\tDrug 67 77\\tdisulfiram\\n', 'T5\\tAdverse_event 46 52\\tcaused\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSeverity E1 High']\n",
            "['T3\\tTreatment 32 48\\t6-mercaptopurine\\n', 'T4\\tEffect 49 86\\tmyelotoxicity and therapeutic failure\\n', 'T5\\tSubject 90 132\\tchildren with acute lymphoblastic leukemia\\n', 'T7\\tAge 90 98\\tchildren\\n', 'T9\\tDrug 32 48\\t6-mercaptopurine\\n', 'T10\\tTreat-Disorder 104 132\\tacute lymphoblastic leukemia\\n', 'T6\\tAdverse_event 87 89\\tin\\n', 'E1\\tAdverse_event:T6 \\n']\n",
            "['T5\\tSubject 48 55\\tpatient\\n', 'T6\\tEffect 102 142\\tsevere agitation and aggressive behavior\\n', 'T7\\tTreatment 0 42\\tAfter three weeks of carbamazepine therapy\\n', 'T9\\tSeverity_cue 102 108\\tsevere\\n', 'T10\\tDuration 6 17\\tthree weeks\\n', 'T11\\tDrug 21 34\\tcarbamazepine\\n', 'T8\\tAdverse_event 0 5\\tAfter\\n', 'E1\\tAdverse_event:T8']\n",
            "['T3\\tEffect 0 11\\tOtotoxicity\\n', 'T4\\tTreatment 27 54\\tcis-platinum administration\\n', 'T6\\tDrug 27 39\\tcis-platinum\\n', 'T5\\tAdverse_event 17 23\\tresult\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tTreatment 55 66\\tpropranolol\\n', 'T4\\tEffect 101 114\\t2/1 S-A block\\n', 'T6\\tDrug 55 66\\tpropranolol\\n', 'T5\\tAdverse_event 119 123\\tseen\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 53 107\\ta 69-year-old male with severe chronic tophaceous gout\\n', 'T4\\tEffect 0 39\\tTelescoped digits of the hands and feet\\n', 'T6\\tTreatment 115 136\\tallopurinol treatment\\n', 'T7\\tAge 55 66\\t69-year-old\\n', 'T8\\tGender 67 71\\tmale\\n', 'T10\\tTreat-Disorder 77 107\\tsevere chronic tophaceous gout\\n', 'T11\\tDrug 115 126\\tallopurinol\\n', 'T5\\tAdverse_event 40 49\\tdeveloped\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 10 21\\tthree cases\\n', 'T4\\tEffect 25 46\\tsevere hepatotoxicity\\n', 'T6\\tTreatment 58 67\\tbenzarone\\n', 'T7\\tPopulation 10 15\\tthree\\n', 'T8\\tDrug 58 67\\tbenzarone\\n', 'T5\\tAdverse_event 47 54\\trelated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 0 133\\tA woman with a 20-year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T5\\tEffect 145 173\\ta B-cell lymphoma of the lip\\n', 'T6\\tTreatment 184 222\\t4 1/2 years of treatment with razoxane\\n', 'T7\\tGender 2 7\\twoman\\n', 'T9\\tDuration 174 195\\tfollowing 4 1/2 years\\n', 'T10\\tDrug 214 222\\trazoxane\\n', 'T11\\tTreat-Disorder 34 133\\tacral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T4\\tAdverse_event 135 144\\tdeveloped\\n', 'E1\\tAdverse_event:T4']\n",
            "['T3\\tEffect 0 34\\tInappropriate antidiuretic hormone\\n', 'T5\\tTreatment 45 64\\tadenine arabinoside\\n', 'T6\\tDrug 45 64\\tadenine arabinoside\\n', 'T4\\tAdverse_event 35 44\\tfollowing\\n', 'E1\\tAdverse_event:T4']\n",
            "['T6\\tEffect 143 170\\tdisseminated cryptococcosis\\n', 'T7\\tSpeculation_cue 109 123\\tmay facilitate\\n', 'T8\\tTreatment 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T9\\tDrug 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T5\\tAdverse_event 128 139\\tdevelopment\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tSubject 81 86\\ta man\\n', 'T4\\tTreatment 67 77\\tdisulfiram\\n', 'T6\\tEffect 20 45\\tfatal fulminant hepatitis\\n', 'T7\\tGender 83 86\\tman\\n', 'T8\\tSeverity_cue 20 25\\tfatal\\n', 'T9\\tDrug 67 77\\tdisulfiram\\n', 'T5\\tAdverse_event 46 52\\tcaused\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSeverity E1 High']\n",
            "['T3\\tTreatment 32 48\\t6-mercaptopurine\\n', 'T4\\tEffect 49 86\\tmyelotoxicity and therapeutic failure\\n', 'T5\\tSubject 90 132\\tchildren with acute lymphoblastic leukemia\\n', 'T7\\tAge 90 98\\tchildren\\n', 'T9\\tDrug 32 48\\t6-mercaptopurine\\n', 'T10\\tTreat-Disorder 104 132\\tacute lymphoblastic leukemia\\n', 'T6\\tAdverse_event 87 89\\tin\\n', 'E1\\tAdverse_event:T6 \\n']\n",
            "['T5\\tSubject 48 55\\tpatient\\n', 'T6\\tEffect 102 142\\tsevere agitation and aggressive behavior\\n', 'T7\\tTreatment 0 42\\tAfter three weeks of carbamazepine therapy\\n', 'T9\\tSeverity_cue 102 108\\tsevere\\n', 'T10\\tDuration 6 17\\tthree weeks\\n', 'T11\\tDrug 21 34\\tcarbamazepine\\n', 'T8\\tAdverse_event 0 5\\tAfter\\n', 'E1\\tAdverse_event:T8']\n",
            "['T3\\tEffect 0 11\\tOtotoxicity\\n', 'T4\\tTreatment 27 54\\tcis-platinum administration\\n', 'T6\\tDrug 27 39\\tcis-platinum\\n', 'T5\\tAdverse_event 17 23\\tresult\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tTreatment 55 66\\tpropranolol\\n', 'T4\\tEffect 101 114\\t2/1 S-A block\\n', 'T6\\tDrug 55 66\\tpropranolol\\n', 'T5\\tAdverse_event 119 123\\tseen\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 53 107\\ta 69-year-old male with severe chronic tophaceous gout\\n', 'T4\\tEffect 0 39\\tTelescoped digits of the hands and feet\\n', 'T6\\tTreatment 115 136\\tallopurinol treatment\\n', 'T7\\tAge 55 66\\t69-year-old\\n', 'T8\\tGender 67 71\\tmale\\n', 'T10\\tTreat-Disorder 77 107\\tsevere chronic tophaceous gout\\n', 'T11\\tDrug 115 126\\tallopurinol\\n', 'T5\\tAdverse_event 40 49\\tdeveloped\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 10 21\\tthree cases\\n', 'T4\\tEffect 25 46\\tsevere hepatotoxicity\\n', 'T6\\tTreatment 58 67\\tbenzarone\\n', 'T7\\tPopulation 10 15\\tthree\\n', 'T8\\tDrug 58 67\\tbenzarone\\n', 'T5\\tAdverse_event 47 54\\trelated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 0 133\\tA woman with a 20-year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T5\\tEffect 145 173\\ta B-cell lymphoma of the lip\\n', 'T6\\tTreatment 184 222\\t4 1/2 years of treatment with razoxane\\n', 'T7\\tGender 2 7\\twoman\\n', 'T9\\tDuration 174 195\\tfollowing 4 1/2 years\\n', 'T10\\tDrug 214 222\\trazoxane\\n', 'T11\\tTreat-Disorder 34 133\\tacral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T4\\tAdverse_event 135 144\\tdeveloped\\n', 'E1\\tAdverse_event:T4']\n",
            "['T3\\tEffect 0 34\\tInappropriate antidiuretic hormone\\n', 'T5\\tTreatment 45 64\\tadenine arabinoside\\n', 'T6\\tDrug 45 64\\tadenine arabinoside\\n', 'T4\\tAdverse_event 35 44\\tfollowing\\n', 'E1\\tAdverse_event:T4']\n",
            "['T6\\tEffect 143 170\\tdisseminated cryptococcosis\\n', 'T7\\tSpeculation_cue 109 123\\tmay facilitate\\n', 'T8\\tTreatment 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T9\\tDrug 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T5\\tAdverse_event 128 139\\tdevelopment\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tSubject 81 86\\ta man\\n', 'T4\\tTreatment 67 77\\tdisulfiram\\n', 'T6\\tEffect 20 45\\tfatal fulminant hepatitis\\n', 'T7\\tGender 83 86\\tman\\n', 'T8\\tSeverity_cue 20 25\\tfatal\\n', 'T9\\tDrug 67 77\\tdisulfiram\\n', 'T5\\tAdverse_event 46 52\\tcaused\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSeverity E1 High']\n",
            "['T3\\tTreatment 32 48\\t6-mercaptopurine\\n', 'T4\\tEffect 49 86\\tmyelotoxicity and therapeutic failure\\n', 'T5\\tSubject 90 132\\tchildren with acute lymphoblastic leukemia\\n', 'T7\\tAge 90 98\\tchildren\\n', 'T9\\tDrug 32 48\\t6-mercaptopurine\\n', 'T10\\tTreat-Disorder 104 132\\tacute lymphoblastic leukemia\\n', 'T6\\tAdverse_event 87 89\\tin\\n', 'E1\\tAdverse_event:T6 \\n']\n",
            "['T5\\tSubject 48 55\\tpatient\\n', 'T6\\tEffect 102 142\\tsevere agitation and aggressive behavior\\n', 'T7\\tTreatment 0 42\\tAfter three weeks of carbamazepine therapy\\n', 'T9\\tSeverity_cue 102 108\\tsevere\\n', 'T10\\tDuration 6 17\\tthree weeks\\n', 'T11\\tDrug 21 34\\tcarbamazepine\\n', 'T8\\tAdverse_event 0 5\\tAfter\\n', 'E1\\tAdverse_event:T8']\n",
            "['T3\\tEffect 0 11\\tOtotoxicity\\n', 'T4\\tTreatment 27 54\\tcis-platinum administration\\n', 'T6\\tDrug 27 39\\tcis-platinum\\n', 'T5\\tAdverse_event 17 23\\tresult\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tTreatment 55 66\\tpropranolol\\n', 'T4\\tEffect 101 114\\t2/1 S-A block\\n', 'T6\\tDrug 55 66\\tpropranolol\\n', 'T5\\tAdverse_event 119 123\\tseen\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 53 107\\ta 69-year-old male with severe chronic tophaceous gout\\n', 'T4\\tEffect 0 39\\tTelescoped digits of the hands and feet\\n', 'T6\\tTreatment 115 136\\tallopurinol treatment\\n', 'T7\\tAge 55 66\\t69-year-old\\n', 'T8\\tGender 67 71\\tmale\\n', 'T10\\tTreat-Disorder 77 107\\tsevere chronic tophaceous gout\\n', 'T11\\tDrug 115 126\\tallopurinol\\n', 'T5\\tAdverse_event 40 49\\tdeveloped\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 10 21\\tthree cases\\n', 'T4\\tEffect 25 46\\tsevere hepatotoxicity\\n', 'T6\\tTreatment 58 67\\tbenzarone\\n', 'T7\\tPopulation 10 15\\tthree\\n', 'T8\\tDrug 58 67\\tbenzarone\\n', 'T5\\tAdverse_event 47 54\\trelated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 0 133\\tA woman with a 20-year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T5\\tEffect 145 173\\ta B-cell lymphoma of the lip\\n', 'T6\\tTreatment 184 222\\t4 1/2 years of treatment with razoxane\\n', 'T7\\tGender 2 7\\twoman\\n', 'T9\\tDuration 174 195\\tfollowing 4 1/2 years\\n', 'T10\\tDrug 214 222\\trazoxane\\n', 'T11\\tTreat-Disorder 34 133\\tacral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T4\\tAdverse_event 135 144\\tdeveloped\\n', 'E1\\tAdverse_event:T4']\n",
            "['T3\\tEffect 0 34\\tInappropriate antidiuretic hormone\\n', 'T5\\tTreatment 45 64\\tadenine arabinoside\\n', 'T6\\tDrug 45 64\\tadenine arabinoside\\n', 'T4\\tAdverse_event 35 44\\tfollowing\\n', 'E1\\tAdverse_event:T4']\n",
            "['T6\\tEffect 143 170\\tdisseminated cryptococcosis\\n', 'T7\\tSpeculation_cue 109 123\\tmay facilitate\\n', 'T8\\tTreatment 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T9\\tDrug 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T5\\tAdverse_event 128 139\\tdevelopment\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tSubject 81 86\\ta man\\n', 'T4\\tTreatment 67 77\\tdisulfiram\\n', 'T6\\tEffect 20 45\\tfatal fulminant hepatitis\\n', 'T7\\tGender 83 86\\tman\\n', 'T8\\tSeverity_cue 20 25\\tfatal\\n', 'T9\\tDrug 67 77\\tdisulfiram\\n', 'T5\\tAdverse_event 46 52\\tcaused\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSeverity E1 High']\n",
            "['T3\\tTreatment 32 48\\t6-mercaptopurine\\n', 'T4\\tEffect 49 86\\tmyelotoxicity and therapeutic failure\\n', 'T5\\tSubject 90 132\\tchildren with acute lymphoblastic leukemia\\n', 'T7\\tAge 90 98\\tchildren\\n', 'T9\\tDrug 32 48\\t6-mercaptopurine\\n', 'T10\\tTreat-Disorder 104 132\\tacute lymphoblastic leukemia\\n', 'T6\\tAdverse_event 87 89\\tin\\n', 'E1\\tAdverse_event:T6 \\n']\n",
            "['T5\\tSubject 48 55\\tpatient\\n', 'T6\\tEffect 102 142\\tsevere agitation and aggressive behavior\\n', 'T7\\tTreatment 0 42\\tAfter three weeks of carbamazepine therapy\\n', 'T9\\tSeverity_cue 102 108\\tsevere\\n', 'T10\\tDuration 6 17\\tthree weeks\\n', 'T11\\tDrug 21 34\\tcarbamazepine\\n', 'T8\\tAdverse_event 0 5\\tAfter\\n', 'E1\\tAdverse_event:T8']\n",
            "['T3\\tEffect 0 11\\tOtotoxicity\\n', 'T4\\tTreatment 27 54\\tcis-platinum administration\\n', 'T6\\tDrug 27 39\\tcis-platinum\\n', 'T5\\tAdverse_event 17 23\\tresult\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tTreatment 55 66\\tpropranolol\\n', 'T4\\tEffect 101 114\\t2/1 S-A block\\n', 'T6\\tDrug 55 66\\tpropranolol\\n', 'T5\\tAdverse_event 119 123\\tseen\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 53 107\\ta 69-year-old male with severe chronic tophaceous gout\\n', 'T4\\tEffect 0 39\\tTelescoped digits of the hands and feet\\n', 'T6\\tTreatment 115 136\\tallopurinol treatment\\n', 'T7\\tAge 55 66\\t69-year-old\\n', 'T8\\tGender 67 71\\tmale\\n', 'T10\\tTreat-Disorder 77 107\\tsevere chronic tophaceous gout\\n', 'T11\\tDrug 115 126\\tallopurinol\\n', 'T5\\tAdverse_event 40 49\\tdeveloped\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 10 21\\tthree cases\\n', 'T4\\tEffect 25 46\\tsevere hepatotoxicity\\n', 'T6\\tTreatment 58 67\\tbenzarone\\n', 'T7\\tPopulation 10 15\\tthree\\n', 'T8\\tDrug 58 67\\tbenzarone\\n', 'T5\\tAdverse_event 47 54\\trelated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 0 133\\tA woman with a 20-year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T5\\tEffect 145 173\\ta B-cell lymphoma of the lip\\n', 'T6\\tTreatment 184 222\\t4 1/2 years of treatment with razoxane\\n', 'T7\\tGender 2 7\\twoman\\n', 'T9\\tDuration 174 195\\tfollowing 4 1/2 years\\n', 'T10\\tDrug 214 222\\trazoxane\\n', 'T11\\tTreat-Disorder 34 133\\tacral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T4\\tAdverse_event 135 144\\tdeveloped\\n', 'E1\\tAdverse_event:T4']\n",
            "['T3\\tEffect 0 34\\tInappropriate antidiuretic hormone\\n', 'T5\\tTreatment 45 64\\tadenine arabinoside\\n', 'T6\\tDrug 45 64\\tadenine arabinoside\\n', 'T4\\tAdverse_event 35 44\\tfollowing\\n', 'E1\\tAdverse_event:T4']\n",
            "['T6\\tEffect 143 170\\tdisseminated cryptococcosis\\n', 'T7\\tSpeculation_cue 109 123\\tmay facilitate\\n', 'T8\\tTreatment 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T9\\tDrug 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T5\\tAdverse_event 128 139\\tdevelopment\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tSubject 81 86\\ta man\\n', 'T4\\tTreatment 67 77\\tdisulfiram\\n', 'T6\\tEffect 20 45\\tfatal fulminant hepatitis\\n', 'T7\\tGender 83 86\\tman\\n', 'T8\\tSeverity_cue 20 25\\tfatal\\n', 'T9\\tDrug 67 77\\tdisulfiram\\n', 'T5\\tAdverse_event 46 52\\tcaused\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSeverity E1 High']\n",
            "['T3\\tTreatment 32 48\\t6-mercaptopurine\\n', 'T4\\tEffect 49 86\\tmyelotoxicity and therapeutic failure\\n', 'T5\\tSubject 90 132\\tchildren with acute lymphoblastic leukemia\\n', 'T7\\tAge 90 98\\tchildren\\n', 'T9\\tDrug 32 48\\t6-mercaptopurine\\n', 'T10\\tTreat-Disorder 104 132\\tacute lymphoblastic leukemia\\n', 'T6\\tAdverse_event 87 89\\tin\\n', 'E1\\tAdverse_event:T6 \\n']\n",
            "['T5\\tSubject 48 55\\tpatient\\n', 'T6\\tEffect 102 142\\tsevere agitation and aggressive behavior\\n', 'T7\\tTreatment 0 42\\tAfter three weeks of carbamazepine therapy\\n', 'T9\\tSeverity_cue 102 108\\tsevere\\n', 'T10\\tDuration 6 17\\tthree weeks\\n', 'T11\\tDrug 21 34\\tcarbamazepine\\n', 'T8\\tAdverse_event 0 5\\tAfter\\n', 'E1\\tAdverse_event:T8']\n",
            "['T3\\tEffect 0 11\\tOtotoxicity\\n', 'T4\\tTreatment 27 54\\tcis-platinum administration\\n', 'T6\\tDrug 27 39\\tcis-platinum\\n', 'T5\\tAdverse_event 17 23\\tresult\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tTreatment 55 66\\tpropranolol\\n', 'T4\\tEffect 101 114\\t2/1 S-A block\\n', 'T6\\tDrug 55 66\\tpropranolol\\n', 'T5\\tAdverse_event 119 123\\tseen\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 53 107\\ta 69-year-old male with severe chronic tophaceous gout\\n', 'T4\\tEffect 0 39\\tTelescoped digits of the hands and feet\\n', 'T6\\tTreatment 115 136\\tallopurinol treatment\\n', 'T7\\tAge 55 66\\t69-year-old\\n', 'T8\\tGender 67 71\\tmale\\n', 'T10\\tTreat-Disorder 77 107\\tsevere chronic tophaceous gout\\n', 'T11\\tDrug 115 126\\tallopurinol\\n', 'T5\\tAdverse_event 40 49\\tdeveloped\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 10 21\\tthree cases\\n', 'T4\\tEffect 25 46\\tsevere hepatotoxicity\\n', 'T6\\tTreatment 58 67\\tbenzarone\\n', 'T7\\tPopulation 10 15\\tthree\\n', 'T8\\tDrug 58 67\\tbenzarone\\n', 'T5\\tAdverse_event 47 54\\trelated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 0 133\\tA woman with a 20-year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T5\\tEffect 145 173\\ta B-cell lymphoma of the lip\\n', 'T6\\tTreatment 184 222\\t4 1/2 years of treatment with razoxane\\n', 'T7\\tGender 2 7\\twoman\\n', 'T9\\tDuration 174 195\\tfollowing 4 1/2 years\\n', 'T10\\tDrug 214 222\\trazoxane\\n', 'T11\\tTreat-Disorder 34 133\\tacral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T4\\tAdverse_event 135 144\\tdeveloped\\n', 'E1\\tAdverse_event:T4']\n",
            "['T3\\tEffect 0 34\\tInappropriate antidiuretic hormone\\n', 'T5\\tTreatment 45 64\\tadenine arabinoside\\n', 'T6\\tDrug 45 64\\tadenine arabinoside\\n', 'T4\\tAdverse_event 35 44\\tfollowing\\n', 'E1\\tAdverse_event:T4']\n",
            "['T6\\tEffect 143 170\\tdisseminated cryptococcosis\\n', 'T7\\tSpeculation_cue 109 123\\tmay facilitate\\n', 'T8\\tTreatment 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T9\\tDrug 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T5\\tAdverse_event 128 139\\tdevelopment\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tSubject 81 86\\ta man\\n', 'T4\\tTreatment 67 77\\tdisulfiram\\n', 'T6\\tEffect 20 45\\tfatal fulminant hepatitis\\n', 'T7\\tGender 83 86\\tman\\n', 'T8\\tSeverity_cue 20 25\\tfatal\\n', 'T9\\tDrug 67 77\\tdisulfiram\\n', 'T5\\tAdverse_event 46 52\\tcaused\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSeverity E1 High']\n",
            "['T3\\tTreatment 32 48\\t6-mercaptopurine\\n', 'T4\\tEffect 49 86\\tmyelotoxicity and therapeutic failure\\n', 'T5\\tSubject 90 132\\tchildren with acute lymphoblastic leukemia\\n', 'T7\\tAge 90 98\\tchildren\\n', 'T9\\tDrug 32 48\\t6-mercaptopurine\\n', 'T10\\tTreat-Disorder 104 132\\tacute lymphoblastic leukemia\\n', 'T6\\tAdverse_event 87 89\\tin\\n', 'E1\\tAdverse_event:T6 \\n']\n",
            "['T5\\tSubject 48 55\\tpatient\\n', 'T6\\tEffect 102 142\\tsevere agitation and aggressive behavior\\n', 'T7\\tTreatment 0 42\\tAfter three weeks of carbamazepine therapy\\n', 'T9\\tSeverity_cue 102 108\\tsevere\\n', 'T10\\tDuration 6 17\\tthree weeks\\n', 'T11\\tDrug 21 34\\tcarbamazepine\\n', 'T8\\tAdverse_event 0 5\\tAfter\\n', 'E1\\tAdverse_event:T8']\n",
            "['T3\\tEffect 0 11\\tOtotoxicity\\n', 'T4\\tTreatment 27 54\\tcis-platinum administration\\n', 'T6\\tDrug 27 39\\tcis-platinum\\n', 'T5\\tAdverse_event 17 23\\tresult\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tTreatment 55 66\\tpropranolol\\n', 'T4\\tEffect 101 114\\t2/1 S-A block\\n', 'T6\\tDrug 55 66\\tpropranolol\\n', 'T5\\tAdverse_event 119 123\\tseen\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 53 107\\ta 69-year-old male with severe chronic tophaceous gout\\n', 'T4\\tEffect 0 39\\tTelescoped digits of the hands and feet\\n', 'T6\\tTreatment 115 136\\tallopurinol treatment\\n', 'T7\\tAge 55 66\\t69-year-old\\n', 'T8\\tGender 67 71\\tmale\\n', 'T10\\tTreat-Disorder 77 107\\tsevere chronic tophaceous gout\\n', 'T11\\tDrug 115 126\\tallopurinol\\n', 'T5\\tAdverse_event 40 49\\tdeveloped\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 10 21\\tthree cases\\n', 'T4\\tEffect 25 46\\tsevere hepatotoxicity\\n', 'T6\\tTreatment 58 67\\tbenzarone\\n', 'T7\\tPopulation 10 15\\tthree\\n', 'T8\\tDrug 58 67\\tbenzarone\\n', 'T5\\tAdverse_event 47 54\\trelated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 0 133\\tA woman with a 20-year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T5\\tEffect 145 173\\ta B-cell lymphoma of the lip\\n', 'T6\\tTreatment 184 222\\t4 1/2 years of treatment with razoxane\\n', 'T7\\tGender 2 7\\twoman\\n', 'T9\\tDuration 174 195\\tfollowing 4 1/2 years\\n', 'T10\\tDrug 214 222\\trazoxane\\n', 'T11\\tTreat-Disorder 34 133\\tacral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T4\\tAdverse_event 135 144\\tdeveloped\\n', 'E1\\tAdverse_event:T4']\n",
            "['T3\\tEffect 0 34\\tInappropriate antidiuretic hormone\\n', 'T5\\tTreatment 45 64\\tadenine arabinoside\\n', 'T6\\tDrug 45 64\\tadenine arabinoside\\n', 'T4\\tAdverse_event 35 44\\tfollowing\\n', 'E1\\tAdverse_event:T4']\n",
            "['T6\\tEffect 143 170\\tdisseminated cryptococcosis\\n', 'T7\\tSpeculation_cue 109 123\\tmay facilitate\\n', 'T8\\tTreatment 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T9\\tDrug 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T5\\tAdverse_event 128 139\\tdevelopment\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tSubject 81 86\\ta man\\n', 'T4\\tTreatment 67 77\\tdisulfiram\\n', 'T6\\tEffect 20 45\\tfatal fulminant hepatitis\\n', 'T7\\tGender 83 86\\tman\\n', 'T8\\tSeverity_cue 20 25\\tfatal\\n', 'T9\\tDrug 67 77\\tdisulfiram\\n', 'T5\\tAdverse_event 46 52\\tcaused\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSeverity E1 High']\n",
            "['T3\\tTreatment 32 48\\t6-mercaptopurine\\n', 'T4\\tEffect 49 86\\tmyelotoxicity and therapeutic failure\\n', 'T5\\tSubject 90 132\\tchildren with acute lymphoblastic leukemia\\n', 'T7\\tAge 90 98\\tchildren\\n', 'T9\\tDrug 32 48\\t6-mercaptopurine\\n', 'T10\\tTreat-Disorder 104 132\\tacute lymphoblastic leukemia\\n', 'T6\\tAdverse_event 87 89\\tin\\n', 'E1\\tAdverse_event:T6 \\n']\n",
            "['T5\\tSubject 48 55\\tpatient\\n', 'T6\\tEffect 102 142\\tsevere agitation and aggressive behavior\\n', 'T7\\tTreatment 0 42\\tAfter three weeks of carbamazepine therapy\\n', 'T9\\tSeverity_cue 102 108\\tsevere\\n', 'T10\\tDuration 6 17\\tthree weeks\\n', 'T11\\tDrug 21 34\\tcarbamazepine\\n', 'T8\\tAdverse_event 0 5\\tAfter\\n', 'E1\\tAdverse_event:T8']\n",
            "['T3\\tEffect 0 11\\tOtotoxicity\\n', 'T4\\tTreatment 27 54\\tcis-platinum administration\\n', 'T6\\tDrug 27 39\\tcis-platinum\\n', 'T5\\tAdverse_event 17 23\\tresult\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tTreatment 55 66\\tpropranolol\\n', 'T4\\tEffect 101 114\\t2/1 S-A block\\n', 'T6\\tDrug 55 66\\tpropranolol\\n', 'T5\\tAdverse_event 119 123\\tseen\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 53 107\\ta 69-year-old male with severe chronic tophaceous gout\\n', 'T4\\tEffect 0 39\\tTelescoped digits of the hands and feet\\n', 'T6\\tTreatment 115 136\\tallopurinol treatment\\n', 'T7\\tAge 55 66\\t69-year-old\\n', 'T8\\tGender 67 71\\tmale\\n', 'T10\\tTreat-Disorder 77 107\\tsevere chronic tophaceous gout\\n', 'T11\\tDrug 115 126\\tallopurinol\\n', 'T5\\tAdverse_event 40 49\\tdeveloped\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 10 21\\tthree cases\\n', 'T4\\tEffect 25 46\\tsevere hepatotoxicity\\n', 'T6\\tTreatment 58 67\\tbenzarone\\n', 'T7\\tPopulation 10 15\\tthree\\n', 'T8\\tDrug 58 67\\tbenzarone\\n', 'T5\\tAdverse_event 47 54\\trelated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 0 133\\tA woman with a 20-year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T5\\tEffect 145 173\\ta B-cell lymphoma of the lip\\n', 'T6\\tTreatment 184 222\\t4 1/2 years of treatment with razoxane\\n', 'T7\\tGender 2 7\\twoman\\n', 'T9\\tDuration 174 195\\tfollowing 4 1/2 years\\n', 'T10\\tDrug 214 222\\trazoxane\\n', 'T11\\tTreat-Disorder 34 133\\tacral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T4\\tAdverse_event 135 144\\tdeveloped\\n', 'E1\\tAdverse_event:T4']\n",
            "['T3\\tEffect 0 34\\tInappropriate antidiuretic hormone\\n', 'T5\\tTreatment 45 64\\tadenine arabinoside\\n', 'T6\\tDrug 45 64\\tadenine arabinoside\\n', 'T4\\tAdverse_event 35 44\\tfollowing\\n', 'E1\\tAdverse_event:T4']\n",
            "['T6\\tEffect 143 170\\tdisseminated cryptococcosis\\n', 'T7\\tSpeculation_cue 109 123\\tmay facilitate\\n', 'T8\\tTreatment 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T9\\tDrug 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T5\\tAdverse_event 128 139\\tdevelopment\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tSubject 81 86\\ta man\\n', 'T4\\tTreatment 67 77\\tdisulfiram\\n', 'T6\\tEffect 20 45\\tfatal fulminant hepatitis\\n', 'T7\\tGender 83 86\\tman\\n', 'T8\\tSeverity_cue 20 25\\tfatal\\n', 'T9\\tDrug 67 77\\tdisulfiram\\n', 'T5\\tAdverse_event 46 52\\tcaused\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSeverity E1 High']\n",
            "['T3\\tTreatment 32 48\\t6-mercaptopurine\\n', 'T4\\tEffect 49 86\\tmyelotoxicity and therapeutic failure\\n', 'T5\\tSubject 90 132\\tchildren with acute lymphoblastic leukemia\\n', 'T7\\tAge 90 98\\tchildren\\n', 'T9\\tDrug 32 48\\t6-mercaptopurine\\n', 'T10\\tTreat-Disorder 104 132\\tacute lymphoblastic leukemia\\n', 'T6\\tAdverse_event 87 89\\tin\\n', 'E1\\tAdverse_event:T6 \\n']\n",
            "['T5\\tSubject 48 55\\tpatient\\n', 'T6\\tEffect 102 142\\tsevere agitation and aggressive behavior\\n', 'T7\\tTreatment 0 42\\tAfter three weeks of carbamazepine therapy\\n', 'T9\\tSeverity_cue 102 108\\tsevere\\n', 'T10\\tDuration 6 17\\tthree weeks\\n', 'T11\\tDrug 21 34\\tcarbamazepine\\n', 'T8\\tAdverse_event 0 5\\tAfter\\n', 'E1\\tAdverse_event:T8']\n",
            "['T3\\tEffect 0 11\\tOtotoxicity\\n', 'T4\\tTreatment 27 54\\tcis-platinum administration\\n', 'T6\\tDrug 27 39\\tcis-platinum\\n', 'T5\\tAdverse_event 17 23\\tresult\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tTreatment 55 66\\tpropranolol\\n', 'T4\\tEffect 101 114\\t2/1 S-A block\\n', 'T6\\tDrug 55 66\\tpropranolol\\n', 'T5\\tAdverse_event 119 123\\tseen\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 53 107\\ta 69-year-old male with severe chronic tophaceous gout\\n', 'T4\\tEffect 0 39\\tTelescoped digits of the hands and feet\\n', 'T6\\tTreatment 115 136\\tallopurinol treatment\\n', 'T7\\tAge 55 66\\t69-year-old\\n', 'T8\\tGender 67 71\\tmale\\n', 'T10\\tTreat-Disorder 77 107\\tsevere chronic tophaceous gout\\n', 'T11\\tDrug 115 126\\tallopurinol\\n', 'T5\\tAdverse_event 40 49\\tdeveloped\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 10 21\\tthree cases\\n', 'T4\\tEffect 25 46\\tsevere hepatotoxicity\\n', 'T6\\tTreatment 58 67\\tbenzarone\\n', 'T7\\tPopulation 10 15\\tthree\\n', 'T8\\tDrug 58 67\\tbenzarone\\n', 'T5\\tAdverse_event 47 54\\trelated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 0 133\\tA woman with a 20-year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T5\\tEffect 145 173\\ta B-cell lymphoma of the lip\\n', 'T6\\tTreatment 184 222\\t4 1/2 years of treatment with razoxane\\n', 'T7\\tGender 2 7\\twoman\\n', 'T9\\tDuration 174 195\\tfollowing 4 1/2 years\\n', 'T10\\tDrug 214 222\\trazoxane\\n', 'T11\\tTreat-Disorder 34 133\\tacral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T4\\tAdverse_event 135 144\\tdeveloped\\n', 'E1\\tAdverse_event:T4']\n",
            "['T3\\tEffect 0 34\\tInappropriate antidiuretic hormone\\n', 'T5\\tTreatment 45 64\\tadenine arabinoside\\n', 'T6\\tDrug 45 64\\tadenine arabinoside\\n', 'T4\\tAdverse_event 35 44\\tfollowing\\n', 'E1\\tAdverse_event:T4']\n",
            "['T6\\tEffect 143 170\\tdisseminated cryptococcosis\\n', 'T7\\tSpeculation_cue 109 123\\tmay facilitate\\n', 'T8\\tTreatment 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T9\\tDrug 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T5\\tAdverse_event 128 139\\tdevelopment\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tSubject 81 86\\ta man\\n', 'T4\\tTreatment 67 77\\tdisulfiram\\n', 'T6\\tEffect 20 45\\tfatal fulminant hepatitis\\n', 'T7\\tGender 83 86\\tman\\n', 'T8\\tSeverity_cue 20 25\\tfatal\\n', 'T9\\tDrug 67 77\\tdisulfiram\\n', 'T5\\tAdverse_event 46 52\\tcaused\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSeverity E1 High']\n",
            "['T3\\tTreatment 32 48\\t6-mercaptopurine\\n', 'T4\\tEffect 49 86\\tmyelotoxicity and therapeutic failure\\n', 'T5\\tSubject 90 132\\tchildren with acute lymphoblastic leukemia\\n', 'T7\\tAge 90 98\\tchildren\\n', 'T9\\tDrug 32 48\\t6-mercaptopurine\\n', 'T10\\tTreat-Disorder 104 132\\tacute lymphoblastic leukemia\\n', 'T6\\tAdverse_event 87 89\\tin\\n', 'E1\\tAdverse_event:T6 \\n']\n",
            "['T5\\tSubject 48 55\\tpatient\\n', 'T6\\tEffect 102 142\\tsevere agitation and aggressive behavior\\n', 'T7\\tTreatment 0 42\\tAfter three weeks of carbamazepine therapy\\n', 'T9\\tSeverity_cue 102 108\\tsevere\\n', 'T10\\tDuration 6 17\\tthree weeks\\n', 'T11\\tDrug 21 34\\tcarbamazepine\\n', 'T8\\tAdverse_event 0 5\\tAfter\\n', 'E1\\tAdverse_event:T8']\n",
            "['T3\\tEffect 0 11\\tOtotoxicity\\n', 'T4\\tTreatment 27 54\\tcis-platinum administration\\n', 'T6\\tDrug 27 39\\tcis-platinum\\n', 'T5\\tAdverse_event 17 23\\tresult\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tTreatment 55 66\\tpropranolol\\n', 'T4\\tEffect 101 114\\t2/1 S-A block\\n', 'T6\\tDrug 55 66\\tpropranolol\\n', 'T5\\tAdverse_event 119 123\\tseen\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 53 107\\ta 69-year-old male with severe chronic tophaceous gout\\n', 'T4\\tEffect 0 39\\tTelescoped digits of the hands and feet\\n', 'T6\\tTreatment 115 136\\tallopurinol treatment\\n', 'T7\\tAge 55 66\\t69-year-old\\n', 'T8\\tGender 67 71\\tmale\\n', 'T10\\tTreat-Disorder 77 107\\tsevere chronic tophaceous gout\\n', 'T11\\tDrug 115 126\\tallopurinol\\n', 'T5\\tAdverse_event 40 49\\tdeveloped\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 10 21\\tthree cases\\n', 'T4\\tEffect 25 46\\tsevere hepatotoxicity\\n', 'T6\\tTreatment 58 67\\tbenzarone\\n', 'T7\\tPopulation 10 15\\tthree\\n', 'T8\\tDrug 58 67\\tbenzarone\\n', 'T5\\tAdverse_event 47 54\\trelated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 0 133\\tA woman with a 20-year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T5\\tEffect 145 173\\ta B-cell lymphoma of the lip\\n', 'T6\\tTreatment 184 222\\t4 1/2 years of treatment with razoxane\\n', 'T7\\tGender 2 7\\twoman\\n', 'T9\\tDuration 174 195\\tfollowing 4 1/2 years\\n', 'T10\\tDrug 214 222\\trazoxane\\n', 'T11\\tTreat-Disorder 34 133\\tacral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs\\n', 'T4\\tAdverse_event 135 144\\tdeveloped\\n', 'E1\\tAdverse_event:T4']\n",
            "['T3\\tEffect 0 34\\tInappropriate antidiuretic hormone\\n', 'T5\\tTreatment 45 64\\tadenine arabinoside\\n', 'T6\\tDrug 45 64\\tadenine arabinoside\\n', 'T4\\tAdverse_event 35 44\\tfollowing\\n', 'E1\\tAdverse_event:T4']\n",
            "['T6\\tEffect 143 170\\tdisseminated cryptococcosis\\n', 'T7\\tSpeculation_cue 109 123\\tmay facilitate\\n', 'T8\\tTreatment 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T9\\tDrug 15 59\\ttumor necrosis factor (TNF)-alpha inhibitors\\n', 'T5\\tAdverse_event 128 139\\tdevelopment\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tSubject 81 86\\ta man\\n', 'T4\\tTreatment 67 77\\tdisulfiram\\n', 'T6\\tEffect 20 45\\tfatal fulminant hepatitis\\n', 'T7\\tGender 83 86\\tman\\n', 'T8\\tSeverity_cue 20 25\\tfatal\\n', 'T9\\tDrug 67 77\\tdisulfiram\\n', 'T5\\tAdverse_event 46 52\\tcaused\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSeverity E1 High']\n",
            "['T3\\tTreatment 32 48\\t6-mercaptopurine\\n', 'T4\\tEffect 49 86\\tmyelotoxicity and therapeutic failure\\n', 'T5\\tSubject 90 132\\tchildren with acute lymphoblastic leukemia\\n', 'T7\\tAge 90 98\\tchildren\\n', 'T9\\tDrug 32 48\\t6-mercaptopurine\\n', 'T10\\tTreat-Disorder 104 132\\tacute lymphoblastic leukemia\\n', 'T6\\tAdverse_event 87 89\\tin\\n', 'E1\\tAdverse_event:T6 \\n']\n",
            "['T9\\tSubject 22 38\\telderly patients\\n', 'T11\\tTreatment 77 100;105 120\\tatypical antipsychotics antidepressants\\n', 'T12\\tEffect 0 18\\tSerotonin syndrome\\n', 'T14\\tAge 22 29\\telderly\\n', 'T15\\tDrug 77 100\\tatypical antipsychotics\\n', 'T16\\tDrug 105 120\\tantidepressants\\n', 'T18\\tTreat-Disorder 51 71\\tpsychotic depression\\n', 'T13\\tAdverse_event 72 76\\twith\\n', 'T17\\tCombination 101 104\\tand\\n', 'E1\\tAdverse_event:T13 \\n', 'E2\\tCombination:T17 arg:T15 arg2:T16']\n",
            "['T7\\tTreatment 13 48\\tsimvastatin and all antiviral drugs\\n', 'T8\\tEffect 75 83\\ttoxicity\\n', 'T10\\tDrug 13 24\\tsimvastatin\\n', 'T11\\tSpeculation_cue 119 128\\tsuspected\\n', 'T9\\tAdverse_event 84 87\\tdue\\n', 'E1\\tAdverse_event:T9 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tEffect 0 19\\tAcute renal failure\\n', 'T4\\tSubject 23 30\\ta child\\n', 'T6\\tTreatment 47 56\\tacyclovir\\n', 'T7\\tAge 25 30\\tchild\\n', 'T8\\tDrug 47 56\\tacyclovir\\n', 'T5\\tAdverse_event 31 41\\tassociated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T4\\tTreatment 24 67\\thigh-dose tamoxifen for greater than 1 year\\n', 'T5\\tEffect 94 109\\tretinal changes\\n', 'T6\\tSubject 0 13\\tFour patients\\n', 'T7\\tPopulation 0 4\\tFour\\n', 'T8\\tDuration 61 67\\t1 year\\n', 'T9\\tDosage 24 33\\thigh-dose\\n', 'T10\\tDrug 34 43\\ttamoxifen\\n', 'T3\\tAdverse_event 14 23\\treceiving\\n', 'E1\\tAdverse_event:T3']\n",
            "['T3\\tSubject 0 14\\tThree patients\\n', 'T4\\tSub-Disorder 35 64\\tneuroleptic-induced akathisia\\n', 'T5\\tTreatment 107 117\\tfluoxetine\\n', 'T7\\tEffect 126 135\\takathisia\\n', 'T8\\tPopulation 0 5\\tThree\\n', 'T9\\tSeverity_cue 170 176\\tmilder\\n', 'T11\\tDrug 107 117\\tfluoxetine\\n', 'T13\\tTreatment 35 46\\tneuroleptic\\n', 'T14\\tDrug 35 46\\tneuroleptic\\n', 'T15\\tEffect 55 64\\takathisia\\n', 'T6\\tAdverse_event 118 125\\tinduced\\n', 'T12\\tAdverse_event 47 54\\tinduced\\n', 'E1\\tAdverse_event:T6 arg:T3 arg2:T5 arg3:T7\\n', 'E2\\tAdverse_event:T12 arg:T13 arg2:T15 arg3:T3\\n', 'R1\\thas_cue Arg1:E1 Arg2:T9\\t\\n', 'A1\\tSeverity E1 Low\\n']\n",
            "['T4\\tTreatment 27 41\\tCyclosporine A\\n', 'T5\\tSubject 45 64\\ttransplant patients\\n', 'T6\\tEffect 83 115\\therpes esophagitis may increase.\\n', 'T7\\tSub-Disorder 45 55\\ttransplant\\n', 'T8\\tDrug 27 41\\tCyclosporine A\\n', 'T9\\tSpeculation_cue 102 105\\tmay\\n', 'T3\\tAdverse_event 70 79\\tincidence\\n', 'E1\\tAdverse_event:T3 \\n']\n",
            "['T3\\tEffect 30 54\\tdisulfiram-like reaction\\n', 'T4\\tTreatment 60 71\\tcefmenoxime\\n', 'T6\\tDrug 60 71\\tcefmenoxime\\n', 'T5\\tAdverse_event 55 59\\twith\\n', 'E1\\tAdverse_event:T5']\n",
            "['T5\\tEffect 0 36\\tNephrogenic diabetes insipidus (NDI)\\n', 'T7\\tTreatment 74 81\\tlithium\\n', 'T8\\tDrug 74 81\\tlithium\\n', 'T6\\tAdverse_event 58 70\\tcomplication\\n', 'E1\\tAdverse_event:T6']\n",
            "['T3\\tTreatment 53 67\\tsalt repletion\\n', 'T5\\tEffect 0 49\\tAmphotericin B nephrotoxicity in humans decreased\\n', 'T6\\tDrug 53 57\\tsalt\\n', 'T7\\tSubject 33 39\\thumans\\n', 'T4\\tPotential_therapeutic_event 40 49\\tdecreased\\n', 'E1\\tPotential_therapeutic_event:T4']\n",
            "['T5\\tEffect 0 36\\tSpontaneous nasal septal perforation\\n', 'T7\\tTreatment 42 76\\tantiangiogenic bevacizumab therapy\\n', 'T8\\tDrug 57 68\\tbevacizumab\\n', 'T6\\tAdverse_event 37 41\\twith\\n', 'E1\\tAdverse_event:T6']\n",
            "['T9\\tSubject 22 38\\telderly patients\\n', 'T11\\tTreatment 77 100;105 120\\tatypical antipsychotics antidepressants\\n', 'T12\\tEffect 0 18\\tSerotonin syndrome\\n', 'T14\\tAge 22 29\\telderly\\n', 'T15\\tDrug 77 100\\tatypical antipsychotics\\n', 'T16\\tDrug 105 120\\tantidepressants\\n', 'T18\\tTreat-Disorder 51 71\\tpsychotic depression\\n', 'T13\\tAdverse_event 72 76\\twith\\n', 'T17\\tCombination 101 104\\tand\\n', 'E1\\tAdverse_event:T13 \\n', 'E2\\tCombination:T17 arg:T15 arg2:T16']\n",
            "['T7\\tTreatment 13 48\\tsimvastatin and all antiviral drugs\\n', 'T8\\tEffect 75 83\\ttoxicity\\n', 'T10\\tDrug 13 24\\tsimvastatin\\n', 'T11\\tSpeculation_cue 119 128\\tsuspected\\n', 'T9\\tAdverse_event 84 87\\tdue\\n', 'E1\\tAdverse_event:T9 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tEffect 0 19\\tAcute renal failure\\n', 'T4\\tSubject 23 30\\ta child\\n', 'T6\\tTreatment 47 56\\tacyclovir\\n', 'T7\\tAge 25 30\\tchild\\n', 'T8\\tDrug 47 56\\tacyclovir\\n', 'T5\\tAdverse_event 31 41\\tassociated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T4\\tTreatment 24 67\\thigh-dose tamoxifen for greater than 1 year\\n', 'T5\\tEffect 94 109\\tretinal changes\\n', 'T6\\tSubject 0 13\\tFour patients\\n', 'T7\\tPopulation 0 4\\tFour\\n', 'T8\\tDuration 61 67\\t1 year\\n', 'T9\\tDosage 24 33\\thigh-dose\\n', 'T10\\tDrug 34 43\\ttamoxifen\\n', 'T3\\tAdverse_event 14 23\\treceiving\\n', 'E1\\tAdverse_event:T3']\n",
            "['T3\\tSubject 0 14\\tThree patients\\n', 'T4\\tSub-Disorder 35 64\\tneuroleptic-induced akathisia\\n', 'T5\\tTreatment 107 117\\tfluoxetine\\n', 'T7\\tEffect 126 135\\takathisia\\n', 'T8\\tPopulation 0 5\\tThree\\n', 'T9\\tSeverity_cue 170 176\\tmilder\\n', 'T11\\tDrug 107 117\\tfluoxetine\\n', 'T13\\tTreatment 35 46\\tneuroleptic\\n', 'T14\\tDrug 35 46\\tneuroleptic\\n', 'T15\\tEffect 55 64\\takathisia\\n', 'T6\\tAdverse_event 118 125\\tinduced\\n', 'T12\\tAdverse_event 47 54\\tinduced\\n', 'E1\\tAdverse_event:T6 arg:T3 arg2:T5 arg3:T7\\n', 'E2\\tAdverse_event:T12 arg:T13 arg2:T15 arg3:T3\\n', 'R1\\thas_cue Arg1:E1 Arg2:T9\\t\\n', 'A1\\tSeverity E1 Low\\n']\n",
            "['T4\\tTreatment 27 41\\tCyclosporine A\\n', 'T5\\tSubject 45 64\\ttransplant patients\\n', 'T6\\tEffect 83 115\\therpes esophagitis may increase.\\n', 'T7\\tSub-Disorder 45 55\\ttransplant\\n', 'T8\\tDrug 27 41\\tCyclosporine A\\n', 'T9\\tSpeculation_cue 102 105\\tmay\\n', 'T3\\tAdverse_event 70 79\\tincidence\\n', 'E1\\tAdverse_event:T3 \\n']\n",
            "['T3\\tEffect 30 54\\tdisulfiram-like reaction\\n', 'T4\\tTreatment 60 71\\tcefmenoxime\\n', 'T6\\tDrug 60 71\\tcefmenoxime\\n', 'T5\\tAdverse_event 55 59\\twith\\n', 'E1\\tAdverse_event:T5']\n",
            "['T5\\tEffect 0 36\\tNephrogenic diabetes insipidus (NDI)\\n', 'T7\\tTreatment 74 81\\tlithium\\n', 'T8\\tDrug 74 81\\tlithium\\n', 'T6\\tAdverse_event 58 70\\tcomplication\\n', 'E1\\tAdverse_event:T6']\n",
            "['T3\\tTreatment 53 67\\tsalt repletion\\n', 'T5\\tEffect 0 49\\tAmphotericin B nephrotoxicity in humans decreased\\n', 'T6\\tDrug 53 57\\tsalt\\n', 'T7\\tSubject 33 39\\thumans\\n', 'T4\\tPotential_therapeutic_event 40 49\\tdecreased\\n', 'E1\\tPotential_therapeutic_event:T4']\n",
            "['T5\\tEffect 0 36\\tSpontaneous nasal septal perforation\\n', 'T7\\tTreatment 42 76\\tantiangiogenic bevacizumab therapy\\n', 'T8\\tDrug 57 68\\tbevacizumab\\n', 'T6\\tAdverse_event 37 41\\twith\\n', 'E1\\tAdverse_event:T6']\n",
            "['T9\\tSubject 22 38\\telderly patients\\n', 'T11\\tTreatment 77 100;105 120\\tatypical antipsychotics antidepressants\\n', 'T12\\tEffect 0 18\\tSerotonin syndrome\\n', 'T14\\tAge 22 29\\telderly\\n', 'T15\\tDrug 77 100\\tatypical antipsychotics\\n', 'T16\\tDrug 105 120\\tantidepressants\\n', 'T18\\tTreat-Disorder 51 71\\tpsychotic depression\\n', 'T13\\tAdverse_event 72 76\\twith\\n', 'T17\\tCombination 101 104\\tand\\n', 'E1\\tAdverse_event:T13 \\n', 'E2\\tCombination:T17 arg:T15 arg2:T16']\n",
            "['T7\\tTreatment 13 48\\tsimvastatin and all antiviral drugs\\n', 'T8\\tEffect 75 83\\ttoxicity\\n', 'T10\\tDrug 13 24\\tsimvastatin\\n', 'T11\\tSpeculation_cue 119 128\\tsuspected\\n', 'T9\\tAdverse_event 84 87\\tdue\\n', 'E1\\tAdverse_event:T9 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tEffect 0 19\\tAcute renal failure\\n', 'T4\\tSubject 23 30\\ta child\\n', 'T6\\tTreatment 47 56\\tacyclovir\\n', 'T7\\tAge 25 30\\tchild\\n', 'T8\\tDrug 47 56\\tacyclovir\\n', 'T5\\tAdverse_event 31 41\\tassociated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T4\\tTreatment 24 67\\thigh-dose tamoxifen for greater than 1 year\\n', 'T5\\tEffect 94 109\\tretinal changes\\n', 'T6\\tSubject 0 13\\tFour patients\\n', 'T7\\tPopulation 0 4\\tFour\\n', 'T8\\tDuration 61 67\\t1 year\\n', 'T9\\tDosage 24 33\\thigh-dose\\n', 'T10\\tDrug 34 43\\ttamoxifen\\n', 'T3\\tAdverse_event 14 23\\treceiving\\n', 'E1\\tAdverse_event:T3']\n",
            "['T3\\tSubject 0 14\\tThree patients\\n', 'T4\\tSub-Disorder 35 64\\tneuroleptic-induced akathisia\\n', 'T5\\tTreatment 107 117\\tfluoxetine\\n', 'T7\\tEffect 126 135\\takathisia\\n', 'T8\\tPopulation 0 5\\tThree\\n', 'T9\\tSeverity_cue 170 176\\tmilder\\n', 'T11\\tDrug 107 117\\tfluoxetine\\n', 'T13\\tTreatment 35 46\\tneuroleptic\\n', 'T14\\tDrug 35 46\\tneuroleptic\\n', 'T15\\tEffect 55 64\\takathisia\\n', 'T6\\tAdverse_event 118 125\\tinduced\\n', 'T12\\tAdverse_event 47 54\\tinduced\\n', 'E1\\tAdverse_event:T6 arg:T3 arg2:T5 arg3:T7\\n', 'E2\\tAdverse_event:T12 arg:T13 arg2:T15 arg3:T3\\n', 'R1\\thas_cue Arg1:E1 Arg2:T9\\t\\n', 'A1\\tSeverity E1 Low\\n']\n",
            "['T4\\tTreatment 27 41\\tCyclosporine A\\n', 'T5\\tSubject 45 64\\ttransplant patients\\n', 'T6\\tEffect 83 115\\therpes esophagitis may increase.\\n', 'T7\\tSub-Disorder 45 55\\ttransplant\\n', 'T8\\tDrug 27 41\\tCyclosporine A\\n', 'T9\\tSpeculation_cue 102 105\\tmay\\n', 'T3\\tAdverse_event 70 79\\tincidence\\n', 'E1\\tAdverse_event:T3 \\n']\n",
            "['T3\\tEffect 30 54\\tdisulfiram-like reaction\\n', 'T4\\tTreatment 60 71\\tcefmenoxime\\n', 'T6\\tDrug 60 71\\tcefmenoxime\\n', 'T5\\tAdverse_event 55 59\\twith\\n', 'E1\\tAdverse_event:T5']\n",
            "['T5\\tEffect 0 36\\tNephrogenic diabetes insipidus (NDI)\\n', 'T7\\tTreatment 74 81\\tlithium\\n', 'T8\\tDrug 74 81\\tlithium\\n', 'T6\\tAdverse_event 58 70\\tcomplication\\n', 'E1\\tAdverse_event:T6']\n",
            "['T3\\tTreatment 53 67\\tsalt repletion\\n', 'T5\\tEffect 0 49\\tAmphotericin B nephrotoxicity in humans decreased\\n', 'T6\\tDrug 53 57\\tsalt\\n', 'T7\\tSubject 33 39\\thumans\\n', 'T4\\tPotential_therapeutic_event 40 49\\tdecreased\\n', 'E1\\tPotential_therapeutic_event:T4']\n",
            "['T5\\tEffect 0 36\\tSpontaneous nasal septal perforation\\n', 'T7\\tTreatment 42 76\\tantiangiogenic bevacizumab therapy\\n', 'T8\\tDrug 57 68\\tbevacizumab\\n', 'T6\\tAdverse_event 37 41\\twith\\n', 'E1\\tAdverse_event:T6']\n",
            "['T9\\tSubject 22 38\\telderly patients\\n', 'T11\\tTreatment 77 100;105 120\\tatypical antipsychotics antidepressants\\n', 'T12\\tEffect 0 18\\tSerotonin syndrome\\n', 'T14\\tAge 22 29\\telderly\\n', 'T15\\tDrug 77 100\\tatypical antipsychotics\\n', 'T16\\tDrug 105 120\\tantidepressants\\n', 'T18\\tTreat-Disorder 51 71\\tpsychotic depression\\n', 'T13\\tAdverse_event 72 76\\twith\\n', 'T17\\tCombination 101 104\\tand\\n', 'E1\\tAdverse_event:T13 \\n', 'E2\\tCombination:T17 arg:T15 arg2:T16']\n",
            "['T7\\tTreatment 13 48\\tsimvastatin and all antiviral drugs\\n', 'T8\\tEffect 75 83\\ttoxicity\\n', 'T10\\tDrug 13 24\\tsimvastatin\\n', 'T11\\tSpeculation_cue 119 128\\tsuspected\\n', 'T9\\tAdverse_event 84 87\\tdue\\n', 'E1\\tAdverse_event:T9 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tEffect 0 19\\tAcute renal failure\\n', 'T4\\tSubject 23 30\\ta child\\n', 'T6\\tTreatment 47 56\\tacyclovir\\n', 'T7\\tAge 25 30\\tchild\\n', 'T8\\tDrug 47 56\\tacyclovir\\n', 'T5\\tAdverse_event 31 41\\tassociated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T4\\tTreatment 24 67\\thigh-dose tamoxifen for greater than 1 year\\n', 'T5\\tEffect 94 109\\tretinal changes\\n', 'T6\\tSubject 0 13\\tFour patients\\n', 'T7\\tPopulation 0 4\\tFour\\n', 'T8\\tDuration 61 67\\t1 year\\n', 'T9\\tDosage 24 33\\thigh-dose\\n', 'T10\\tDrug 34 43\\ttamoxifen\\n', 'T3\\tAdverse_event 14 23\\treceiving\\n', 'E1\\tAdverse_event:T3']\n",
            "['T3\\tSubject 0 14\\tThree patients\\n', 'T4\\tSub-Disorder 35 64\\tneuroleptic-induced akathisia\\n', 'T5\\tTreatment 107 117\\tfluoxetine\\n', 'T7\\tEffect 126 135\\takathisia\\n', 'T8\\tPopulation 0 5\\tThree\\n', 'T9\\tSeverity_cue 170 176\\tmilder\\n', 'T11\\tDrug 107 117\\tfluoxetine\\n', 'T13\\tTreatment 35 46\\tneuroleptic\\n', 'T14\\tDrug 35 46\\tneuroleptic\\n', 'T15\\tEffect 55 64\\takathisia\\n', 'T6\\tAdverse_event 118 125\\tinduced\\n', 'T12\\tAdverse_event 47 54\\tinduced\\n', 'E1\\tAdverse_event:T6 arg:T3 arg2:T5 arg3:T7\\n', 'E2\\tAdverse_event:T12 arg:T13 arg2:T15 arg3:T3\\n', 'R1\\thas_cue Arg1:E1 Arg2:T9\\t\\n', 'A1\\tSeverity E1 Low\\n']\n",
            "['T4\\tTreatment 27 41\\tCyclosporine A\\n', 'T5\\tSubject 45 64\\ttransplant patients\\n', 'T6\\tEffect 83 115\\therpes esophagitis may increase.\\n', 'T7\\tSub-Disorder 45 55\\ttransplant\\n', 'T8\\tDrug 27 41\\tCyclosporine A\\n', 'T9\\tSpeculation_cue 102 105\\tmay\\n', 'T3\\tAdverse_event 70 79\\tincidence\\n', 'E1\\tAdverse_event:T3 \\n']\n",
            "['T3\\tEffect 30 54\\tdisulfiram-like reaction\\n', 'T4\\tTreatment 60 71\\tcefmenoxime\\n', 'T6\\tDrug 60 71\\tcefmenoxime\\n', 'T5\\tAdverse_event 55 59\\twith\\n', 'E1\\tAdverse_event:T5']\n",
            "['T5\\tEffect 0 36\\tNephrogenic diabetes insipidus (NDI)\\n', 'T7\\tTreatment 74 81\\tlithium\\n', 'T8\\tDrug 74 81\\tlithium\\n', 'T6\\tAdverse_event 58 70\\tcomplication\\n', 'E1\\tAdverse_event:T6']\n",
            "['T3\\tTreatment 53 67\\tsalt repletion\\n', 'T5\\tEffect 0 49\\tAmphotericin B nephrotoxicity in humans decreased\\n', 'T6\\tDrug 53 57\\tsalt\\n', 'T7\\tSubject 33 39\\thumans\\n', 'T4\\tPotential_therapeutic_event 40 49\\tdecreased\\n', 'E1\\tPotential_therapeutic_event:T4']\n",
            "['T5\\tEffect 0 36\\tSpontaneous nasal septal perforation\\n', 'T7\\tTreatment 42 76\\tantiangiogenic bevacizumab therapy\\n', 'T8\\tDrug 57 68\\tbevacizumab\\n', 'T6\\tAdverse_event 37 41\\twith\\n', 'E1\\tAdverse_event:T6']\n",
            "['T9\\tSubject 22 38\\telderly patients\\n', 'T11\\tTreatment 77 100;105 120\\tatypical antipsychotics antidepressants\\n', 'T12\\tEffect 0 18\\tSerotonin syndrome\\n', 'T14\\tAge 22 29\\telderly\\n', 'T15\\tDrug 77 100\\tatypical antipsychotics\\n', 'T16\\tDrug 105 120\\tantidepressants\\n', 'T18\\tTreat-Disorder 51 71\\tpsychotic depression\\n', 'T13\\tAdverse_event 72 76\\twith\\n', 'T17\\tCombination 101 104\\tand\\n', 'E1\\tAdverse_event:T13 \\n', 'E2\\tCombination:T17 arg:T15 arg2:T16']\n",
            "['T7\\tTreatment 13 48\\tsimvastatin and all antiviral drugs\\n', 'T8\\tEffect 75 83\\ttoxicity\\n', 'T10\\tDrug 13 24\\tsimvastatin\\n', 'T11\\tSpeculation_cue 119 128\\tsuspected\\n', 'T9\\tAdverse_event 84 87\\tdue\\n', 'E1\\tAdverse_event:T9 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tEffect 0 19\\tAcute renal failure\\n', 'T4\\tSubject 23 30\\ta child\\n', 'T6\\tTreatment 47 56\\tacyclovir\\n', 'T7\\tAge 25 30\\tchild\\n', 'T8\\tDrug 47 56\\tacyclovir\\n', 'T5\\tAdverse_event 31 41\\tassociated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T4\\tTreatment 24 67\\thigh-dose tamoxifen for greater than 1 year\\n', 'T5\\tEffect 94 109\\tretinal changes\\n', 'T6\\tSubject 0 13\\tFour patients\\n', 'T7\\tPopulation 0 4\\tFour\\n', 'T8\\tDuration 61 67\\t1 year\\n', 'T9\\tDosage 24 33\\thigh-dose\\n', 'T10\\tDrug 34 43\\ttamoxifen\\n', 'T3\\tAdverse_event 14 23\\treceiving\\n', 'E1\\tAdverse_event:T3']\n",
            "['T3\\tSubject 0 14\\tThree patients\\n', 'T4\\tSub-Disorder 35 64\\tneuroleptic-induced akathisia\\n', 'T5\\tTreatment 107 117\\tfluoxetine\\n', 'T7\\tEffect 126 135\\takathisia\\n', 'T8\\tPopulation 0 5\\tThree\\n', 'T9\\tSeverity_cue 170 176\\tmilder\\n', 'T11\\tDrug 107 117\\tfluoxetine\\n', 'T13\\tTreatment 35 46\\tneuroleptic\\n', 'T14\\tDrug 35 46\\tneuroleptic\\n', 'T15\\tEffect 55 64\\takathisia\\n', 'T6\\tAdverse_event 118 125\\tinduced\\n', 'T12\\tAdverse_event 47 54\\tinduced\\n', 'E1\\tAdverse_event:T6 arg:T3 arg2:T5 arg3:T7\\n', 'E2\\tAdverse_event:T12 arg:T13 arg2:T15 arg3:T3\\n', 'R1\\thas_cue Arg1:E1 Arg2:T9\\t\\n', 'A1\\tSeverity E1 Low\\n']\n",
            "['T4\\tTreatment 27 41\\tCyclosporine A\\n', 'T5\\tSubject 45 64\\ttransplant patients\\n', 'T6\\tEffect 83 115\\therpes esophagitis may increase.\\n', 'T7\\tSub-Disorder 45 55\\ttransplant\\n', 'T8\\tDrug 27 41\\tCyclosporine A\\n', 'T9\\tSpeculation_cue 102 105\\tmay\\n', 'T3\\tAdverse_event 70 79\\tincidence\\n', 'E1\\tAdverse_event:T3 \\n']\n",
            "['T3\\tEffect 30 54\\tdisulfiram-like reaction\\n', 'T4\\tTreatment 60 71\\tcefmenoxime\\n', 'T6\\tDrug 60 71\\tcefmenoxime\\n', 'T5\\tAdverse_event 55 59\\twith\\n', 'E1\\tAdverse_event:T5']\n",
            "['T5\\tEffect 0 36\\tNephrogenic diabetes insipidus (NDI)\\n', 'T7\\tTreatment 74 81\\tlithium\\n', 'T8\\tDrug 74 81\\tlithium\\n', 'T6\\tAdverse_event 58 70\\tcomplication\\n', 'E1\\tAdverse_event:T6']\n",
            "['T3\\tTreatment 53 67\\tsalt repletion\\n', 'T5\\tEffect 0 49\\tAmphotericin B nephrotoxicity in humans decreased\\n', 'T6\\tDrug 53 57\\tsalt\\n', 'T7\\tSubject 33 39\\thumans\\n', 'T4\\tPotential_therapeutic_event 40 49\\tdecreased\\n', 'E1\\tPotential_therapeutic_event:T4']\n",
            "['T5\\tEffect 0 36\\tSpontaneous nasal septal perforation\\n', 'T7\\tTreatment 42 76\\tantiangiogenic bevacizumab therapy\\n', 'T8\\tDrug 57 68\\tbevacizumab\\n', 'T6\\tAdverse_event 37 41\\twith\\n', 'E1\\tAdverse_event:T6']\n",
            "['T9\\tSubject 22 38\\telderly patients\\n', 'T11\\tTreatment 77 100;105 120\\tatypical antipsychotics antidepressants\\n', 'T12\\tEffect 0 18\\tSerotonin syndrome\\n', 'T14\\tAge 22 29\\telderly\\n', 'T15\\tDrug 77 100\\tatypical antipsychotics\\n', 'T16\\tDrug 105 120\\tantidepressants\\n', 'T18\\tTreat-Disorder 51 71\\tpsychotic depression\\n', 'T13\\tAdverse_event 72 76\\twith\\n', 'T17\\tCombination 101 104\\tand\\n', 'E1\\tAdverse_event:T13 \\n', 'E2\\tCombination:T17 arg:T15 arg2:T16']\n",
            "['T7\\tTreatment 13 48\\tsimvastatin and all antiviral drugs\\n', 'T8\\tEffect 75 83\\ttoxicity\\n', 'T10\\tDrug 13 24\\tsimvastatin\\n', 'T11\\tSpeculation_cue 119 128\\tsuspected\\n', 'T9\\tAdverse_event 84 87\\tdue\\n', 'E1\\tAdverse_event:T9 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tEffect 0 19\\tAcute renal failure\\n', 'T4\\tSubject 23 30\\ta child\\n', 'T6\\tTreatment 47 56\\tacyclovir\\n', 'T7\\tAge 25 30\\tchild\\n', 'T8\\tDrug 47 56\\tacyclovir\\n', 'T5\\tAdverse_event 31 41\\tassociated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T4\\tTreatment 24 67\\thigh-dose tamoxifen for greater than 1 year\\n', 'T5\\tEffect 94 109\\tretinal changes\\n', 'T6\\tSubject 0 13\\tFour patients\\n', 'T7\\tPopulation 0 4\\tFour\\n', 'T8\\tDuration 61 67\\t1 year\\n', 'T9\\tDosage 24 33\\thigh-dose\\n', 'T10\\tDrug 34 43\\ttamoxifen\\n', 'T3\\tAdverse_event 14 23\\treceiving\\n', 'E1\\tAdverse_event:T3']\n",
            "['T3\\tSubject 0 14\\tThree patients\\n', 'T4\\tSub-Disorder 35 64\\tneuroleptic-induced akathisia\\n', 'T5\\tTreatment 107 117\\tfluoxetine\\n', 'T7\\tEffect 126 135\\takathisia\\n', 'T8\\tPopulation 0 5\\tThree\\n', 'T9\\tSeverity_cue 170 176\\tmilder\\n', 'T11\\tDrug 107 117\\tfluoxetine\\n', 'T13\\tTreatment 35 46\\tneuroleptic\\n', 'T14\\tDrug 35 46\\tneuroleptic\\n', 'T15\\tEffect 55 64\\takathisia\\n', 'T6\\tAdverse_event 118 125\\tinduced\\n', 'T12\\tAdverse_event 47 54\\tinduced\\n', 'E1\\tAdverse_event:T6 arg:T3 arg2:T5 arg3:T7\\n', 'E2\\tAdverse_event:T12 arg:T13 arg2:T15 arg3:T3\\n', 'R1\\thas_cue Arg1:E1 Arg2:T9\\t\\n', 'A1\\tSeverity E1 Low\\n']\n",
            "['T4\\tTreatment 27 41\\tCyclosporine A\\n', 'T5\\tSubject 45 64\\ttransplant patients\\n', 'T6\\tEffect 83 115\\therpes esophagitis may increase.\\n', 'T7\\tSub-Disorder 45 55\\ttransplant\\n', 'T8\\tDrug 27 41\\tCyclosporine A\\n', 'T9\\tSpeculation_cue 102 105\\tmay\\n', 'T3\\tAdverse_event 70 79\\tincidence\\n', 'E1\\tAdverse_event:T3 \\n']\n",
            "['T3\\tEffect 30 54\\tdisulfiram-like reaction\\n', 'T4\\tTreatment 60 71\\tcefmenoxime\\n', 'T6\\tDrug 60 71\\tcefmenoxime\\n', 'T5\\tAdverse_event 55 59\\twith\\n', 'E1\\tAdverse_event:T5']\n",
            "['T5\\tEffect 0 36\\tNephrogenic diabetes insipidus (NDI)\\n', 'T7\\tTreatment 74 81\\tlithium\\n', 'T8\\tDrug 74 81\\tlithium\\n', 'T6\\tAdverse_event 58 70\\tcomplication\\n', 'E1\\tAdverse_event:T6']\n",
            "['T3\\tTreatment 53 67\\tsalt repletion\\n', 'T5\\tEffect 0 49\\tAmphotericin B nephrotoxicity in humans decreased\\n', 'T6\\tDrug 53 57\\tsalt\\n', 'T7\\tSubject 33 39\\thumans\\n', 'T4\\tPotential_therapeutic_event 40 49\\tdecreased\\n', 'E1\\tPotential_therapeutic_event:T4']\n",
            "['T5\\tEffect 0 36\\tSpontaneous nasal septal perforation\\n', 'T7\\tTreatment 42 76\\tantiangiogenic bevacizumab therapy\\n', 'T8\\tDrug 57 68\\tbevacizumab\\n', 'T6\\tAdverse_event 37 41\\twith\\n', 'E1\\tAdverse_event:T6']\n",
            "['T9\\tSubject 22 38\\telderly patients\\n', 'T11\\tTreatment 77 100;105 120\\tatypical antipsychotics antidepressants\\n', 'T12\\tEffect 0 18\\tSerotonin syndrome\\n', 'T14\\tAge 22 29\\telderly\\n', 'T15\\tDrug 77 100\\tatypical antipsychotics\\n', 'T16\\tDrug 105 120\\tantidepressants\\n', 'T18\\tTreat-Disorder 51 71\\tpsychotic depression\\n', 'T13\\tAdverse_event 72 76\\twith\\n', 'T17\\tCombination 101 104\\tand\\n', 'E1\\tAdverse_event:T13 \\n', 'E2\\tCombination:T17 arg:T15 arg2:T16']\n",
            "['T7\\tTreatment 13 48\\tsimvastatin and all antiviral drugs\\n', 'T8\\tEffect 75 83\\ttoxicity\\n', 'T10\\tDrug 13 24\\tsimvastatin\\n', 'T11\\tSpeculation_cue 119 128\\tsuspected\\n', 'T9\\tAdverse_event 84 87\\tdue\\n', 'E1\\tAdverse_event:T9 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tEffect 0 19\\tAcute renal failure\\n', 'T4\\tSubject 23 30\\ta child\\n', 'T6\\tTreatment 47 56\\tacyclovir\\n', 'T7\\tAge 25 30\\tchild\\n', 'T8\\tDrug 47 56\\tacyclovir\\n', 'T5\\tAdverse_event 31 41\\tassociated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T4\\tTreatment 24 67\\thigh-dose tamoxifen for greater than 1 year\\n', 'T5\\tEffect 94 109\\tretinal changes\\n', 'T6\\tSubject 0 13\\tFour patients\\n', 'T7\\tPopulation 0 4\\tFour\\n', 'T8\\tDuration 61 67\\t1 year\\n', 'T9\\tDosage 24 33\\thigh-dose\\n', 'T10\\tDrug 34 43\\ttamoxifen\\n', 'T3\\tAdverse_event 14 23\\treceiving\\n', 'E1\\tAdverse_event:T3']\n",
            "['T3\\tSubject 0 14\\tThree patients\\n', 'T4\\tSub-Disorder 35 64\\tneuroleptic-induced akathisia\\n', 'T5\\tTreatment 107 117\\tfluoxetine\\n', 'T7\\tEffect 126 135\\takathisia\\n', 'T8\\tPopulation 0 5\\tThree\\n', 'T9\\tSeverity_cue 170 176\\tmilder\\n', 'T11\\tDrug 107 117\\tfluoxetine\\n', 'T13\\tTreatment 35 46\\tneuroleptic\\n', 'T14\\tDrug 35 46\\tneuroleptic\\n', 'T15\\tEffect 55 64\\takathisia\\n', 'T6\\tAdverse_event 118 125\\tinduced\\n', 'T12\\tAdverse_event 47 54\\tinduced\\n', 'E1\\tAdverse_event:T6 arg:T3 arg2:T5 arg3:T7\\n', 'E2\\tAdverse_event:T12 arg:T13 arg2:T15 arg3:T3\\n', 'R1\\thas_cue Arg1:E1 Arg2:T9\\t\\n', 'A1\\tSeverity E1 Low\\n']\n",
            "['T4\\tTreatment 27 41\\tCyclosporine A\\n', 'T5\\tSubject 45 64\\ttransplant patients\\n', 'T6\\tEffect 83 115\\therpes esophagitis may increase.\\n', 'T7\\tSub-Disorder 45 55\\ttransplant\\n', 'T8\\tDrug 27 41\\tCyclosporine A\\n', 'T9\\tSpeculation_cue 102 105\\tmay\\n', 'T3\\tAdverse_event 70 79\\tincidence\\n', 'E1\\tAdverse_event:T3 \\n']\n",
            "['T3\\tEffect 30 54\\tdisulfiram-like reaction\\n', 'T4\\tTreatment 60 71\\tcefmenoxime\\n', 'T6\\tDrug 60 71\\tcefmenoxime\\n', 'T5\\tAdverse_event 55 59\\twith\\n', 'E1\\tAdverse_event:T5']\n",
            "['T5\\tEffect 0 36\\tNephrogenic diabetes insipidus (NDI)\\n', 'T7\\tTreatment 74 81\\tlithium\\n', 'T8\\tDrug 74 81\\tlithium\\n', 'T6\\tAdverse_event 58 70\\tcomplication\\n', 'E1\\tAdverse_event:T6']\n",
            "['T3\\tTreatment 53 67\\tsalt repletion\\n', 'T5\\tEffect 0 49\\tAmphotericin B nephrotoxicity in humans decreased\\n', 'T6\\tDrug 53 57\\tsalt\\n', 'T7\\tSubject 33 39\\thumans\\n', 'T4\\tPotential_therapeutic_event 40 49\\tdecreased\\n', 'E1\\tPotential_therapeutic_event:T4']\n",
            "['T5\\tEffect 0 36\\tSpontaneous nasal septal perforation\\n', 'T7\\tTreatment 42 76\\tantiangiogenic bevacizumab therapy\\n', 'T8\\tDrug 57 68\\tbevacizumab\\n', 'T6\\tAdverse_event 37 41\\twith\\n', 'E1\\tAdverse_event:T6']\n",
            "['T9\\tSubject 22 38\\telderly patients\\n', 'T11\\tTreatment 77 100;105 120\\tatypical antipsychotics antidepressants\\n', 'T12\\tEffect 0 18\\tSerotonin syndrome\\n', 'T14\\tAge 22 29\\telderly\\n', 'T15\\tDrug 77 100\\tatypical antipsychotics\\n', 'T16\\tDrug 105 120\\tantidepressants\\n', 'T18\\tTreat-Disorder 51 71\\tpsychotic depression\\n', 'T13\\tAdverse_event 72 76\\twith\\n', 'T17\\tCombination 101 104\\tand\\n', 'E1\\tAdverse_event:T13 \\n', 'E2\\tCombination:T17 arg:T15 arg2:T16']\n",
            "['T7\\tTreatment 13 48\\tsimvastatin and all antiviral drugs\\n', 'T8\\tEffect 75 83\\ttoxicity\\n', 'T10\\tDrug 13 24\\tsimvastatin\\n', 'T11\\tSpeculation_cue 119 128\\tsuspected\\n', 'T9\\tAdverse_event 84 87\\tdue\\n', 'E1\\tAdverse_event:T9 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tEffect 0 19\\tAcute renal failure\\n', 'T4\\tSubject 23 30\\ta child\\n', 'T6\\tTreatment 47 56\\tacyclovir\\n', 'T7\\tAge 25 30\\tchild\\n', 'T8\\tDrug 47 56\\tacyclovir\\n', 'T5\\tAdverse_event 31 41\\tassociated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T4\\tTreatment 24 67\\thigh-dose tamoxifen for greater than 1 year\\n', 'T5\\tEffect 94 109\\tretinal changes\\n', 'T6\\tSubject 0 13\\tFour patients\\n', 'T7\\tPopulation 0 4\\tFour\\n', 'T8\\tDuration 61 67\\t1 year\\n', 'T9\\tDosage 24 33\\thigh-dose\\n', 'T10\\tDrug 34 43\\ttamoxifen\\n', 'T3\\tAdverse_event 14 23\\treceiving\\n', 'E1\\tAdverse_event:T3']\n",
            "['T3\\tSubject 0 14\\tThree patients\\n', 'T4\\tSub-Disorder 35 64\\tneuroleptic-induced akathisia\\n', 'T5\\tTreatment 107 117\\tfluoxetine\\n', 'T7\\tEffect 126 135\\takathisia\\n', 'T8\\tPopulation 0 5\\tThree\\n', 'T9\\tSeverity_cue 170 176\\tmilder\\n', 'T11\\tDrug 107 117\\tfluoxetine\\n', 'T13\\tTreatment 35 46\\tneuroleptic\\n', 'T14\\tDrug 35 46\\tneuroleptic\\n', 'T15\\tEffect 55 64\\takathisia\\n', 'T6\\tAdverse_event 118 125\\tinduced\\n', 'T12\\tAdverse_event 47 54\\tinduced\\n', 'E1\\tAdverse_event:T6 arg:T3 arg2:T5 arg3:T7\\n', 'E2\\tAdverse_event:T12 arg:T13 arg2:T15 arg3:T3\\n', 'R1\\thas_cue Arg1:E1 Arg2:T9\\t\\n', 'A1\\tSeverity E1 Low\\n']\n",
            "['T4\\tTreatment 27 41\\tCyclosporine A\\n', 'T5\\tSubject 45 64\\ttransplant patients\\n', 'T6\\tEffect 83 115\\therpes esophagitis may increase.\\n', 'T7\\tSub-Disorder 45 55\\ttransplant\\n', 'T8\\tDrug 27 41\\tCyclosporine A\\n', 'T9\\tSpeculation_cue 102 105\\tmay\\n', 'T3\\tAdverse_event 70 79\\tincidence\\n', 'E1\\tAdverse_event:T3 \\n']\n",
            "['T3\\tEffect 30 54\\tdisulfiram-like reaction\\n', 'T4\\tTreatment 60 71\\tcefmenoxime\\n', 'T6\\tDrug 60 71\\tcefmenoxime\\n', 'T5\\tAdverse_event 55 59\\twith\\n', 'E1\\tAdverse_event:T5']\n",
            "['T5\\tEffect 0 36\\tNephrogenic diabetes insipidus (NDI)\\n', 'T7\\tTreatment 74 81\\tlithium\\n', 'T8\\tDrug 74 81\\tlithium\\n', 'T6\\tAdverse_event 58 70\\tcomplication\\n', 'E1\\tAdverse_event:T6']\n",
            "['T3\\tTreatment 53 67\\tsalt repletion\\n', 'T5\\tEffect 0 49\\tAmphotericin B nephrotoxicity in humans decreased\\n', 'T6\\tDrug 53 57\\tsalt\\n', 'T7\\tSubject 33 39\\thumans\\n', 'T4\\tPotential_therapeutic_event 40 49\\tdecreased\\n', 'E1\\tPotential_therapeutic_event:T4']\n",
            "['T5\\tEffect 0 36\\tSpontaneous nasal septal perforation\\n', 'T7\\tTreatment 42 76\\tantiangiogenic bevacizumab therapy\\n', 'T8\\tDrug 57 68\\tbevacizumab\\n', 'T6\\tAdverse_event 37 41\\twith\\n', 'E1\\tAdverse_event:T6']\n",
            "['T9\\tSubject 22 38\\telderly patients\\n', 'T11\\tTreatment 77 100;105 120\\tatypical antipsychotics antidepressants\\n', 'T12\\tEffect 0 18\\tSerotonin syndrome\\n', 'T14\\tAge 22 29\\telderly\\n', 'T15\\tDrug 77 100\\tatypical antipsychotics\\n', 'T16\\tDrug 105 120\\tantidepressants\\n', 'T18\\tTreat-Disorder 51 71\\tpsychotic depression\\n', 'T13\\tAdverse_event 72 76\\twith\\n', 'T17\\tCombination 101 104\\tand\\n', 'E1\\tAdverse_event:T13 \\n', 'E2\\tCombination:T17 arg:T15 arg2:T16']\n",
            "['T7\\tTreatment 13 48\\tsimvastatin and all antiviral drugs\\n', 'T8\\tEffect 75 83\\ttoxicity\\n', 'T10\\tDrug 13 24\\tsimvastatin\\n', 'T11\\tSpeculation_cue 119 128\\tsuspected\\n', 'T9\\tAdverse_event 84 87\\tdue\\n', 'E1\\tAdverse_event:T9 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tEffect 0 19\\tAcute renal failure\\n', 'T4\\tSubject 23 30\\ta child\\n', 'T6\\tTreatment 47 56\\tacyclovir\\n', 'T7\\tAge 25 30\\tchild\\n', 'T8\\tDrug 47 56\\tacyclovir\\n', 'T5\\tAdverse_event 31 41\\tassociated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T4\\tTreatment 24 67\\thigh-dose tamoxifen for greater than 1 year\\n', 'T5\\tEffect 94 109\\tretinal changes\\n', 'T6\\tSubject 0 13\\tFour patients\\n', 'T7\\tPopulation 0 4\\tFour\\n', 'T8\\tDuration 61 67\\t1 year\\n', 'T9\\tDosage 24 33\\thigh-dose\\n', 'T10\\tDrug 34 43\\ttamoxifen\\n', 'T3\\tAdverse_event 14 23\\treceiving\\n', 'E1\\tAdverse_event:T3']\n",
            "['T3\\tSubject 0 14\\tThree patients\\n', 'T4\\tSub-Disorder 35 64\\tneuroleptic-induced akathisia\\n', 'T5\\tTreatment 107 117\\tfluoxetine\\n', 'T7\\tEffect 126 135\\takathisia\\n', 'T8\\tPopulation 0 5\\tThree\\n', 'T9\\tSeverity_cue 170 176\\tmilder\\n', 'T11\\tDrug 107 117\\tfluoxetine\\n', 'T13\\tTreatment 35 46\\tneuroleptic\\n', 'T14\\tDrug 35 46\\tneuroleptic\\n', 'T15\\tEffect 55 64\\takathisia\\n', 'T6\\tAdverse_event 118 125\\tinduced\\n', 'T12\\tAdverse_event 47 54\\tinduced\\n', 'E1\\tAdverse_event:T6 arg:T3 arg2:T5 arg3:T7\\n', 'E2\\tAdverse_event:T12 arg:T13 arg2:T15 arg3:T3\\n', 'R1\\thas_cue Arg1:E1 Arg2:T9\\t\\n', 'A1\\tSeverity E1 Low\\n']\n",
            "['T4\\tTreatment 27 41\\tCyclosporine A\\n', 'T5\\tSubject 45 64\\ttransplant patients\\n', 'T6\\tEffect 83 115\\therpes esophagitis may increase.\\n', 'T7\\tSub-Disorder 45 55\\ttransplant\\n', 'T8\\tDrug 27 41\\tCyclosporine A\\n', 'T9\\tSpeculation_cue 102 105\\tmay\\n', 'T3\\tAdverse_event 70 79\\tincidence\\n', 'E1\\tAdverse_event:T3 \\n']\n",
            "['T3\\tEffect 30 54\\tdisulfiram-like reaction\\n', 'T4\\tTreatment 60 71\\tcefmenoxime\\n', 'T6\\tDrug 60 71\\tcefmenoxime\\n', 'T5\\tAdverse_event 55 59\\twith\\n', 'E1\\tAdverse_event:T5']\n",
            "['T5\\tEffect 0 36\\tNephrogenic diabetes insipidus (NDI)\\n', 'T7\\tTreatment 74 81\\tlithium\\n', 'T8\\tDrug 74 81\\tlithium\\n', 'T6\\tAdverse_event 58 70\\tcomplication\\n', 'E1\\tAdverse_event:T6']\n",
            "['T3\\tTreatment 53 67\\tsalt repletion\\n', 'T5\\tEffect 0 49\\tAmphotericin B nephrotoxicity in humans decreased\\n', 'T6\\tDrug 53 57\\tsalt\\n', 'T7\\tSubject 33 39\\thumans\\n', 'T4\\tPotential_therapeutic_event 40 49\\tdecreased\\n', 'E1\\tPotential_therapeutic_event:T4']\n",
            "['T5\\tEffect 0 36\\tSpontaneous nasal septal perforation\\n', 'T7\\tTreatment 42 76\\tantiangiogenic bevacizumab therapy\\n', 'T8\\tDrug 57 68\\tbevacizumab\\n', 'T6\\tAdverse_event 37 41\\twith\\n', 'E1\\tAdverse_event:T6']\n",
            "['T9\\tSubject 22 38\\telderly patients\\n', 'T11\\tTreatment 77 100;105 120\\tatypical antipsychotics antidepressants\\n', 'T12\\tEffect 0 18\\tSerotonin syndrome\\n', 'T14\\tAge 22 29\\telderly\\n', 'T15\\tDrug 77 100\\tatypical antipsychotics\\n', 'T16\\tDrug 105 120\\tantidepressants\\n', 'T18\\tTreat-Disorder 51 71\\tpsychotic depression\\n', 'T13\\tAdverse_event 72 76\\twith\\n', 'T17\\tCombination 101 104\\tand\\n', 'E1\\tAdverse_event:T13 \\n', 'E2\\tCombination:T17 arg:T15 arg2:T16']\n",
            "['T7\\tTreatment 13 48\\tsimvastatin and all antiviral drugs\\n', 'T8\\tEffect 75 83\\ttoxicity\\n', 'T10\\tDrug 13 24\\tsimvastatin\\n', 'T11\\tSpeculation_cue 119 128\\tsuspected\\n', 'T9\\tAdverse_event 84 87\\tdue\\n', 'E1\\tAdverse_event:T9 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tEffect 0 19\\tAcute renal failure\\n', 'T4\\tSubject 23 30\\ta child\\n', 'T6\\tTreatment 47 56\\tacyclovir\\n', 'T7\\tAge 25 30\\tchild\\n', 'T8\\tDrug 47 56\\tacyclovir\\n', 'T5\\tAdverse_event 31 41\\tassociated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T4\\tTreatment 24 67\\thigh-dose tamoxifen for greater than 1 year\\n', 'T5\\tEffect 94 109\\tretinal changes\\n', 'T6\\tSubject 0 13\\tFour patients\\n', 'T7\\tPopulation 0 4\\tFour\\n', 'T8\\tDuration 61 67\\t1 year\\n', 'T9\\tDosage 24 33\\thigh-dose\\n', 'T10\\tDrug 34 43\\ttamoxifen\\n', 'T3\\tAdverse_event 14 23\\treceiving\\n', 'E1\\tAdverse_event:T3']\n",
            "['T3\\tSubject 0 14\\tThree patients\\n', 'T4\\tSub-Disorder 35 64\\tneuroleptic-induced akathisia\\n', 'T5\\tTreatment 107 117\\tfluoxetine\\n', 'T7\\tEffect 126 135\\takathisia\\n', 'T8\\tPopulation 0 5\\tThree\\n', 'T9\\tSeverity_cue 170 176\\tmilder\\n', 'T11\\tDrug 107 117\\tfluoxetine\\n', 'T13\\tTreatment 35 46\\tneuroleptic\\n', 'T14\\tDrug 35 46\\tneuroleptic\\n', 'T15\\tEffect 55 64\\takathisia\\n', 'T6\\tAdverse_event 118 125\\tinduced\\n', 'T12\\tAdverse_event 47 54\\tinduced\\n', 'E1\\tAdverse_event:T6 arg:T3 arg2:T5 arg3:T7\\n', 'E2\\tAdverse_event:T12 arg:T13 arg2:T15 arg3:T3\\n', 'R1\\thas_cue Arg1:E1 Arg2:T9\\t\\n', 'A1\\tSeverity E1 Low\\n']\n",
            "['T4\\tTreatment 27 41\\tCyclosporine A\\n', 'T5\\tSubject 45 64\\ttransplant patients\\n', 'T6\\tEffect 83 115\\therpes esophagitis may increase.\\n', 'T7\\tSub-Disorder 45 55\\ttransplant\\n', 'T8\\tDrug 27 41\\tCyclosporine A\\n', 'T9\\tSpeculation_cue 102 105\\tmay\\n', 'T3\\tAdverse_event 70 79\\tincidence\\n', 'E1\\tAdverse_event:T3 \\n']\n",
            "['T3\\tEffect 30 54\\tdisulfiram-like reaction\\n', 'T4\\tTreatment 60 71\\tcefmenoxime\\n', 'T6\\tDrug 60 71\\tcefmenoxime\\n', 'T5\\tAdverse_event 55 59\\twith\\n', 'E1\\tAdverse_event:T5']\n",
            "['T5\\tEffect 0 36\\tNephrogenic diabetes insipidus (NDI)\\n', 'T7\\tTreatment 74 81\\tlithium\\n', 'T8\\tDrug 74 81\\tlithium\\n', 'T6\\tAdverse_event 58 70\\tcomplication\\n', 'E1\\tAdverse_event:T6']\n",
            "['T3\\tTreatment 53 67\\tsalt repletion\\n', 'T5\\tEffect 0 49\\tAmphotericin B nephrotoxicity in humans decreased\\n', 'T6\\tDrug 53 57\\tsalt\\n', 'T7\\tSubject 33 39\\thumans\\n', 'T4\\tPotential_therapeutic_event 40 49\\tdecreased\\n', 'E1\\tPotential_therapeutic_event:T4']\n",
            "['T5\\tEffect 0 36\\tSpontaneous nasal septal perforation\\n', 'T7\\tTreatment 42 76\\tantiangiogenic bevacizumab therapy\\n', 'T8\\tDrug 57 68\\tbevacizumab\\n', 'T6\\tAdverse_event 37 41\\twith\\n', 'E1\\tAdverse_event:T6']\n",
            "['T9\\tSubject 22 38\\telderly patients\\n', 'T11\\tTreatment 77 100;105 120\\tatypical antipsychotics antidepressants\\n', 'T12\\tEffect 0 18\\tSerotonin syndrome\\n', 'T14\\tAge 22 29\\telderly\\n', 'T15\\tDrug 77 100\\tatypical antipsychotics\\n', 'T16\\tDrug 105 120\\tantidepressants\\n', 'T18\\tTreat-Disorder 51 71\\tpsychotic depression\\n', 'T13\\tAdverse_event 72 76\\twith\\n', 'T17\\tCombination 101 104\\tand\\n', 'E1\\tAdverse_event:T13 \\n', 'E2\\tCombination:T17 arg:T15 arg2:T16']\n",
            "['T7\\tTreatment 13 48\\tsimvastatin and all antiviral drugs\\n', 'T8\\tEffect 75 83\\ttoxicity\\n', 'T10\\tDrug 13 24\\tsimvastatin\\n', 'T11\\tSpeculation_cue 119 128\\tsuspected\\n', 'T9\\tAdverse_event 84 87\\tdue\\n', 'E1\\tAdverse_event:T9 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tEffect 0 19\\tAcute renal failure\\n', 'T4\\tSubject 23 30\\ta child\\n', 'T6\\tTreatment 47 56\\tacyclovir\\n', 'T7\\tAge 25 30\\tchild\\n', 'T8\\tDrug 47 56\\tacyclovir\\n', 'T5\\tAdverse_event 31 41\\tassociated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T4\\tTreatment 24 67\\thigh-dose tamoxifen for greater than 1 year\\n', 'T5\\tEffect 94 109\\tretinal changes\\n', 'T6\\tSubject 0 13\\tFour patients\\n', 'T7\\tPopulation 0 4\\tFour\\n', 'T8\\tDuration 61 67\\t1 year\\n', 'T9\\tDosage 24 33\\thigh-dose\\n', 'T10\\tDrug 34 43\\ttamoxifen\\n', 'T3\\tAdverse_event 14 23\\treceiving\\n', 'E1\\tAdverse_event:T3']\n",
            "['T3\\tSubject 0 14\\tThree patients\\n', 'T4\\tSub-Disorder 35 64\\tneuroleptic-induced akathisia\\n', 'T5\\tTreatment 107 117\\tfluoxetine\\n', 'T7\\tEffect 126 135\\takathisia\\n', 'T8\\tPopulation 0 5\\tThree\\n', 'T9\\tSeverity_cue 170 176\\tmilder\\n', 'T11\\tDrug 107 117\\tfluoxetine\\n', 'T13\\tTreatment 35 46\\tneuroleptic\\n', 'T14\\tDrug 35 46\\tneuroleptic\\n', 'T15\\tEffect 55 64\\takathisia\\n', 'T6\\tAdverse_event 118 125\\tinduced\\n', 'T12\\tAdverse_event 47 54\\tinduced\\n', 'E1\\tAdverse_event:T6 arg:T3 arg2:T5 arg3:T7\\n', 'E2\\tAdverse_event:T12 arg:T13 arg2:T15 arg3:T3\\n', 'R1\\thas_cue Arg1:E1 Arg2:T9\\t\\n', 'A1\\tSeverity E1 Low\\n']\n",
            "['T4\\tTreatment 27 41\\tCyclosporine A\\n', 'T5\\tSubject 45 64\\ttransplant patients\\n', 'T6\\tEffect 83 115\\therpes esophagitis may increase.\\n', 'T7\\tSub-Disorder 45 55\\ttransplant\\n', 'T8\\tDrug 27 41\\tCyclosporine A\\n', 'T9\\tSpeculation_cue 102 105\\tmay\\n', 'T3\\tAdverse_event 70 79\\tincidence\\n', 'E1\\tAdverse_event:T3 \\n']\n",
            "['T3\\tEffect 30 54\\tdisulfiram-like reaction\\n', 'T4\\tTreatment 60 71\\tcefmenoxime\\n', 'T6\\tDrug 60 71\\tcefmenoxime\\n', 'T5\\tAdverse_event 55 59\\twith\\n', 'E1\\tAdverse_event:T5']\n",
            "['T5\\tEffect 0 36\\tNephrogenic diabetes insipidus (NDI)\\n', 'T7\\tTreatment 74 81\\tlithium\\n', 'T8\\tDrug 74 81\\tlithium\\n', 'T6\\tAdverse_event 58 70\\tcomplication\\n', 'E1\\tAdverse_event:T6']\n",
            "['T3\\tTreatment 53 67\\tsalt repletion\\n', 'T5\\tEffect 0 49\\tAmphotericin B nephrotoxicity in humans decreased\\n', 'T6\\tDrug 53 57\\tsalt\\n', 'T7\\tSubject 33 39\\thumans\\n', 'T4\\tPotential_therapeutic_event 40 49\\tdecreased\\n', 'E1\\tPotential_therapeutic_event:T4']\n",
            "['T5\\tEffect 0 36\\tSpontaneous nasal septal perforation\\n', 'T7\\tTreatment 42 76\\tantiangiogenic bevacizumab therapy\\n', 'T8\\tDrug 57 68\\tbevacizumab\\n', 'T6\\tAdverse_event 37 41\\twith\\n', 'E1\\tAdverse_event:T6']\n",
            "['T9\\tSubject 22 38\\telderly patients\\n', 'T11\\tTreatment 77 100;105 120\\tatypical antipsychotics antidepressants\\n', 'T12\\tEffect 0 18\\tSerotonin syndrome\\n', 'T14\\tAge 22 29\\telderly\\n', 'T15\\tDrug 77 100\\tatypical antipsychotics\\n', 'T16\\tDrug 105 120\\tantidepressants\\n', 'T18\\tTreat-Disorder 51 71\\tpsychotic depression\\n', 'T13\\tAdverse_event 72 76\\twith\\n', 'T17\\tCombination 101 104\\tand\\n', 'E1\\tAdverse_event:T13 \\n', 'E2\\tCombination:T17 arg:T15 arg2:T16']\n",
            "['T7\\tTreatment 13 48\\tsimvastatin and all antiviral drugs\\n', 'T8\\tEffect 75 83\\ttoxicity\\n', 'T10\\tDrug 13 24\\tsimvastatin\\n', 'T11\\tSpeculation_cue 119 128\\tsuspected\\n', 'T9\\tAdverse_event 84 87\\tdue\\n', 'E1\\tAdverse_event:T9 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tEffect 0 19\\tAcute renal failure\\n', 'T4\\tSubject 23 30\\ta child\\n', 'T6\\tTreatment 47 56\\tacyclovir\\n', 'T7\\tAge 25 30\\tchild\\n', 'T8\\tDrug 47 56\\tacyclovir\\n', 'T5\\tAdverse_event 31 41\\tassociated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T4\\tTreatment 24 67\\thigh-dose tamoxifen for greater than 1 year\\n', 'T5\\tEffect 94 109\\tretinal changes\\n', 'T6\\tSubject 0 13\\tFour patients\\n', 'T7\\tPopulation 0 4\\tFour\\n', 'T8\\tDuration 61 67\\t1 year\\n', 'T9\\tDosage 24 33\\thigh-dose\\n', 'T10\\tDrug 34 43\\ttamoxifen\\n', 'T3\\tAdverse_event 14 23\\treceiving\\n', 'E1\\tAdverse_event:T3']\n",
            "['T3\\tSubject 0 14\\tThree patients\\n', 'T4\\tSub-Disorder 35 64\\tneuroleptic-induced akathisia\\n', 'T5\\tTreatment 107 117\\tfluoxetine\\n', 'T7\\tEffect 126 135\\takathisia\\n', 'T8\\tPopulation 0 5\\tThree\\n', 'T9\\tSeverity_cue 170 176\\tmilder\\n', 'T11\\tDrug 107 117\\tfluoxetine\\n', 'T13\\tTreatment 35 46\\tneuroleptic\\n', 'T14\\tDrug 35 46\\tneuroleptic\\n', 'T15\\tEffect 55 64\\takathisia\\n', 'T6\\tAdverse_event 118 125\\tinduced\\n', 'T12\\tAdverse_event 47 54\\tinduced\\n', 'E1\\tAdverse_event:T6 arg:T3 arg2:T5 arg3:T7\\n', 'E2\\tAdverse_event:T12 arg:T13 arg2:T15 arg3:T3\\n', 'R1\\thas_cue Arg1:E1 Arg2:T9\\t\\n', 'A1\\tSeverity E1 Low\\n']\n",
            "['T4\\tTreatment 27 41\\tCyclosporine A\\n', 'T5\\tSubject 45 64\\ttransplant patients\\n', 'T6\\tEffect 83 115\\therpes esophagitis may increase.\\n', 'T7\\tSub-Disorder 45 55\\ttransplant\\n', 'T8\\tDrug 27 41\\tCyclosporine A\\n', 'T9\\tSpeculation_cue 102 105\\tmay\\n', 'T3\\tAdverse_event 70 79\\tincidence\\n', 'E1\\tAdverse_event:T3 \\n']\n",
            "['T3\\tEffect 30 54\\tdisulfiram-like reaction\\n', 'T4\\tTreatment 60 71\\tcefmenoxime\\n', 'T6\\tDrug 60 71\\tcefmenoxime\\n', 'T5\\tAdverse_event 55 59\\twith\\n', 'E1\\tAdverse_event:T5']\n",
            "['T5\\tEffect 0 36\\tNephrogenic diabetes insipidus (NDI)\\n', 'T7\\tTreatment 74 81\\tlithium\\n', 'T8\\tDrug 74 81\\tlithium\\n', 'T6\\tAdverse_event 58 70\\tcomplication\\n', 'E1\\tAdverse_event:T6']\n",
            "['T3\\tTreatment 53 67\\tsalt repletion\\n', 'T5\\tEffect 0 49\\tAmphotericin B nephrotoxicity in humans decreased\\n', 'T6\\tDrug 53 57\\tsalt\\n', 'T7\\tSubject 33 39\\thumans\\n', 'T4\\tPotential_therapeutic_event 40 49\\tdecreased\\n', 'E1\\tPotential_therapeutic_event:T4']\n",
            "['T5\\tEffect 0 36\\tSpontaneous nasal septal perforation\\n', 'T7\\tTreatment 42 76\\tantiangiogenic bevacizumab therapy\\n', 'T8\\tDrug 57 68\\tbevacizumab\\n', 'T6\\tAdverse_event 37 41\\twith\\n', 'E1\\tAdverse_event:T6']\n",
            "['T9\\tSubject 22 38\\telderly patients\\n', 'T11\\tTreatment 77 100;105 120\\tatypical antipsychotics antidepressants\\n', 'T12\\tEffect 0 18\\tSerotonin syndrome\\n', 'T14\\tAge 22 29\\telderly\\n', 'T15\\tDrug 77 100\\tatypical antipsychotics\\n', 'T16\\tDrug 105 120\\tantidepressants\\n', 'T18\\tTreat-Disorder 51 71\\tpsychotic depression\\n', 'T13\\tAdverse_event 72 76\\twith\\n', 'T17\\tCombination 101 104\\tand\\n', 'E1\\tAdverse_event:T13 \\n', 'E2\\tCombination:T17 arg:T15 arg2:T16']\n",
            "['T7\\tTreatment 13 48\\tsimvastatin and all antiviral drugs\\n', 'T8\\tEffect 75 83\\ttoxicity\\n', 'T10\\tDrug 13 24\\tsimvastatin\\n', 'T11\\tSpeculation_cue 119 128\\tsuspected\\n', 'T9\\tAdverse_event 84 87\\tdue\\n', 'E1\\tAdverse_event:T9 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tEffect 0 19\\tAcute renal failure\\n', 'T4\\tSubject 23 30\\ta child\\n', 'T6\\tTreatment 47 56\\tacyclovir\\n', 'T7\\tAge 25 30\\tchild\\n', 'T8\\tDrug 47 56\\tacyclovir\\n', 'T5\\tAdverse_event 31 41\\tassociated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T4\\tTreatment 24 67\\thigh-dose tamoxifen for greater than 1 year\\n', 'T5\\tEffect 94 109\\tretinal changes\\n', 'T6\\tSubject 0 13\\tFour patients\\n', 'T7\\tPopulation 0 4\\tFour\\n', 'T8\\tDuration 61 67\\t1 year\\n', 'T9\\tDosage 24 33\\thigh-dose\\n', 'T10\\tDrug 34 43\\ttamoxifen\\n', 'T3\\tAdverse_event 14 23\\treceiving\\n', 'E1\\tAdverse_event:T3']\n",
            "['T3\\tSubject 0 14\\tThree patients\\n', 'T4\\tSub-Disorder 35 64\\tneuroleptic-induced akathisia\\n', 'T5\\tTreatment 107 117\\tfluoxetine\\n', 'T7\\tEffect 126 135\\takathisia\\n', 'T8\\tPopulation 0 5\\tThree\\n', 'T9\\tSeverity_cue 170 176\\tmilder\\n', 'T11\\tDrug 107 117\\tfluoxetine\\n', 'T13\\tTreatment 35 46\\tneuroleptic\\n', 'T14\\tDrug 35 46\\tneuroleptic\\n', 'T15\\tEffect 55 64\\takathisia\\n', 'T6\\tAdverse_event 118 125\\tinduced\\n', 'T12\\tAdverse_event 47 54\\tinduced\\n', 'E1\\tAdverse_event:T6 arg:T3 arg2:T5 arg3:T7\\n', 'E2\\tAdverse_event:T12 arg:T13 arg2:T15 arg3:T3\\n', 'R1\\thas_cue Arg1:E1 Arg2:T9\\t\\n', 'A1\\tSeverity E1 Low\\n']\n",
            "['T4\\tTreatment 27 41\\tCyclosporine A\\n', 'T5\\tSubject 45 64\\ttransplant patients\\n', 'T6\\tEffect 83 115\\therpes esophagitis may increase.\\n', 'T7\\tSub-Disorder 45 55\\ttransplant\\n', 'T8\\tDrug 27 41\\tCyclosporine A\\n', 'T9\\tSpeculation_cue 102 105\\tmay\\n', 'T3\\tAdverse_event 70 79\\tincidence\\n', 'E1\\tAdverse_event:T3 \\n']\n",
            "['T3\\tEffect 30 54\\tdisulfiram-like reaction\\n', 'T4\\tTreatment 60 71\\tcefmenoxime\\n', 'T6\\tDrug 60 71\\tcefmenoxime\\n', 'T5\\tAdverse_event 55 59\\twith\\n', 'E1\\tAdverse_event:T5']\n",
            "['T5\\tEffect 0 36\\tNephrogenic diabetes insipidus (NDI)\\n', 'T7\\tTreatment 74 81\\tlithium\\n', 'T8\\tDrug 74 81\\tlithium\\n', 'T6\\tAdverse_event 58 70\\tcomplication\\n', 'E1\\tAdverse_event:T6']\n",
            "['T3\\tTreatment 53 67\\tsalt repletion\\n', 'T5\\tEffect 0 49\\tAmphotericin B nephrotoxicity in humans decreased\\n', 'T6\\tDrug 53 57\\tsalt\\n', 'T7\\tSubject 33 39\\thumans\\n', 'T4\\tPotential_therapeutic_event 40 49\\tdecreased\\n', 'E1\\tPotential_therapeutic_event:T4']\n",
            "['T5\\tEffect 0 36\\tSpontaneous nasal septal perforation\\n', 'T7\\tTreatment 42 76\\tantiangiogenic bevacizumab therapy\\n', 'T8\\tDrug 57 68\\tbevacizumab\\n', 'T6\\tAdverse_event 37 41\\twith\\n', 'E1\\tAdverse_event:T6']\n",
            "['T9\\tSubject 22 38\\telderly patients\\n', 'T11\\tTreatment 77 100;105 120\\tatypical antipsychotics antidepressants\\n', 'T12\\tEffect 0 18\\tSerotonin syndrome\\n', 'T14\\tAge 22 29\\telderly\\n', 'T15\\tDrug 77 100\\tatypical antipsychotics\\n', 'T16\\tDrug 105 120\\tantidepressants\\n', 'T18\\tTreat-Disorder 51 71\\tpsychotic depression\\n', 'T13\\tAdverse_event 72 76\\twith\\n', 'T17\\tCombination 101 104\\tand\\n', 'E1\\tAdverse_event:T13 \\n', 'E2\\tCombination:T17 arg:T15 arg2:T16']\n",
            "['T7\\tTreatment 13 48\\tsimvastatin and all antiviral drugs\\n', 'T8\\tEffect 75 83\\ttoxicity\\n', 'T10\\tDrug 13 24\\tsimvastatin\\n', 'T11\\tSpeculation_cue 119 128\\tsuspected\\n', 'T9\\tAdverse_event 84 87\\tdue\\n', 'E1\\tAdverse_event:T9 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tEffect 0 19\\tAcute renal failure\\n', 'T4\\tSubject 23 30\\ta child\\n', 'T6\\tTreatment 47 56\\tacyclovir\\n', 'T7\\tAge 25 30\\tchild\\n', 'T8\\tDrug 47 56\\tacyclovir\\n', 'T5\\tAdverse_event 31 41\\tassociated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T4\\tTreatment 24 67\\thigh-dose tamoxifen for greater than 1 year\\n', 'T5\\tEffect 94 109\\tretinal changes\\n', 'T6\\tSubject 0 13\\tFour patients\\n', 'T7\\tPopulation 0 4\\tFour\\n', 'T8\\tDuration 61 67\\t1 year\\n', 'T9\\tDosage 24 33\\thigh-dose\\n', 'T10\\tDrug 34 43\\ttamoxifen\\n', 'T3\\tAdverse_event 14 23\\treceiving\\n', 'E1\\tAdverse_event:T3']\n",
            "['T3\\tSubject 0 14\\tThree patients\\n', 'T4\\tSub-Disorder 35 64\\tneuroleptic-induced akathisia\\n', 'T5\\tTreatment 107 117\\tfluoxetine\\n', 'T7\\tEffect 126 135\\takathisia\\n', 'T8\\tPopulation 0 5\\tThree\\n', 'T9\\tSeverity_cue 170 176\\tmilder\\n', 'T11\\tDrug 107 117\\tfluoxetine\\n', 'T13\\tTreatment 35 46\\tneuroleptic\\n', 'T14\\tDrug 35 46\\tneuroleptic\\n', 'T15\\tEffect 55 64\\takathisia\\n', 'T6\\tAdverse_event 118 125\\tinduced\\n', 'T12\\tAdverse_event 47 54\\tinduced\\n', 'E1\\tAdverse_event:T6 arg:T3 arg2:T5 arg3:T7\\n', 'E2\\tAdverse_event:T12 arg:T13 arg2:T15 arg3:T3\\n', 'R1\\thas_cue Arg1:E1 Arg2:T9\\t\\n', 'A1\\tSeverity E1 Low\\n']\n",
            "['T4\\tTreatment 27 41\\tCyclosporine A\\n', 'T5\\tSubject 45 64\\ttransplant patients\\n', 'T6\\tEffect 83 115\\therpes esophagitis may increase.\\n', 'T7\\tSub-Disorder 45 55\\ttransplant\\n', 'T8\\tDrug 27 41\\tCyclosporine A\\n', 'T9\\tSpeculation_cue 102 105\\tmay\\n', 'T3\\tAdverse_event 70 79\\tincidence\\n', 'E1\\tAdverse_event:T3 \\n']\n",
            "['T3\\tEffect 30 54\\tdisulfiram-like reaction\\n', 'T4\\tTreatment 60 71\\tcefmenoxime\\n', 'T6\\tDrug 60 71\\tcefmenoxime\\n', 'T5\\tAdverse_event 55 59\\twith\\n', 'E1\\tAdverse_event:T5']\n",
            "['T5\\tEffect 0 36\\tNephrogenic diabetes insipidus (NDI)\\n', 'T7\\tTreatment 74 81\\tlithium\\n', 'T8\\tDrug 74 81\\tlithium\\n', 'T6\\tAdverse_event 58 70\\tcomplication\\n', 'E1\\tAdverse_event:T6']\n",
            "['T3\\tTreatment 53 67\\tsalt repletion\\n', 'T5\\tEffect 0 49\\tAmphotericin B nephrotoxicity in humans decreased\\n', 'T6\\tDrug 53 57\\tsalt\\n', 'T7\\tSubject 33 39\\thumans\\n', 'T4\\tPotential_therapeutic_event 40 49\\tdecreased\\n', 'E1\\tPotential_therapeutic_event:T4']\n",
            "['T5\\tEffect 0 36\\tSpontaneous nasal septal perforation\\n', 'T7\\tTreatment 42 76\\tantiangiogenic bevacizumab therapy\\n', 'T8\\tDrug 57 68\\tbevacizumab\\n', 'T6\\tAdverse_event 37 41\\twith\\n', 'E1\\tAdverse_event:T6']\n",
            "['T9\\tSubject 22 38\\telderly patients\\n', 'T11\\tTreatment 77 100;105 120\\tatypical antipsychotics antidepressants\\n', 'T12\\tEffect 0 18\\tSerotonin syndrome\\n', 'T14\\tAge 22 29\\telderly\\n', 'T15\\tDrug 77 100\\tatypical antipsychotics\\n', 'T16\\tDrug 105 120\\tantidepressants\\n', 'T18\\tTreat-Disorder 51 71\\tpsychotic depression\\n', 'T13\\tAdverse_event 72 76\\twith\\n', 'T17\\tCombination 101 104\\tand\\n', 'E1\\tAdverse_event:T13 \\n', 'E2\\tCombination:T17 arg:T15 arg2:T16']\n",
            "['T7\\tTreatment 13 48\\tsimvastatin and all antiviral drugs\\n', 'T8\\tEffect 75 83\\ttoxicity\\n', 'T10\\tDrug 13 24\\tsimvastatin\\n', 'T11\\tSpeculation_cue 119 128\\tsuspected\\n', 'T9\\tAdverse_event 84 87\\tdue\\n', 'E1\\tAdverse_event:T9 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tEffect 0 19\\tAcute renal failure\\n', 'T4\\tSubject 23 30\\ta child\\n', 'T6\\tTreatment 47 56\\tacyclovir\\n', 'T7\\tAge 25 30\\tchild\\n', 'T8\\tDrug 47 56\\tacyclovir\\n', 'T5\\tAdverse_event 31 41\\tassociated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T4\\tTreatment 24 67\\thigh-dose tamoxifen for greater than 1 year\\n', 'T5\\tEffect 94 109\\tretinal changes\\n', 'T6\\tSubject 0 13\\tFour patients\\n', 'T7\\tPopulation 0 4\\tFour\\n', 'T8\\tDuration 61 67\\t1 year\\n', 'T9\\tDosage 24 33\\thigh-dose\\n', 'T10\\tDrug 34 43\\ttamoxifen\\n', 'T3\\tAdverse_event 14 23\\treceiving\\n', 'E1\\tAdverse_event:T3']\n",
            "['T3\\tSubject 0 14\\tThree patients\\n', 'T4\\tSub-Disorder 35 64\\tneuroleptic-induced akathisia\\n', 'T5\\tTreatment 107 117\\tfluoxetine\\n', 'T7\\tEffect 126 135\\takathisia\\n', 'T8\\tPopulation 0 5\\tThree\\n', 'T9\\tSeverity_cue 170 176\\tmilder\\n', 'T11\\tDrug 107 117\\tfluoxetine\\n', 'T13\\tTreatment 35 46\\tneuroleptic\\n', 'T14\\tDrug 35 46\\tneuroleptic\\n', 'T15\\tEffect 55 64\\takathisia\\n', 'T6\\tAdverse_event 118 125\\tinduced\\n', 'T12\\tAdverse_event 47 54\\tinduced\\n', 'E1\\tAdverse_event:T6 arg:T3 arg2:T5 arg3:T7\\n', 'E2\\tAdverse_event:T12 arg:T13 arg2:T15 arg3:T3\\n', 'R1\\thas_cue Arg1:E1 Arg2:T9\\t\\n', 'A1\\tSeverity E1 Low\\n']\n",
            "['T4\\tTreatment 27 41\\tCyclosporine A\\n', 'T5\\tSubject 45 64\\ttransplant patients\\n', 'T6\\tEffect 83 115\\therpes esophagitis may increase.\\n', 'T7\\tSub-Disorder 45 55\\ttransplant\\n', 'T8\\tDrug 27 41\\tCyclosporine A\\n', 'T9\\tSpeculation_cue 102 105\\tmay\\n', 'T3\\tAdverse_event 70 79\\tincidence\\n', 'E1\\tAdverse_event:T3 \\n']\n",
            "['T3\\tEffect 30 54\\tdisulfiram-like reaction\\n', 'T4\\tTreatment 60 71\\tcefmenoxime\\n', 'T6\\tDrug 60 71\\tcefmenoxime\\n', 'T5\\tAdverse_event 55 59\\twith\\n', 'E1\\tAdverse_event:T5']\n",
            "['T5\\tEffect 0 36\\tNephrogenic diabetes insipidus (NDI)\\n', 'T7\\tTreatment 74 81\\tlithium\\n', 'T8\\tDrug 74 81\\tlithium\\n', 'T6\\tAdverse_event 58 70\\tcomplication\\n', 'E1\\tAdverse_event:T6']\n",
            "['T3\\tTreatment 53 67\\tsalt repletion\\n', 'T5\\tEffect 0 49\\tAmphotericin B nephrotoxicity in humans decreased\\n', 'T6\\tDrug 53 57\\tsalt\\n', 'T7\\tSubject 33 39\\thumans\\n', 'T4\\tPotential_therapeutic_event 40 49\\tdecreased\\n', 'E1\\tPotential_therapeutic_event:T4']\n",
            "['T5\\tEffect 0 36\\tSpontaneous nasal septal perforation\\n', 'T7\\tTreatment 42 76\\tantiangiogenic bevacizumab therapy\\n', 'T8\\tDrug 57 68\\tbevacizumab\\n', 'T6\\tAdverse_event 37 41\\twith\\n', 'E1\\tAdverse_event:T6']\n",
            "['T9\\tSubject 22 38\\telderly patients\\n', 'T11\\tTreatment 77 100;105 120\\tatypical antipsychotics antidepressants\\n', 'T12\\tEffect 0 18\\tSerotonin syndrome\\n', 'T14\\tAge 22 29\\telderly\\n', 'T15\\tDrug 77 100\\tatypical antipsychotics\\n', 'T16\\tDrug 105 120\\tantidepressants\\n', 'T18\\tTreat-Disorder 51 71\\tpsychotic depression\\n', 'T13\\tAdverse_event 72 76\\twith\\n', 'T17\\tCombination 101 104\\tand\\n', 'E1\\tAdverse_event:T13 \\n', 'E2\\tCombination:T17 arg:T15 arg2:T16']\n",
            "['T7\\tTreatment 13 48\\tsimvastatin and all antiviral drugs\\n', 'T8\\tEffect 75 83\\ttoxicity\\n', 'T10\\tDrug 13 24\\tsimvastatin\\n', 'T11\\tSpeculation_cue 119 128\\tsuspected\\n', 'T9\\tAdverse_event 84 87\\tdue\\n', 'E1\\tAdverse_event:T9 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tEffect 0 19\\tAcute renal failure\\n', 'T4\\tSubject 23 30\\ta child\\n', 'T6\\tTreatment 47 56\\tacyclovir\\n', 'T7\\tAge 25 30\\tchild\\n', 'T8\\tDrug 47 56\\tacyclovir\\n', 'T5\\tAdverse_event 31 41\\tassociated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T4\\tTreatment 24 67\\thigh-dose tamoxifen for greater than 1 year\\n', 'T5\\tEffect 94 109\\tretinal changes\\n', 'T6\\tSubject 0 13\\tFour patients\\n', 'T7\\tPopulation 0 4\\tFour\\n', 'T8\\tDuration 61 67\\t1 year\\n', 'T9\\tDosage 24 33\\thigh-dose\\n', 'T10\\tDrug 34 43\\ttamoxifen\\n', 'T3\\tAdverse_event 14 23\\treceiving\\n', 'E1\\tAdverse_event:T3']\n",
            "['T3\\tSubject 0 14\\tThree patients\\n', 'T4\\tSub-Disorder 35 64\\tneuroleptic-induced akathisia\\n', 'T5\\tTreatment 107 117\\tfluoxetine\\n', 'T7\\tEffect 126 135\\takathisia\\n', 'T8\\tPopulation 0 5\\tThree\\n', 'T9\\tSeverity_cue 170 176\\tmilder\\n', 'T11\\tDrug 107 117\\tfluoxetine\\n', 'T13\\tTreatment 35 46\\tneuroleptic\\n', 'T14\\tDrug 35 46\\tneuroleptic\\n', 'T15\\tEffect 55 64\\takathisia\\n', 'T6\\tAdverse_event 118 125\\tinduced\\n', 'T12\\tAdverse_event 47 54\\tinduced\\n', 'E1\\tAdverse_event:T6 arg:T3 arg2:T5 arg3:T7\\n', 'E2\\tAdverse_event:T12 arg:T13 arg2:T15 arg3:T3\\n', 'R1\\thas_cue Arg1:E1 Arg2:T9\\t\\n', 'A1\\tSeverity E1 Low\\n']\n",
            "['T4\\tTreatment 27 41\\tCyclosporine A\\n', 'T5\\tSubject 45 64\\ttransplant patients\\n', 'T6\\tEffect 83 115\\therpes esophagitis may increase.\\n', 'T7\\tSub-Disorder 45 55\\ttransplant\\n', 'T8\\tDrug 27 41\\tCyclosporine A\\n', 'T9\\tSpeculation_cue 102 105\\tmay\\n', 'T3\\tAdverse_event 70 79\\tincidence\\n', 'E1\\tAdverse_event:T3 \\n']\n",
            "['T3\\tEffect 30 54\\tdisulfiram-like reaction\\n', 'T4\\tTreatment 60 71\\tcefmenoxime\\n', 'T6\\tDrug 60 71\\tcefmenoxime\\n', 'T5\\tAdverse_event 55 59\\twith\\n', 'E1\\tAdverse_event:T5']\n",
            "['T5\\tEffect 0 36\\tNephrogenic diabetes insipidus (NDI)\\n', 'T7\\tTreatment 74 81\\tlithium\\n', 'T8\\tDrug 74 81\\tlithium\\n', 'T6\\tAdverse_event 58 70\\tcomplication\\n', 'E1\\tAdverse_event:T6']\n",
            "['T3\\tTreatment 53 67\\tsalt repletion\\n', 'T5\\tEffect 0 49\\tAmphotericin B nephrotoxicity in humans decreased\\n', 'T6\\tDrug 53 57\\tsalt\\n', 'T7\\tSubject 33 39\\thumans\\n', 'T4\\tPotential_therapeutic_event 40 49\\tdecreased\\n', 'E1\\tPotential_therapeutic_event:T4']\n",
            "['T5\\tEffect 0 36\\tSpontaneous nasal septal perforation\\n', 'T7\\tTreatment 42 76\\tantiangiogenic bevacizumab therapy\\n', 'T8\\tDrug 57 68\\tbevacizumab\\n', 'T6\\tAdverse_event 37 41\\twith\\n', 'E1\\tAdverse_event:T6']\n",
            "['T9\\tSubject 22 38\\telderly patients\\n', 'T11\\tTreatment 77 100;105 120\\tatypical antipsychotics antidepressants\\n', 'T12\\tEffect 0 18\\tSerotonin syndrome\\n', 'T14\\tAge 22 29\\telderly\\n', 'T15\\tDrug 77 100\\tatypical antipsychotics\\n', 'T16\\tDrug 105 120\\tantidepressants\\n', 'T18\\tTreat-Disorder 51 71\\tpsychotic depression\\n', 'T13\\tAdverse_event 72 76\\twith\\n', 'T17\\tCombination 101 104\\tand\\n', 'E1\\tAdverse_event:T13 \\n', 'E2\\tCombination:T17 arg:T15 arg2:T16']\n",
            "['T7\\tTreatment 13 48\\tsimvastatin and all antiviral drugs\\n', 'T8\\tEffect 75 83\\ttoxicity\\n', 'T10\\tDrug 13 24\\tsimvastatin\\n', 'T11\\tSpeculation_cue 119 128\\tsuspected\\n', 'T9\\tAdverse_event 84 87\\tdue\\n', 'E1\\tAdverse_event:T9 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tEffect 0 19\\tAcute renal failure\\n', 'T4\\tSubject 23 30\\ta child\\n', 'T6\\tTreatment 47 56\\tacyclovir\\n', 'T7\\tAge 25 30\\tchild\\n', 'T8\\tDrug 47 56\\tacyclovir\\n', 'T5\\tAdverse_event 31 41\\tassociated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T4\\tTreatment 24 67\\thigh-dose tamoxifen for greater than 1 year\\n', 'T5\\tEffect 94 109\\tretinal changes\\n', 'T6\\tSubject 0 13\\tFour patients\\n', 'T7\\tPopulation 0 4\\tFour\\n', 'T8\\tDuration 61 67\\t1 year\\n', 'T9\\tDosage 24 33\\thigh-dose\\n', 'T10\\tDrug 34 43\\ttamoxifen\\n', 'T3\\tAdverse_event 14 23\\treceiving\\n', 'E1\\tAdverse_event:T3']\n",
            "['T3\\tSubject 0 14\\tThree patients\\n', 'T4\\tSub-Disorder 35 64\\tneuroleptic-induced akathisia\\n', 'T5\\tTreatment 107 117\\tfluoxetine\\n', 'T7\\tEffect 126 135\\takathisia\\n', 'T8\\tPopulation 0 5\\tThree\\n', 'T9\\tSeverity_cue 170 176\\tmilder\\n', 'T11\\tDrug 107 117\\tfluoxetine\\n', 'T13\\tTreatment 35 46\\tneuroleptic\\n', 'T14\\tDrug 35 46\\tneuroleptic\\n', 'T15\\tEffect 55 64\\takathisia\\n', 'T6\\tAdverse_event 118 125\\tinduced\\n', 'T12\\tAdverse_event 47 54\\tinduced\\n', 'E1\\tAdverse_event:T6 arg:T3 arg2:T5 arg3:T7\\n', 'E2\\tAdverse_event:T12 arg:T13 arg2:T15 arg3:T3\\n', 'R1\\thas_cue Arg1:E1 Arg2:T9\\t\\n', 'A1\\tSeverity E1 Low\\n']\n",
            "['T4\\tTreatment 27 41\\tCyclosporine A\\n', 'T5\\tSubject 45 64\\ttransplant patients\\n', 'T6\\tEffect 83 115\\therpes esophagitis may increase.\\n', 'T7\\tSub-Disorder 45 55\\ttransplant\\n', 'T8\\tDrug 27 41\\tCyclosporine A\\n', 'T9\\tSpeculation_cue 102 105\\tmay\\n', 'T3\\tAdverse_event 70 79\\tincidence\\n', 'E1\\tAdverse_event:T3 \\n']\n",
            "['T3\\tEffect 30 54\\tdisulfiram-like reaction\\n', 'T4\\tTreatment 60 71\\tcefmenoxime\\n', 'T6\\tDrug 60 71\\tcefmenoxime\\n', 'T5\\tAdverse_event 55 59\\twith\\n', 'E1\\tAdverse_event:T5']\n",
            "['T5\\tEffect 0 36\\tNephrogenic diabetes insipidus (NDI)\\n', 'T7\\tTreatment 74 81\\tlithium\\n', 'T8\\tDrug 74 81\\tlithium\\n', 'T6\\tAdverse_event 58 70\\tcomplication\\n', 'E1\\tAdverse_event:T6']\n",
            "['T3\\tTreatment 53 67\\tsalt repletion\\n', 'T5\\tEffect 0 49\\tAmphotericin B nephrotoxicity in humans decreased\\n', 'T6\\tDrug 53 57\\tsalt\\n', 'T7\\tSubject 33 39\\thumans\\n', 'T4\\tPotential_therapeutic_event 40 49\\tdecreased\\n', 'E1\\tPotential_therapeutic_event:T4']\n",
            "['T5\\tEffect 0 36\\tSpontaneous nasal septal perforation\\n', 'T7\\tTreatment 42 76\\tantiangiogenic bevacizumab therapy\\n', 'T8\\tDrug 57 68\\tbevacizumab\\n', 'T6\\tAdverse_event 37 41\\twith\\n', 'E1\\tAdverse_event:T6']\n",
            "['T9\\tSubject 22 38\\telderly patients\\n', 'T11\\tTreatment 77 100;105 120\\tatypical antipsychotics antidepressants\\n', 'T12\\tEffect 0 18\\tSerotonin syndrome\\n', 'T14\\tAge 22 29\\telderly\\n', 'T15\\tDrug 77 100\\tatypical antipsychotics\\n', 'T16\\tDrug 105 120\\tantidepressants\\n', 'T18\\tTreat-Disorder 51 71\\tpsychotic depression\\n', 'T13\\tAdverse_event 72 76\\twith\\n', 'T17\\tCombination 101 104\\tand\\n', 'E1\\tAdverse_event:T13 \\n', 'E2\\tCombination:T17 arg:T15 arg2:T16']\n",
            "['T7\\tTreatment 13 48\\tsimvastatin and all antiviral drugs\\n', 'T8\\tEffect 75 83\\ttoxicity\\n', 'T10\\tDrug 13 24\\tsimvastatin\\n', 'T11\\tSpeculation_cue 119 128\\tsuspected\\n', 'T9\\tAdverse_event 84 87\\tdue\\n', 'E1\\tAdverse_event:T9 \\n', 'A1\\tSpeculated E1']\n",
            "['T3\\tEffect 0 19\\tAcute renal failure\\n', 'T4\\tSubject 23 30\\ta child\\n', 'T6\\tTreatment 47 56\\tacyclovir\\n', 'T7\\tAge 25 30\\tchild\\n', 'T8\\tDrug 47 56\\tacyclovir\\n', 'T5\\tAdverse_event 31 41\\tassociated\\n', 'E1\\tAdverse_event:T5']\n",
            "['T4\\tTreatment 24 67\\thigh-dose tamoxifen for greater than 1 year\\n', 'T5\\tEffect 94 109\\tretinal changes\\n', 'T6\\tSubject 0 13\\tFour patients\\n', 'T7\\tPopulation 0 4\\tFour\\n', 'T8\\tDuration 61 67\\t1 year\\n', 'T9\\tDosage 24 33\\thigh-dose\\n', 'T10\\tDrug 34 43\\ttamoxifen\\n', 'T3\\tAdverse_event 14 23\\treceiving\\n', 'E1\\tAdverse_event:T3']\n",
            "['T3\\tSubject 0 14\\tThree patients\\n', 'T4\\tSub-Disorder 35 64\\tneuroleptic-induced akathisia\\n', 'T5\\tTreatment 107 117\\tfluoxetine\\n', 'T7\\tEffect 126 135\\takathisia\\n', 'T8\\tPopulation 0 5\\tThree\\n', 'T9\\tSeverity_cue 170 176\\tmilder\\n', 'T11\\tDrug 107 117\\tfluoxetine\\n', 'T13\\tTreatment 35 46\\tneuroleptic\\n', 'T14\\tDrug 35 46\\tneuroleptic\\n', 'T15\\tEffect 55 64\\takathisia\\n', 'T6\\tAdverse_event 118 125\\tinduced\\n', 'T12\\tAdverse_event 47 54\\tinduced\\n', 'E1\\tAdverse_event:T6 arg:T3 arg2:T5 arg3:T7\\n', 'E2\\tAdverse_event:T12 arg:T13 arg2:T15 arg3:T3\\n', 'R1\\thas_cue Arg1:E1 Arg2:T9\\t\\n', 'A1\\tSeverity E1 Low\\n']\n",
            "['T4\\tTreatment 27 41\\tCyclosporine A\\n', 'T5\\tSubject 45 64\\ttransplant patients\\n', 'T6\\tEffect 83 115\\therpes esophagitis may increase.\\n', 'T7\\tSub-Disorder 45 55\\ttransplant\\n', 'T8\\tDrug 27 41\\tCyclosporine A\\n', 'T9\\tSpeculation_cue 102 105\\tmay\\n', 'T3\\tAdverse_event 70 79\\tincidence\\n', 'E1\\tAdverse_event:T3 \\n']\n",
            "['T3\\tEffect 30 54\\tdisulfiram-like reaction\\n', 'T4\\tTreatment 60 71\\tcefmenoxime\\n', 'T6\\tDrug 60 71\\tcefmenoxime\\n', 'T5\\tAdverse_event 55 59\\twith\\n', 'E1\\tAdverse_event:T5']\n",
            "['T5\\tEffect 0 36\\tNephrogenic diabetes insipidus (NDI)\\n', 'T7\\tTreatment 74 81\\tlithium\\n', 'T8\\tDrug 74 81\\tlithium\\n', 'T6\\tAdverse_event 58 70\\tcomplication\\n', 'E1\\tAdverse_event:T6']\n",
            "['T3\\tTreatment 53 67\\tsalt repletion\\n', 'T5\\tEffect 0 49\\tAmphotericin B nephrotoxicity in humans decreased\\n', 'T6\\tDrug 53 57\\tsalt\\n', 'T7\\tSubject 33 39\\thumans\\n', 'T4\\tPotential_therapeutic_event 40 49\\tdecreased\\n', 'E1\\tPotential_therapeutic_event:T4']\n",
            "['T5\\tEffect 0 36\\tSpontaneous nasal septal perforation\\n', 'T7\\tTreatment 42 76\\tantiangiogenic bevacizumab therapy\\n', 'T8\\tDrug 57 68\\tbevacizumab\\n', 'T6\\tAdverse_event 37 41\\twith\\n', 'E1\\tAdverse_event:T6']\n",
            "['T4\\tSubject 24 84\\ta 50-year-old woman with advanced non-small cell lung cancer\\n', 'T7\\tEffect 99 117\\tstatus epilepticus\\n', 'T8\\tTreatment 142 180\\tcisplatin and gemcitabine chemotherapy\\n', 'T9\\tAge 26 37\\t50-year-old\\n', 'T10\\tGender 38 43\\twoman\\n', 'T5\\tDrug 142 151\\tcisplatin\\n', 'T13\\tDrug 156 167\\tgemcitabine\\n', 'T14\\tTreat-Disorder 73 84\\tlung cancer\\n', 'T15\\tRoute 168 180\\tchemotherapy\\n', 'T6\\tAdverse_event 89 98\\tdeveloped\\n', 'T12\\tCombination 152 155\\tand\\n', 'E1\\tAdverse_event:T6 \\n', 'E2\\tCombination:T12 arg:T5 arg2:T13']\n",
            "['T3\\tEffect 27 30\\tAVP\\n', 'T5\\tTreatment 75 85\\tinfliximab\\n', 'T7\\tTime_elapsed 31 42\\tthree weeks\\n', 'T8\\tDrug 75 85\\tinfliximab\\n', \"T9\\tTreat-Disorder 107 122\\tCrohn's disease\\n\", 'T10\\tSeverity_cue 20 26\\tsevere\\n', 'T4\\tAdverse_event 43 52\\tfollowing\\n', 'E1\\tAdverse_event:T4 \\n', 'A1\\tSeverity E1 High']\n",
            "['T5\\tTreatment 33 44\\tzafirlukast\\n', 'T6\\tEffect 89 159\\timpaired clearance of  S-warfarin and enhanced anti-thrombotic effects\\n', 'T8\\tSpeculation_cue 48 58\\tconsistent\\n', 'T9\\tDrug 33 44\\tzafirlukast\\n', 'T7\\tPotential_therapeutic_event 81 88\\tshowing\\n', 'E1\\tPotential_therapeutic_event:T7']\n",
            "[\"T3\\tEffect 15 33\\tPeyronie's disease\\n\", 'T6\\tDrug 51 61\\tcolchicine\\n', 'T7\\tFreq 41 50\\tlong-term\\n', 'T4\\tTreatment 41 71\\tlong-term colchicine treatment\\n', 'T5\\tAdverse_event 34 40\\tduring\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 118 190\\ta 29-year Nigerian female patient with generalized tonic-elonic seizures\\n', 'T4\\tEffect 14 52\\tsyndrome of inappropriate antidiuresis\\n', 'T5\\tTreatment 86 99\\tcarbamazepine\\n', 'T8\\tAge 120 127\\t29-year\\n', 'T9\\tRace 128 136\\tNigerian\\n', 'T10\\tGender 137 143\\tfemale\\n', 'T6\\tDrug 86 99\\tcarbamazepine\\n', 'T12\\tTime_elapsed 58 70\\tmuch earlier\\n', 'T13\\tTreat-Disorder 157 190\\tgeneralized tonic-elonic seizures\\n', 'T7\\tAdverse_event 71 82\\tside-effect\\n', 'E1\\tAdverse_event:T7']\n",
            "['T4\\tTreatment 91 133\\tanticalcineurinic drug (CyA or tacrolimus)\\n', 'T5\\tEffect 15 19\\tRSDS\\n', 'T8\\tDrug 115 118\\tCyA\\n', 'T9\\tDrug 122 132\\ttacrolimus\\n', 'T7\\tAdverse_event 34 61\\tosteoarticular complication\\n', 'E1\\tAdverse_event:T7']\n",
            "['T6\\tTreatment 48 58\\traloxifene\\n', 'T7\\tEffect 82 114\\tmalignant mixed mesodermal tumor\\n', 'T8\\tDrug 48 58\\traloxifene\\n', 'T9\\tSpeculation_cue 18 21\\tmay\\n', 'T5\\tAdverse_event 28 39\\tassociation\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T5\\tSubject 0 100\\tTwo children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis\\n', 'T6\\tEffect 126 158\\tseizures and transient blindness\\n', 'T8\\tTreatment 184 231\\ti.v. pulse methylprednisolone (IVPMP) treatment\\n', 'T9\\tPopulation 0 3\\tTwo\\n', 'T10\\tTreat-Disorder 21 50\\tidiopathic nephrotic syndrome\\n', 'T11\\tTreat-Disorder 62 101\\tendo-extracapillary glomerulonephritis,\\n', 'T12\\tDrug 195 213\\tmethylprednisolone\\n', 'T13\\tSeverity_cue 139 148\\ttransient\\n', 'T7\\tAdverse_event 178 183\\tafter\\n', 'E1\\tAdverse_event:T7 \\n', 'A1\\tSeverity E1 Low\\n', 'T1\\tRoute 184 194\\ti.v. pulse\\n']\n",
            "['T6\\tTreatment 37 86\\tlong-term therapy with the addition of citalopram\\n', 'T7\\tEffect 0 15\\tAdverse effects\\n', 'T9\\tDrug 19 30\\tpropafenone\\n', 'T10\\tTime_elapsed 37 46\\tlong-term\\n', 'T11\\tDrug 76 86\\tcitalopram\\n', 'T5\\tAdverse_event 31 36\\tafter\\n', 'T12\\tCombination 64 72\\taddition\\n', 'E1\\tAdverse_event:T5 \\n', 'E2\\tCombination:T12 arg:T11 arg2:T9']\n",
            "['T3\\tSubject 5 13\\tone case\\n', 'T4\\tEffect 17 45\\tsevere symptomatic hepatitis\\n', 'T5\\tTreat-Disorder 98 111\\tonychomycosis\\n', 'T7\\tTreatment 62 93\\tpulse therapy with itraconazole\\n', 'T9\\tPopulation 5 8\\tone\\n', 'T10\\tDrug 81 93\\titraconazole\\n', 'T6\\tAdverse_event 46 55\\toccurring\\n', 'E1\\tAdverse_event:T6']\n",
            "['T4\\tSubject 24 84\\ta 50-year-old woman with advanced non-small cell lung cancer\\n', 'T7\\tEffect 99 117\\tstatus epilepticus\\n', 'T8\\tTreatment 142 180\\tcisplatin and gemcitabine chemotherapy\\n', 'T9\\tAge 26 37\\t50-year-old\\n', 'T10\\tGender 38 43\\twoman\\n', 'T5\\tDrug 142 151\\tcisplatin\\n', 'T13\\tDrug 156 167\\tgemcitabine\\n', 'T14\\tTreat-Disorder 73 84\\tlung cancer\\n', 'T15\\tRoute 168 180\\tchemotherapy\\n', 'T6\\tAdverse_event 89 98\\tdeveloped\\n', 'T12\\tCombination 152 155\\tand\\n', 'E1\\tAdverse_event:T6 \\n', 'E2\\tCombination:T12 arg:T5 arg2:T13']\n",
            "['T3\\tEffect 27 30\\tAVP\\n', 'T5\\tTreatment 75 85\\tinfliximab\\n', 'T7\\tTime_elapsed 31 42\\tthree weeks\\n', 'T8\\tDrug 75 85\\tinfliximab\\n', \"T9\\tTreat-Disorder 107 122\\tCrohn's disease\\n\", 'T10\\tSeverity_cue 20 26\\tsevere\\n', 'T4\\tAdverse_event 43 52\\tfollowing\\n', 'E1\\tAdverse_event:T4 \\n', 'A1\\tSeverity E1 High']\n",
            "['T5\\tTreatment 33 44\\tzafirlukast\\n', 'T6\\tEffect 89 159\\timpaired clearance of  S-warfarin and enhanced anti-thrombotic effects\\n', 'T8\\tSpeculation_cue 48 58\\tconsistent\\n', 'T9\\tDrug 33 44\\tzafirlukast\\n', 'T7\\tPotential_therapeutic_event 81 88\\tshowing\\n', 'E1\\tPotential_therapeutic_event:T7']\n",
            "[\"T3\\tEffect 15 33\\tPeyronie's disease\\n\", 'T6\\tDrug 51 61\\tcolchicine\\n', 'T7\\tFreq 41 50\\tlong-term\\n', 'T4\\tTreatment 41 71\\tlong-term colchicine treatment\\n', 'T5\\tAdverse_event 34 40\\tduring\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 118 190\\ta 29-year Nigerian female patient with generalized tonic-elonic seizures\\n', 'T4\\tEffect 14 52\\tsyndrome of inappropriate antidiuresis\\n', 'T5\\tTreatment 86 99\\tcarbamazepine\\n', 'T8\\tAge 120 127\\t29-year\\n', 'T9\\tRace 128 136\\tNigerian\\n', 'T10\\tGender 137 143\\tfemale\\n', 'T6\\tDrug 86 99\\tcarbamazepine\\n', 'T12\\tTime_elapsed 58 70\\tmuch earlier\\n', 'T13\\tTreat-Disorder 157 190\\tgeneralized tonic-elonic seizures\\n', 'T7\\tAdverse_event 71 82\\tside-effect\\n', 'E1\\tAdverse_event:T7']\n",
            "['T4\\tTreatment 91 133\\tanticalcineurinic drug (CyA or tacrolimus)\\n', 'T5\\tEffect 15 19\\tRSDS\\n', 'T8\\tDrug 115 118\\tCyA\\n', 'T9\\tDrug 122 132\\ttacrolimus\\n', 'T7\\tAdverse_event 34 61\\tosteoarticular complication\\n', 'E1\\tAdverse_event:T7']\n",
            "['T6\\tTreatment 48 58\\traloxifene\\n', 'T7\\tEffect 82 114\\tmalignant mixed mesodermal tumor\\n', 'T8\\tDrug 48 58\\traloxifene\\n', 'T9\\tSpeculation_cue 18 21\\tmay\\n', 'T5\\tAdverse_event 28 39\\tassociation\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T5\\tSubject 0 100\\tTwo children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis\\n', 'T6\\tEffect 126 158\\tseizures and transient blindness\\n', 'T8\\tTreatment 184 231\\ti.v. pulse methylprednisolone (IVPMP) treatment\\n', 'T9\\tPopulation 0 3\\tTwo\\n', 'T10\\tTreat-Disorder 21 50\\tidiopathic nephrotic syndrome\\n', 'T11\\tTreat-Disorder 62 101\\tendo-extracapillary glomerulonephritis,\\n', 'T12\\tDrug 195 213\\tmethylprednisolone\\n', 'T13\\tSeverity_cue 139 148\\ttransient\\n', 'T7\\tAdverse_event 178 183\\tafter\\n', 'E1\\tAdverse_event:T7 \\n', 'A1\\tSeverity E1 Low\\n', 'T1\\tRoute 184 194\\ti.v. pulse\\n']\n",
            "['T6\\tTreatment 37 86\\tlong-term therapy with the addition of citalopram\\n', 'T7\\tEffect 0 15\\tAdverse effects\\n', 'T9\\tDrug 19 30\\tpropafenone\\n', 'T10\\tTime_elapsed 37 46\\tlong-term\\n', 'T11\\tDrug 76 86\\tcitalopram\\n', 'T5\\tAdverse_event 31 36\\tafter\\n', 'T12\\tCombination 64 72\\taddition\\n', 'E1\\tAdverse_event:T5 \\n', 'E2\\tCombination:T12 arg:T11 arg2:T9']\n",
            "['T3\\tSubject 5 13\\tone case\\n', 'T4\\tEffect 17 45\\tsevere symptomatic hepatitis\\n', 'T5\\tTreat-Disorder 98 111\\tonychomycosis\\n', 'T7\\tTreatment 62 93\\tpulse therapy with itraconazole\\n', 'T9\\tPopulation 5 8\\tone\\n', 'T10\\tDrug 81 93\\titraconazole\\n', 'T6\\tAdverse_event 46 55\\toccurring\\n', 'E1\\tAdverse_event:T6']\n",
            "['T4\\tSubject 24 84\\ta 50-year-old woman with advanced non-small cell lung cancer\\n', 'T7\\tEffect 99 117\\tstatus epilepticus\\n', 'T8\\tTreatment 142 180\\tcisplatin and gemcitabine chemotherapy\\n', 'T9\\tAge 26 37\\t50-year-old\\n', 'T10\\tGender 38 43\\twoman\\n', 'T5\\tDrug 142 151\\tcisplatin\\n', 'T13\\tDrug 156 167\\tgemcitabine\\n', 'T14\\tTreat-Disorder 73 84\\tlung cancer\\n', 'T15\\tRoute 168 180\\tchemotherapy\\n', 'T6\\tAdverse_event 89 98\\tdeveloped\\n', 'T12\\tCombination 152 155\\tand\\n', 'E1\\tAdverse_event:T6 \\n', 'E2\\tCombination:T12 arg:T5 arg2:T13']\n",
            "['T3\\tEffect 27 30\\tAVP\\n', 'T5\\tTreatment 75 85\\tinfliximab\\n', 'T7\\tTime_elapsed 31 42\\tthree weeks\\n', 'T8\\tDrug 75 85\\tinfliximab\\n', \"T9\\tTreat-Disorder 107 122\\tCrohn's disease\\n\", 'T10\\tSeverity_cue 20 26\\tsevere\\n', 'T4\\tAdverse_event 43 52\\tfollowing\\n', 'E1\\tAdverse_event:T4 \\n', 'A1\\tSeverity E1 High']\n",
            "['T5\\tTreatment 33 44\\tzafirlukast\\n', 'T6\\tEffect 89 159\\timpaired clearance of  S-warfarin and enhanced anti-thrombotic effects\\n', 'T8\\tSpeculation_cue 48 58\\tconsistent\\n', 'T9\\tDrug 33 44\\tzafirlukast\\n', 'T7\\tPotential_therapeutic_event 81 88\\tshowing\\n', 'E1\\tPotential_therapeutic_event:T7']\n",
            "[\"T3\\tEffect 15 33\\tPeyronie's disease\\n\", 'T6\\tDrug 51 61\\tcolchicine\\n', 'T7\\tFreq 41 50\\tlong-term\\n', 'T4\\tTreatment 41 71\\tlong-term colchicine treatment\\n', 'T5\\tAdverse_event 34 40\\tduring\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 118 190\\ta 29-year Nigerian female patient with generalized tonic-elonic seizures\\n', 'T4\\tEffect 14 52\\tsyndrome of inappropriate antidiuresis\\n', 'T5\\tTreatment 86 99\\tcarbamazepine\\n', 'T8\\tAge 120 127\\t29-year\\n', 'T9\\tRace 128 136\\tNigerian\\n', 'T10\\tGender 137 143\\tfemale\\n', 'T6\\tDrug 86 99\\tcarbamazepine\\n', 'T12\\tTime_elapsed 58 70\\tmuch earlier\\n', 'T13\\tTreat-Disorder 157 190\\tgeneralized tonic-elonic seizures\\n', 'T7\\tAdverse_event 71 82\\tside-effect\\n', 'E1\\tAdverse_event:T7']\n",
            "['T4\\tTreatment 91 133\\tanticalcineurinic drug (CyA or tacrolimus)\\n', 'T5\\tEffect 15 19\\tRSDS\\n', 'T8\\tDrug 115 118\\tCyA\\n', 'T9\\tDrug 122 132\\ttacrolimus\\n', 'T7\\tAdverse_event 34 61\\tosteoarticular complication\\n', 'E1\\tAdverse_event:T7']\n",
            "['T6\\tTreatment 48 58\\traloxifene\\n', 'T7\\tEffect 82 114\\tmalignant mixed mesodermal tumor\\n', 'T8\\tDrug 48 58\\traloxifene\\n', 'T9\\tSpeculation_cue 18 21\\tmay\\n', 'T5\\tAdverse_event 28 39\\tassociation\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T5\\tSubject 0 100\\tTwo children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis\\n', 'T6\\tEffect 126 158\\tseizures and transient blindness\\n', 'T8\\tTreatment 184 231\\ti.v. pulse methylprednisolone (IVPMP) treatment\\n', 'T9\\tPopulation 0 3\\tTwo\\n', 'T10\\tTreat-Disorder 21 50\\tidiopathic nephrotic syndrome\\n', 'T11\\tTreat-Disorder 62 101\\tendo-extracapillary glomerulonephritis,\\n', 'T12\\tDrug 195 213\\tmethylprednisolone\\n', 'T13\\tSeverity_cue 139 148\\ttransient\\n', 'T7\\tAdverse_event 178 183\\tafter\\n', 'E1\\tAdverse_event:T7 \\n', 'A1\\tSeverity E1 Low\\n', 'T1\\tRoute 184 194\\ti.v. pulse\\n']\n",
            "['T6\\tTreatment 37 86\\tlong-term therapy with the addition of citalopram\\n', 'T7\\tEffect 0 15\\tAdverse effects\\n', 'T9\\tDrug 19 30\\tpropafenone\\n', 'T10\\tTime_elapsed 37 46\\tlong-term\\n', 'T11\\tDrug 76 86\\tcitalopram\\n', 'T5\\tAdverse_event 31 36\\tafter\\n', 'T12\\tCombination 64 72\\taddition\\n', 'E1\\tAdverse_event:T5 \\n', 'E2\\tCombination:T12 arg:T11 arg2:T9']\n",
            "['T3\\tSubject 5 13\\tone case\\n', 'T4\\tEffect 17 45\\tsevere symptomatic hepatitis\\n', 'T5\\tTreat-Disorder 98 111\\tonychomycosis\\n', 'T7\\tTreatment 62 93\\tpulse therapy with itraconazole\\n', 'T9\\tPopulation 5 8\\tone\\n', 'T10\\tDrug 81 93\\titraconazole\\n', 'T6\\tAdverse_event 46 55\\toccurring\\n', 'E1\\tAdverse_event:T6']\n",
            "['T4\\tSubject 24 84\\ta 50-year-old woman with advanced non-small cell lung cancer\\n', 'T7\\tEffect 99 117\\tstatus epilepticus\\n', 'T8\\tTreatment 142 180\\tcisplatin and gemcitabine chemotherapy\\n', 'T9\\tAge 26 37\\t50-year-old\\n', 'T10\\tGender 38 43\\twoman\\n', 'T5\\tDrug 142 151\\tcisplatin\\n', 'T13\\tDrug 156 167\\tgemcitabine\\n', 'T14\\tTreat-Disorder 73 84\\tlung cancer\\n', 'T15\\tRoute 168 180\\tchemotherapy\\n', 'T6\\tAdverse_event 89 98\\tdeveloped\\n', 'T12\\tCombination 152 155\\tand\\n', 'E1\\tAdverse_event:T6 \\n', 'E2\\tCombination:T12 arg:T5 arg2:T13']\n",
            "['T3\\tEffect 27 30\\tAVP\\n', 'T5\\tTreatment 75 85\\tinfliximab\\n', 'T7\\tTime_elapsed 31 42\\tthree weeks\\n', 'T8\\tDrug 75 85\\tinfliximab\\n', \"T9\\tTreat-Disorder 107 122\\tCrohn's disease\\n\", 'T10\\tSeverity_cue 20 26\\tsevere\\n', 'T4\\tAdverse_event 43 52\\tfollowing\\n', 'E1\\tAdverse_event:T4 \\n', 'A1\\tSeverity E1 High']\n",
            "['T5\\tTreatment 33 44\\tzafirlukast\\n', 'T6\\tEffect 89 159\\timpaired clearance of  S-warfarin and enhanced anti-thrombotic effects\\n', 'T8\\tSpeculation_cue 48 58\\tconsistent\\n', 'T9\\tDrug 33 44\\tzafirlukast\\n', 'T7\\tPotential_therapeutic_event 81 88\\tshowing\\n', 'E1\\tPotential_therapeutic_event:T7']\n",
            "[\"T3\\tEffect 15 33\\tPeyronie's disease\\n\", 'T6\\tDrug 51 61\\tcolchicine\\n', 'T7\\tFreq 41 50\\tlong-term\\n', 'T4\\tTreatment 41 71\\tlong-term colchicine treatment\\n', 'T5\\tAdverse_event 34 40\\tduring\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 118 190\\ta 29-year Nigerian female patient with generalized tonic-elonic seizures\\n', 'T4\\tEffect 14 52\\tsyndrome of inappropriate antidiuresis\\n', 'T5\\tTreatment 86 99\\tcarbamazepine\\n', 'T8\\tAge 120 127\\t29-year\\n', 'T9\\tRace 128 136\\tNigerian\\n', 'T10\\tGender 137 143\\tfemale\\n', 'T6\\tDrug 86 99\\tcarbamazepine\\n', 'T12\\tTime_elapsed 58 70\\tmuch earlier\\n', 'T13\\tTreat-Disorder 157 190\\tgeneralized tonic-elonic seizures\\n', 'T7\\tAdverse_event 71 82\\tside-effect\\n', 'E1\\tAdverse_event:T7']\n",
            "['T4\\tTreatment 91 133\\tanticalcineurinic drug (CyA or tacrolimus)\\n', 'T5\\tEffect 15 19\\tRSDS\\n', 'T8\\tDrug 115 118\\tCyA\\n', 'T9\\tDrug 122 132\\ttacrolimus\\n', 'T7\\tAdverse_event 34 61\\tosteoarticular complication\\n', 'E1\\tAdverse_event:T7']\n",
            "['T6\\tTreatment 48 58\\traloxifene\\n', 'T7\\tEffect 82 114\\tmalignant mixed mesodermal tumor\\n', 'T8\\tDrug 48 58\\traloxifene\\n', 'T9\\tSpeculation_cue 18 21\\tmay\\n', 'T5\\tAdverse_event 28 39\\tassociation\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T5\\tSubject 0 100\\tTwo children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis\\n', 'T6\\tEffect 126 158\\tseizures and transient blindness\\n', 'T8\\tTreatment 184 231\\ti.v. pulse methylprednisolone (IVPMP) treatment\\n', 'T9\\tPopulation 0 3\\tTwo\\n', 'T10\\tTreat-Disorder 21 50\\tidiopathic nephrotic syndrome\\n', 'T11\\tTreat-Disorder 62 101\\tendo-extracapillary glomerulonephritis,\\n', 'T12\\tDrug 195 213\\tmethylprednisolone\\n', 'T13\\tSeverity_cue 139 148\\ttransient\\n', 'T7\\tAdverse_event 178 183\\tafter\\n', 'E1\\tAdverse_event:T7 \\n', 'A1\\tSeverity E1 Low\\n', 'T1\\tRoute 184 194\\ti.v. pulse\\n']\n",
            "['T6\\tTreatment 37 86\\tlong-term therapy with the addition of citalopram\\n', 'T7\\tEffect 0 15\\tAdverse effects\\n', 'T9\\tDrug 19 30\\tpropafenone\\n', 'T10\\tTime_elapsed 37 46\\tlong-term\\n', 'T11\\tDrug 76 86\\tcitalopram\\n', 'T5\\tAdverse_event 31 36\\tafter\\n', 'T12\\tCombination 64 72\\taddition\\n', 'E1\\tAdverse_event:T5 \\n', 'E2\\tCombination:T12 arg:T11 arg2:T9']\n",
            "['T3\\tSubject 5 13\\tone case\\n', 'T4\\tEffect 17 45\\tsevere symptomatic hepatitis\\n', 'T5\\tTreat-Disorder 98 111\\tonychomycosis\\n', 'T7\\tTreatment 62 93\\tpulse therapy with itraconazole\\n', 'T9\\tPopulation 5 8\\tone\\n', 'T10\\tDrug 81 93\\titraconazole\\n', 'T6\\tAdverse_event 46 55\\toccurring\\n', 'E1\\tAdverse_event:T6']\n",
            "['T4\\tSubject 24 84\\ta 50-year-old woman with advanced non-small cell lung cancer\\n', 'T7\\tEffect 99 117\\tstatus epilepticus\\n', 'T8\\tTreatment 142 180\\tcisplatin and gemcitabine chemotherapy\\n', 'T9\\tAge 26 37\\t50-year-old\\n', 'T10\\tGender 38 43\\twoman\\n', 'T5\\tDrug 142 151\\tcisplatin\\n', 'T13\\tDrug 156 167\\tgemcitabine\\n', 'T14\\tTreat-Disorder 73 84\\tlung cancer\\n', 'T15\\tRoute 168 180\\tchemotherapy\\n', 'T6\\tAdverse_event 89 98\\tdeveloped\\n', 'T12\\tCombination 152 155\\tand\\n', 'E1\\tAdverse_event:T6 \\n', 'E2\\tCombination:T12 arg:T5 arg2:T13']\n",
            "['T3\\tEffect 27 30\\tAVP\\n', 'T5\\tTreatment 75 85\\tinfliximab\\n', 'T7\\tTime_elapsed 31 42\\tthree weeks\\n', 'T8\\tDrug 75 85\\tinfliximab\\n', \"T9\\tTreat-Disorder 107 122\\tCrohn's disease\\n\", 'T10\\tSeverity_cue 20 26\\tsevere\\n', 'T4\\tAdverse_event 43 52\\tfollowing\\n', 'E1\\tAdverse_event:T4 \\n', 'A1\\tSeverity E1 High']\n",
            "['T5\\tTreatment 33 44\\tzafirlukast\\n', 'T6\\tEffect 89 159\\timpaired clearance of  S-warfarin and enhanced anti-thrombotic effects\\n', 'T8\\tSpeculation_cue 48 58\\tconsistent\\n', 'T9\\tDrug 33 44\\tzafirlukast\\n', 'T7\\tPotential_therapeutic_event 81 88\\tshowing\\n', 'E1\\tPotential_therapeutic_event:T7']\n",
            "[\"T3\\tEffect 15 33\\tPeyronie's disease\\n\", 'T6\\tDrug 51 61\\tcolchicine\\n', 'T7\\tFreq 41 50\\tlong-term\\n', 'T4\\tTreatment 41 71\\tlong-term colchicine treatment\\n', 'T5\\tAdverse_event 34 40\\tduring\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 118 190\\ta 29-year Nigerian female patient with generalized tonic-elonic seizures\\n', 'T4\\tEffect 14 52\\tsyndrome of inappropriate antidiuresis\\n', 'T5\\tTreatment 86 99\\tcarbamazepine\\n', 'T8\\tAge 120 127\\t29-year\\n', 'T9\\tRace 128 136\\tNigerian\\n', 'T10\\tGender 137 143\\tfemale\\n', 'T6\\tDrug 86 99\\tcarbamazepine\\n', 'T12\\tTime_elapsed 58 70\\tmuch earlier\\n', 'T13\\tTreat-Disorder 157 190\\tgeneralized tonic-elonic seizures\\n', 'T7\\tAdverse_event 71 82\\tside-effect\\n', 'E1\\tAdverse_event:T7']\n",
            "['T4\\tTreatment 91 133\\tanticalcineurinic drug (CyA or tacrolimus)\\n', 'T5\\tEffect 15 19\\tRSDS\\n', 'T8\\tDrug 115 118\\tCyA\\n', 'T9\\tDrug 122 132\\ttacrolimus\\n', 'T7\\tAdverse_event 34 61\\tosteoarticular complication\\n', 'E1\\tAdverse_event:T7']\n",
            "['T6\\tTreatment 48 58\\traloxifene\\n', 'T7\\tEffect 82 114\\tmalignant mixed mesodermal tumor\\n', 'T8\\tDrug 48 58\\traloxifene\\n', 'T9\\tSpeculation_cue 18 21\\tmay\\n', 'T5\\tAdverse_event 28 39\\tassociation\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T5\\tSubject 0 100\\tTwo children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis\\n', 'T6\\tEffect 126 158\\tseizures and transient blindness\\n', 'T8\\tTreatment 184 231\\ti.v. pulse methylprednisolone (IVPMP) treatment\\n', 'T9\\tPopulation 0 3\\tTwo\\n', 'T10\\tTreat-Disorder 21 50\\tidiopathic nephrotic syndrome\\n', 'T11\\tTreat-Disorder 62 101\\tendo-extracapillary glomerulonephritis,\\n', 'T12\\tDrug 195 213\\tmethylprednisolone\\n', 'T13\\tSeverity_cue 139 148\\ttransient\\n', 'T7\\tAdverse_event 178 183\\tafter\\n', 'E1\\tAdverse_event:T7 \\n', 'A1\\tSeverity E1 Low\\n', 'T1\\tRoute 184 194\\ti.v. pulse\\n']\n",
            "['T6\\tTreatment 37 86\\tlong-term therapy with the addition of citalopram\\n', 'T7\\tEffect 0 15\\tAdverse effects\\n', 'T9\\tDrug 19 30\\tpropafenone\\n', 'T10\\tTime_elapsed 37 46\\tlong-term\\n', 'T11\\tDrug 76 86\\tcitalopram\\n', 'T5\\tAdverse_event 31 36\\tafter\\n', 'T12\\tCombination 64 72\\taddition\\n', 'E1\\tAdverse_event:T5 \\n', 'E2\\tCombination:T12 arg:T11 arg2:T9']\n",
            "['T3\\tSubject 5 13\\tone case\\n', 'T4\\tEffect 17 45\\tsevere symptomatic hepatitis\\n', 'T5\\tTreat-Disorder 98 111\\tonychomycosis\\n', 'T7\\tTreatment 62 93\\tpulse therapy with itraconazole\\n', 'T9\\tPopulation 5 8\\tone\\n', 'T10\\tDrug 81 93\\titraconazole\\n', 'T6\\tAdverse_event 46 55\\toccurring\\n', 'E1\\tAdverse_event:T6']\n",
            "['T4\\tSubject 24 84\\ta 50-year-old woman with advanced non-small cell lung cancer\\n', 'T7\\tEffect 99 117\\tstatus epilepticus\\n', 'T8\\tTreatment 142 180\\tcisplatin and gemcitabine chemotherapy\\n', 'T9\\tAge 26 37\\t50-year-old\\n', 'T10\\tGender 38 43\\twoman\\n', 'T5\\tDrug 142 151\\tcisplatin\\n', 'T13\\tDrug 156 167\\tgemcitabine\\n', 'T14\\tTreat-Disorder 73 84\\tlung cancer\\n', 'T15\\tRoute 168 180\\tchemotherapy\\n', 'T6\\tAdverse_event 89 98\\tdeveloped\\n', 'T12\\tCombination 152 155\\tand\\n', 'E1\\tAdverse_event:T6 \\n', 'E2\\tCombination:T12 arg:T5 arg2:T13']\n",
            "['T3\\tEffect 27 30\\tAVP\\n', 'T5\\tTreatment 75 85\\tinfliximab\\n', 'T7\\tTime_elapsed 31 42\\tthree weeks\\n', 'T8\\tDrug 75 85\\tinfliximab\\n', \"T9\\tTreat-Disorder 107 122\\tCrohn's disease\\n\", 'T10\\tSeverity_cue 20 26\\tsevere\\n', 'T4\\tAdverse_event 43 52\\tfollowing\\n', 'E1\\tAdverse_event:T4 \\n', 'A1\\tSeverity E1 High']\n",
            "['T5\\tTreatment 33 44\\tzafirlukast\\n', 'T6\\tEffect 89 159\\timpaired clearance of  S-warfarin and enhanced anti-thrombotic effects\\n', 'T8\\tSpeculation_cue 48 58\\tconsistent\\n', 'T9\\tDrug 33 44\\tzafirlukast\\n', 'T7\\tPotential_therapeutic_event 81 88\\tshowing\\n', 'E1\\tPotential_therapeutic_event:T7']\n",
            "[\"T3\\tEffect 15 33\\tPeyronie's disease\\n\", 'T6\\tDrug 51 61\\tcolchicine\\n', 'T7\\tFreq 41 50\\tlong-term\\n', 'T4\\tTreatment 41 71\\tlong-term colchicine treatment\\n', 'T5\\tAdverse_event 34 40\\tduring\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 118 190\\ta 29-year Nigerian female patient with generalized tonic-elonic seizures\\n', 'T4\\tEffect 14 52\\tsyndrome of inappropriate antidiuresis\\n', 'T5\\tTreatment 86 99\\tcarbamazepine\\n', 'T8\\tAge 120 127\\t29-year\\n', 'T9\\tRace 128 136\\tNigerian\\n', 'T10\\tGender 137 143\\tfemale\\n', 'T6\\tDrug 86 99\\tcarbamazepine\\n', 'T12\\tTime_elapsed 58 70\\tmuch earlier\\n', 'T13\\tTreat-Disorder 157 190\\tgeneralized tonic-elonic seizures\\n', 'T7\\tAdverse_event 71 82\\tside-effect\\n', 'E1\\tAdverse_event:T7']\n",
            "['T4\\tTreatment 91 133\\tanticalcineurinic drug (CyA or tacrolimus)\\n', 'T5\\tEffect 15 19\\tRSDS\\n', 'T8\\tDrug 115 118\\tCyA\\n', 'T9\\tDrug 122 132\\ttacrolimus\\n', 'T7\\tAdverse_event 34 61\\tosteoarticular complication\\n', 'E1\\tAdverse_event:T7']\n",
            "['T6\\tTreatment 48 58\\traloxifene\\n', 'T7\\tEffect 82 114\\tmalignant mixed mesodermal tumor\\n', 'T8\\tDrug 48 58\\traloxifene\\n', 'T9\\tSpeculation_cue 18 21\\tmay\\n', 'T5\\tAdverse_event 28 39\\tassociation\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T5\\tSubject 0 100\\tTwo children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis\\n', 'T6\\tEffect 126 158\\tseizures and transient blindness\\n', 'T8\\tTreatment 184 231\\ti.v. pulse methylprednisolone (IVPMP) treatment\\n', 'T9\\tPopulation 0 3\\tTwo\\n', 'T10\\tTreat-Disorder 21 50\\tidiopathic nephrotic syndrome\\n', 'T11\\tTreat-Disorder 62 101\\tendo-extracapillary glomerulonephritis,\\n', 'T12\\tDrug 195 213\\tmethylprednisolone\\n', 'T13\\tSeverity_cue 139 148\\ttransient\\n', 'T7\\tAdverse_event 178 183\\tafter\\n', 'E1\\tAdverse_event:T7 \\n', 'A1\\tSeverity E1 Low\\n', 'T1\\tRoute 184 194\\ti.v. pulse\\n']\n",
            "['T6\\tTreatment 37 86\\tlong-term therapy with the addition of citalopram\\n', 'T7\\tEffect 0 15\\tAdverse effects\\n', 'T9\\tDrug 19 30\\tpropafenone\\n', 'T10\\tTime_elapsed 37 46\\tlong-term\\n', 'T11\\tDrug 76 86\\tcitalopram\\n', 'T5\\tAdverse_event 31 36\\tafter\\n', 'T12\\tCombination 64 72\\taddition\\n', 'E1\\tAdverse_event:T5 \\n', 'E2\\tCombination:T12 arg:T11 arg2:T9']\n",
            "['T3\\tSubject 5 13\\tone case\\n', 'T4\\tEffect 17 45\\tsevere symptomatic hepatitis\\n', 'T5\\tTreat-Disorder 98 111\\tonychomycosis\\n', 'T7\\tTreatment 62 93\\tpulse therapy with itraconazole\\n', 'T9\\tPopulation 5 8\\tone\\n', 'T10\\tDrug 81 93\\titraconazole\\n', 'T6\\tAdverse_event 46 55\\toccurring\\n', 'E1\\tAdverse_event:T6']\n",
            "['T4\\tSubject 24 84\\ta 50-year-old woman with advanced non-small cell lung cancer\\n', 'T7\\tEffect 99 117\\tstatus epilepticus\\n', 'T8\\tTreatment 142 180\\tcisplatin and gemcitabine chemotherapy\\n', 'T9\\tAge 26 37\\t50-year-old\\n', 'T10\\tGender 38 43\\twoman\\n', 'T5\\tDrug 142 151\\tcisplatin\\n', 'T13\\tDrug 156 167\\tgemcitabine\\n', 'T14\\tTreat-Disorder 73 84\\tlung cancer\\n', 'T15\\tRoute 168 180\\tchemotherapy\\n', 'T6\\tAdverse_event 89 98\\tdeveloped\\n', 'T12\\tCombination 152 155\\tand\\n', 'E1\\tAdverse_event:T6 \\n', 'E2\\tCombination:T12 arg:T5 arg2:T13']\n",
            "['T3\\tEffect 27 30\\tAVP\\n', 'T5\\tTreatment 75 85\\tinfliximab\\n', 'T7\\tTime_elapsed 31 42\\tthree weeks\\n', 'T8\\tDrug 75 85\\tinfliximab\\n', \"T9\\tTreat-Disorder 107 122\\tCrohn's disease\\n\", 'T10\\tSeverity_cue 20 26\\tsevere\\n', 'T4\\tAdverse_event 43 52\\tfollowing\\n', 'E1\\tAdverse_event:T4 \\n', 'A1\\tSeverity E1 High']\n",
            "['T5\\tTreatment 33 44\\tzafirlukast\\n', 'T6\\tEffect 89 159\\timpaired clearance of  S-warfarin and enhanced anti-thrombotic effects\\n', 'T8\\tSpeculation_cue 48 58\\tconsistent\\n', 'T9\\tDrug 33 44\\tzafirlukast\\n', 'T7\\tPotential_therapeutic_event 81 88\\tshowing\\n', 'E1\\tPotential_therapeutic_event:T7']\n",
            "[\"T3\\tEffect 15 33\\tPeyronie's disease\\n\", 'T6\\tDrug 51 61\\tcolchicine\\n', 'T7\\tFreq 41 50\\tlong-term\\n', 'T4\\tTreatment 41 71\\tlong-term colchicine treatment\\n', 'T5\\tAdverse_event 34 40\\tduring\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 118 190\\ta 29-year Nigerian female patient with generalized tonic-elonic seizures\\n', 'T4\\tEffect 14 52\\tsyndrome of inappropriate antidiuresis\\n', 'T5\\tTreatment 86 99\\tcarbamazepine\\n', 'T8\\tAge 120 127\\t29-year\\n', 'T9\\tRace 128 136\\tNigerian\\n', 'T10\\tGender 137 143\\tfemale\\n', 'T6\\tDrug 86 99\\tcarbamazepine\\n', 'T12\\tTime_elapsed 58 70\\tmuch earlier\\n', 'T13\\tTreat-Disorder 157 190\\tgeneralized tonic-elonic seizures\\n', 'T7\\tAdverse_event 71 82\\tside-effect\\n', 'E1\\tAdverse_event:T7']\n",
            "['T4\\tTreatment 91 133\\tanticalcineurinic drug (CyA or tacrolimus)\\n', 'T5\\tEffect 15 19\\tRSDS\\n', 'T8\\tDrug 115 118\\tCyA\\n', 'T9\\tDrug 122 132\\ttacrolimus\\n', 'T7\\tAdverse_event 34 61\\tosteoarticular complication\\n', 'E1\\tAdverse_event:T7']\n",
            "['T6\\tTreatment 48 58\\traloxifene\\n', 'T7\\tEffect 82 114\\tmalignant mixed mesodermal tumor\\n', 'T8\\tDrug 48 58\\traloxifene\\n', 'T9\\tSpeculation_cue 18 21\\tmay\\n', 'T5\\tAdverse_event 28 39\\tassociation\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T5\\tSubject 0 100\\tTwo children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis\\n', 'T6\\tEffect 126 158\\tseizures and transient blindness\\n', 'T8\\tTreatment 184 231\\ti.v. pulse methylprednisolone (IVPMP) treatment\\n', 'T9\\tPopulation 0 3\\tTwo\\n', 'T10\\tTreat-Disorder 21 50\\tidiopathic nephrotic syndrome\\n', 'T11\\tTreat-Disorder 62 101\\tendo-extracapillary glomerulonephritis,\\n', 'T12\\tDrug 195 213\\tmethylprednisolone\\n', 'T13\\tSeverity_cue 139 148\\ttransient\\n', 'T7\\tAdverse_event 178 183\\tafter\\n', 'E1\\tAdverse_event:T7 \\n', 'A1\\tSeverity E1 Low\\n', 'T1\\tRoute 184 194\\ti.v. pulse\\n']\n",
            "['T6\\tTreatment 37 86\\tlong-term therapy with the addition of citalopram\\n', 'T7\\tEffect 0 15\\tAdverse effects\\n', 'T9\\tDrug 19 30\\tpropafenone\\n', 'T10\\tTime_elapsed 37 46\\tlong-term\\n', 'T11\\tDrug 76 86\\tcitalopram\\n', 'T5\\tAdverse_event 31 36\\tafter\\n', 'T12\\tCombination 64 72\\taddition\\n', 'E1\\tAdverse_event:T5 \\n', 'E2\\tCombination:T12 arg:T11 arg2:T9']\n",
            "['T3\\tSubject 5 13\\tone case\\n', 'T4\\tEffect 17 45\\tsevere symptomatic hepatitis\\n', 'T5\\tTreat-Disorder 98 111\\tonychomycosis\\n', 'T7\\tTreatment 62 93\\tpulse therapy with itraconazole\\n', 'T9\\tPopulation 5 8\\tone\\n', 'T10\\tDrug 81 93\\titraconazole\\n', 'T6\\tAdverse_event 46 55\\toccurring\\n', 'E1\\tAdverse_event:T6']\n",
            "['T4\\tSubject 24 84\\ta 50-year-old woman with advanced non-small cell lung cancer\\n', 'T7\\tEffect 99 117\\tstatus epilepticus\\n', 'T8\\tTreatment 142 180\\tcisplatin and gemcitabine chemotherapy\\n', 'T9\\tAge 26 37\\t50-year-old\\n', 'T10\\tGender 38 43\\twoman\\n', 'T5\\tDrug 142 151\\tcisplatin\\n', 'T13\\tDrug 156 167\\tgemcitabine\\n', 'T14\\tTreat-Disorder 73 84\\tlung cancer\\n', 'T15\\tRoute 168 180\\tchemotherapy\\n', 'T6\\tAdverse_event 89 98\\tdeveloped\\n', 'T12\\tCombination 152 155\\tand\\n', 'E1\\tAdverse_event:T6 \\n', 'E2\\tCombination:T12 arg:T5 arg2:T13']\n",
            "['T3\\tEffect 27 30\\tAVP\\n', 'T5\\tTreatment 75 85\\tinfliximab\\n', 'T7\\tTime_elapsed 31 42\\tthree weeks\\n', 'T8\\tDrug 75 85\\tinfliximab\\n', \"T9\\tTreat-Disorder 107 122\\tCrohn's disease\\n\", 'T10\\tSeverity_cue 20 26\\tsevere\\n', 'T4\\tAdverse_event 43 52\\tfollowing\\n', 'E1\\tAdverse_event:T4 \\n', 'A1\\tSeverity E1 High']\n",
            "['T5\\tTreatment 33 44\\tzafirlukast\\n', 'T6\\tEffect 89 159\\timpaired clearance of  S-warfarin and enhanced anti-thrombotic effects\\n', 'T8\\tSpeculation_cue 48 58\\tconsistent\\n', 'T9\\tDrug 33 44\\tzafirlukast\\n', 'T7\\tPotential_therapeutic_event 81 88\\tshowing\\n', 'E1\\tPotential_therapeutic_event:T7']\n",
            "[\"T3\\tEffect 15 33\\tPeyronie's disease\\n\", 'T6\\tDrug 51 61\\tcolchicine\\n', 'T7\\tFreq 41 50\\tlong-term\\n', 'T4\\tTreatment 41 71\\tlong-term colchicine treatment\\n', 'T5\\tAdverse_event 34 40\\tduring\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 118 190\\ta 29-year Nigerian female patient with generalized tonic-elonic seizures\\n', 'T4\\tEffect 14 52\\tsyndrome of inappropriate antidiuresis\\n', 'T5\\tTreatment 86 99\\tcarbamazepine\\n', 'T8\\tAge 120 127\\t29-year\\n', 'T9\\tRace 128 136\\tNigerian\\n', 'T10\\tGender 137 143\\tfemale\\n', 'T6\\tDrug 86 99\\tcarbamazepine\\n', 'T12\\tTime_elapsed 58 70\\tmuch earlier\\n', 'T13\\tTreat-Disorder 157 190\\tgeneralized tonic-elonic seizures\\n', 'T7\\tAdverse_event 71 82\\tside-effect\\n', 'E1\\tAdverse_event:T7']\n",
            "['T4\\tTreatment 91 133\\tanticalcineurinic drug (CyA or tacrolimus)\\n', 'T5\\tEffect 15 19\\tRSDS\\n', 'T8\\tDrug 115 118\\tCyA\\n', 'T9\\tDrug 122 132\\ttacrolimus\\n', 'T7\\tAdverse_event 34 61\\tosteoarticular complication\\n', 'E1\\tAdverse_event:T7']\n",
            "['T6\\tTreatment 48 58\\traloxifene\\n', 'T7\\tEffect 82 114\\tmalignant mixed mesodermal tumor\\n', 'T8\\tDrug 48 58\\traloxifene\\n', 'T9\\tSpeculation_cue 18 21\\tmay\\n', 'T5\\tAdverse_event 28 39\\tassociation\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T5\\tSubject 0 100\\tTwo children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis\\n', 'T6\\tEffect 126 158\\tseizures and transient blindness\\n', 'T8\\tTreatment 184 231\\ti.v. pulse methylprednisolone (IVPMP) treatment\\n', 'T9\\tPopulation 0 3\\tTwo\\n', 'T10\\tTreat-Disorder 21 50\\tidiopathic nephrotic syndrome\\n', 'T11\\tTreat-Disorder 62 101\\tendo-extracapillary glomerulonephritis,\\n', 'T12\\tDrug 195 213\\tmethylprednisolone\\n', 'T13\\tSeverity_cue 139 148\\ttransient\\n', 'T7\\tAdverse_event 178 183\\tafter\\n', 'E1\\tAdverse_event:T7 \\n', 'A1\\tSeverity E1 Low\\n', 'T1\\tRoute 184 194\\ti.v. pulse\\n']\n",
            "['T6\\tTreatment 37 86\\tlong-term therapy with the addition of citalopram\\n', 'T7\\tEffect 0 15\\tAdverse effects\\n', 'T9\\tDrug 19 30\\tpropafenone\\n', 'T10\\tTime_elapsed 37 46\\tlong-term\\n', 'T11\\tDrug 76 86\\tcitalopram\\n', 'T5\\tAdverse_event 31 36\\tafter\\n', 'T12\\tCombination 64 72\\taddition\\n', 'E1\\tAdverse_event:T5 \\n', 'E2\\tCombination:T12 arg:T11 arg2:T9']\n",
            "['T3\\tSubject 5 13\\tone case\\n', 'T4\\tEffect 17 45\\tsevere symptomatic hepatitis\\n', 'T5\\tTreat-Disorder 98 111\\tonychomycosis\\n', 'T7\\tTreatment 62 93\\tpulse therapy with itraconazole\\n', 'T9\\tPopulation 5 8\\tone\\n', 'T10\\tDrug 81 93\\titraconazole\\n', 'T6\\tAdverse_event 46 55\\toccurring\\n', 'E1\\tAdverse_event:T6']\n",
            "['T4\\tSubject 24 84\\ta 50-year-old woman with advanced non-small cell lung cancer\\n', 'T7\\tEffect 99 117\\tstatus epilepticus\\n', 'T8\\tTreatment 142 180\\tcisplatin and gemcitabine chemotherapy\\n', 'T9\\tAge 26 37\\t50-year-old\\n', 'T10\\tGender 38 43\\twoman\\n', 'T5\\tDrug 142 151\\tcisplatin\\n', 'T13\\tDrug 156 167\\tgemcitabine\\n', 'T14\\tTreat-Disorder 73 84\\tlung cancer\\n', 'T15\\tRoute 168 180\\tchemotherapy\\n', 'T6\\tAdverse_event 89 98\\tdeveloped\\n', 'T12\\tCombination 152 155\\tand\\n', 'E1\\tAdverse_event:T6 \\n', 'E2\\tCombination:T12 arg:T5 arg2:T13']\n",
            "['T3\\tEffect 27 30\\tAVP\\n', 'T5\\tTreatment 75 85\\tinfliximab\\n', 'T7\\tTime_elapsed 31 42\\tthree weeks\\n', 'T8\\tDrug 75 85\\tinfliximab\\n', \"T9\\tTreat-Disorder 107 122\\tCrohn's disease\\n\", 'T10\\tSeverity_cue 20 26\\tsevere\\n', 'T4\\tAdverse_event 43 52\\tfollowing\\n', 'E1\\tAdverse_event:T4 \\n', 'A1\\tSeverity E1 High']\n",
            "['T5\\tTreatment 33 44\\tzafirlukast\\n', 'T6\\tEffect 89 159\\timpaired clearance of  S-warfarin and enhanced anti-thrombotic effects\\n', 'T8\\tSpeculation_cue 48 58\\tconsistent\\n', 'T9\\tDrug 33 44\\tzafirlukast\\n', 'T7\\tPotential_therapeutic_event 81 88\\tshowing\\n', 'E1\\tPotential_therapeutic_event:T7']\n",
            "[\"T3\\tEffect 15 33\\tPeyronie's disease\\n\", 'T6\\tDrug 51 61\\tcolchicine\\n', 'T7\\tFreq 41 50\\tlong-term\\n', 'T4\\tTreatment 41 71\\tlong-term colchicine treatment\\n', 'T5\\tAdverse_event 34 40\\tduring\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 118 190\\ta 29-year Nigerian female patient with generalized tonic-elonic seizures\\n', 'T4\\tEffect 14 52\\tsyndrome of inappropriate antidiuresis\\n', 'T5\\tTreatment 86 99\\tcarbamazepine\\n', 'T8\\tAge 120 127\\t29-year\\n', 'T9\\tRace 128 136\\tNigerian\\n', 'T10\\tGender 137 143\\tfemale\\n', 'T6\\tDrug 86 99\\tcarbamazepine\\n', 'T12\\tTime_elapsed 58 70\\tmuch earlier\\n', 'T13\\tTreat-Disorder 157 190\\tgeneralized tonic-elonic seizures\\n', 'T7\\tAdverse_event 71 82\\tside-effect\\n', 'E1\\tAdverse_event:T7']\n",
            "['T4\\tTreatment 91 133\\tanticalcineurinic drug (CyA or tacrolimus)\\n', 'T5\\tEffect 15 19\\tRSDS\\n', 'T8\\tDrug 115 118\\tCyA\\n', 'T9\\tDrug 122 132\\ttacrolimus\\n', 'T7\\tAdverse_event 34 61\\tosteoarticular complication\\n', 'E1\\tAdverse_event:T7']\n",
            "['T6\\tTreatment 48 58\\traloxifene\\n', 'T7\\tEffect 82 114\\tmalignant mixed mesodermal tumor\\n', 'T8\\tDrug 48 58\\traloxifene\\n', 'T9\\tSpeculation_cue 18 21\\tmay\\n', 'T5\\tAdverse_event 28 39\\tassociation\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T5\\tSubject 0 100\\tTwo children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis\\n', 'T6\\tEffect 126 158\\tseizures and transient blindness\\n', 'T8\\tTreatment 184 231\\ti.v. pulse methylprednisolone (IVPMP) treatment\\n', 'T9\\tPopulation 0 3\\tTwo\\n', 'T10\\tTreat-Disorder 21 50\\tidiopathic nephrotic syndrome\\n', 'T11\\tTreat-Disorder 62 101\\tendo-extracapillary glomerulonephritis,\\n', 'T12\\tDrug 195 213\\tmethylprednisolone\\n', 'T13\\tSeverity_cue 139 148\\ttransient\\n', 'T7\\tAdverse_event 178 183\\tafter\\n', 'E1\\tAdverse_event:T7 \\n', 'A1\\tSeverity E1 Low\\n', 'T1\\tRoute 184 194\\ti.v. pulse\\n']\n",
            "['T6\\tTreatment 37 86\\tlong-term therapy with the addition of citalopram\\n', 'T7\\tEffect 0 15\\tAdverse effects\\n', 'T9\\tDrug 19 30\\tpropafenone\\n', 'T10\\tTime_elapsed 37 46\\tlong-term\\n', 'T11\\tDrug 76 86\\tcitalopram\\n', 'T5\\tAdverse_event 31 36\\tafter\\n', 'T12\\tCombination 64 72\\taddition\\n', 'E1\\tAdverse_event:T5 \\n', 'E2\\tCombination:T12 arg:T11 arg2:T9']\n",
            "['T3\\tSubject 5 13\\tone case\\n', 'T4\\tEffect 17 45\\tsevere symptomatic hepatitis\\n', 'T5\\tTreat-Disorder 98 111\\tonychomycosis\\n', 'T7\\tTreatment 62 93\\tpulse therapy with itraconazole\\n', 'T9\\tPopulation 5 8\\tone\\n', 'T10\\tDrug 81 93\\titraconazole\\n', 'T6\\tAdverse_event 46 55\\toccurring\\n', 'E1\\tAdverse_event:T6']\n",
            "['T4\\tSubject 24 84\\ta 50-year-old woman with advanced non-small cell lung cancer\\n', 'T7\\tEffect 99 117\\tstatus epilepticus\\n', 'T8\\tTreatment 142 180\\tcisplatin and gemcitabine chemotherapy\\n', 'T9\\tAge 26 37\\t50-year-old\\n', 'T10\\tGender 38 43\\twoman\\n', 'T5\\tDrug 142 151\\tcisplatin\\n', 'T13\\tDrug 156 167\\tgemcitabine\\n', 'T14\\tTreat-Disorder 73 84\\tlung cancer\\n', 'T15\\tRoute 168 180\\tchemotherapy\\n', 'T6\\tAdverse_event 89 98\\tdeveloped\\n', 'T12\\tCombination 152 155\\tand\\n', 'E1\\tAdverse_event:T6 \\n', 'E2\\tCombination:T12 arg:T5 arg2:T13']\n",
            "['T3\\tEffect 27 30\\tAVP\\n', 'T5\\tTreatment 75 85\\tinfliximab\\n', 'T7\\tTime_elapsed 31 42\\tthree weeks\\n', 'T8\\tDrug 75 85\\tinfliximab\\n', \"T9\\tTreat-Disorder 107 122\\tCrohn's disease\\n\", 'T10\\tSeverity_cue 20 26\\tsevere\\n', 'T4\\tAdverse_event 43 52\\tfollowing\\n', 'E1\\tAdverse_event:T4 \\n', 'A1\\tSeverity E1 High']\n",
            "['T5\\tTreatment 33 44\\tzafirlukast\\n', 'T6\\tEffect 89 159\\timpaired clearance of  S-warfarin and enhanced anti-thrombotic effects\\n', 'T8\\tSpeculation_cue 48 58\\tconsistent\\n', 'T9\\tDrug 33 44\\tzafirlukast\\n', 'T7\\tPotential_therapeutic_event 81 88\\tshowing\\n', 'E1\\tPotential_therapeutic_event:T7']\n",
            "[\"T3\\tEffect 15 33\\tPeyronie's disease\\n\", 'T6\\tDrug 51 61\\tcolchicine\\n', 'T7\\tFreq 41 50\\tlong-term\\n', 'T4\\tTreatment 41 71\\tlong-term colchicine treatment\\n', 'T5\\tAdverse_event 34 40\\tduring\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 118 190\\ta 29-year Nigerian female patient with generalized tonic-elonic seizures\\n', 'T4\\tEffect 14 52\\tsyndrome of inappropriate antidiuresis\\n', 'T5\\tTreatment 86 99\\tcarbamazepine\\n', 'T8\\tAge 120 127\\t29-year\\n', 'T9\\tRace 128 136\\tNigerian\\n', 'T10\\tGender 137 143\\tfemale\\n', 'T6\\tDrug 86 99\\tcarbamazepine\\n', 'T12\\tTime_elapsed 58 70\\tmuch earlier\\n', 'T13\\tTreat-Disorder 157 190\\tgeneralized tonic-elonic seizures\\n', 'T7\\tAdverse_event 71 82\\tside-effect\\n', 'E1\\tAdverse_event:T7']\n",
            "['T4\\tTreatment 91 133\\tanticalcineurinic drug (CyA or tacrolimus)\\n', 'T5\\tEffect 15 19\\tRSDS\\n', 'T8\\tDrug 115 118\\tCyA\\n', 'T9\\tDrug 122 132\\ttacrolimus\\n', 'T7\\tAdverse_event 34 61\\tosteoarticular complication\\n', 'E1\\tAdverse_event:T7']\n",
            "['T6\\tTreatment 48 58\\traloxifene\\n', 'T7\\tEffect 82 114\\tmalignant mixed mesodermal tumor\\n', 'T8\\tDrug 48 58\\traloxifene\\n', 'T9\\tSpeculation_cue 18 21\\tmay\\n', 'T5\\tAdverse_event 28 39\\tassociation\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T5\\tSubject 0 100\\tTwo children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis\\n', 'T6\\tEffect 126 158\\tseizures and transient blindness\\n', 'T8\\tTreatment 184 231\\ti.v. pulse methylprednisolone (IVPMP) treatment\\n', 'T9\\tPopulation 0 3\\tTwo\\n', 'T10\\tTreat-Disorder 21 50\\tidiopathic nephrotic syndrome\\n', 'T11\\tTreat-Disorder 62 101\\tendo-extracapillary glomerulonephritis,\\n', 'T12\\tDrug 195 213\\tmethylprednisolone\\n', 'T13\\tSeverity_cue 139 148\\ttransient\\n', 'T7\\tAdverse_event 178 183\\tafter\\n', 'E1\\tAdverse_event:T7 \\n', 'A1\\tSeverity E1 Low\\n', 'T1\\tRoute 184 194\\ti.v. pulse\\n']\n",
            "['T6\\tTreatment 37 86\\tlong-term therapy with the addition of citalopram\\n', 'T7\\tEffect 0 15\\tAdverse effects\\n', 'T9\\tDrug 19 30\\tpropafenone\\n', 'T10\\tTime_elapsed 37 46\\tlong-term\\n', 'T11\\tDrug 76 86\\tcitalopram\\n', 'T5\\tAdverse_event 31 36\\tafter\\n', 'T12\\tCombination 64 72\\taddition\\n', 'E1\\tAdverse_event:T5 \\n', 'E2\\tCombination:T12 arg:T11 arg2:T9']\n",
            "['T3\\tSubject 5 13\\tone case\\n', 'T4\\tEffect 17 45\\tsevere symptomatic hepatitis\\n', 'T5\\tTreat-Disorder 98 111\\tonychomycosis\\n', 'T7\\tTreatment 62 93\\tpulse therapy with itraconazole\\n', 'T9\\tPopulation 5 8\\tone\\n', 'T10\\tDrug 81 93\\titraconazole\\n', 'T6\\tAdverse_event 46 55\\toccurring\\n', 'E1\\tAdverse_event:T6']\n",
            "['T4\\tSubject 24 84\\ta 50-year-old woman with advanced non-small cell lung cancer\\n', 'T7\\tEffect 99 117\\tstatus epilepticus\\n', 'T8\\tTreatment 142 180\\tcisplatin and gemcitabine chemotherapy\\n', 'T9\\tAge 26 37\\t50-year-old\\n', 'T10\\tGender 38 43\\twoman\\n', 'T5\\tDrug 142 151\\tcisplatin\\n', 'T13\\tDrug 156 167\\tgemcitabine\\n', 'T14\\tTreat-Disorder 73 84\\tlung cancer\\n', 'T15\\tRoute 168 180\\tchemotherapy\\n', 'T6\\tAdverse_event 89 98\\tdeveloped\\n', 'T12\\tCombination 152 155\\tand\\n', 'E1\\tAdverse_event:T6 \\n', 'E2\\tCombination:T12 arg:T5 arg2:T13']\n",
            "['T3\\tEffect 27 30\\tAVP\\n', 'T5\\tTreatment 75 85\\tinfliximab\\n', 'T7\\tTime_elapsed 31 42\\tthree weeks\\n', 'T8\\tDrug 75 85\\tinfliximab\\n', \"T9\\tTreat-Disorder 107 122\\tCrohn's disease\\n\", 'T10\\tSeverity_cue 20 26\\tsevere\\n', 'T4\\tAdverse_event 43 52\\tfollowing\\n', 'E1\\tAdverse_event:T4 \\n', 'A1\\tSeverity E1 High']\n",
            "['T5\\tTreatment 33 44\\tzafirlukast\\n', 'T6\\tEffect 89 159\\timpaired clearance of  S-warfarin and enhanced anti-thrombotic effects\\n', 'T8\\tSpeculation_cue 48 58\\tconsistent\\n', 'T9\\tDrug 33 44\\tzafirlukast\\n', 'T7\\tPotential_therapeutic_event 81 88\\tshowing\\n', 'E1\\tPotential_therapeutic_event:T7']\n",
            "[\"T3\\tEffect 15 33\\tPeyronie's disease\\n\", 'T6\\tDrug 51 61\\tcolchicine\\n', 'T7\\tFreq 41 50\\tlong-term\\n', 'T4\\tTreatment 41 71\\tlong-term colchicine treatment\\n', 'T5\\tAdverse_event 34 40\\tduring\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 118 190\\ta 29-year Nigerian female patient with generalized tonic-elonic seizures\\n', 'T4\\tEffect 14 52\\tsyndrome of inappropriate antidiuresis\\n', 'T5\\tTreatment 86 99\\tcarbamazepine\\n', 'T8\\tAge 120 127\\t29-year\\n', 'T9\\tRace 128 136\\tNigerian\\n', 'T10\\tGender 137 143\\tfemale\\n', 'T6\\tDrug 86 99\\tcarbamazepine\\n', 'T12\\tTime_elapsed 58 70\\tmuch earlier\\n', 'T13\\tTreat-Disorder 157 190\\tgeneralized tonic-elonic seizures\\n', 'T7\\tAdverse_event 71 82\\tside-effect\\n', 'E1\\tAdverse_event:T7']\n",
            "['T4\\tTreatment 91 133\\tanticalcineurinic drug (CyA or tacrolimus)\\n', 'T5\\tEffect 15 19\\tRSDS\\n', 'T8\\tDrug 115 118\\tCyA\\n', 'T9\\tDrug 122 132\\ttacrolimus\\n', 'T7\\tAdverse_event 34 61\\tosteoarticular complication\\n', 'E1\\tAdverse_event:T7']\n",
            "['T6\\tTreatment 48 58\\traloxifene\\n', 'T7\\tEffect 82 114\\tmalignant mixed mesodermal tumor\\n', 'T8\\tDrug 48 58\\traloxifene\\n', 'T9\\tSpeculation_cue 18 21\\tmay\\n', 'T5\\tAdverse_event 28 39\\tassociation\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T5\\tSubject 0 100\\tTwo children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis\\n', 'T6\\tEffect 126 158\\tseizures and transient blindness\\n', 'T8\\tTreatment 184 231\\ti.v. pulse methylprednisolone (IVPMP) treatment\\n', 'T9\\tPopulation 0 3\\tTwo\\n', 'T10\\tTreat-Disorder 21 50\\tidiopathic nephrotic syndrome\\n', 'T11\\tTreat-Disorder 62 101\\tendo-extracapillary glomerulonephritis,\\n', 'T12\\tDrug 195 213\\tmethylprednisolone\\n', 'T13\\tSeverity_cue 139 148\\ttransient\\n', 'T7\\tAdverse_event 178 183\\tafter\\n', 'E1\\tAdverse_event:T7 \\n', 'A1\\tSeverity E1 Low\\n', 'T1\\tRoute 184 194\\ti.v. pulse\\n']\n",
            "['T6\\tTreatment 37 86\\tlong-term therapy with the addition of citalopram\\n', 'T7\\tEffect 0 15\\tAdverse effects\\n', 'T9\\tDrug 19 30\\tpropafenone\\n', 'T10\\tTime_elapsed 37 46\\tlong-term\\n', 'T11\\tDrug 76 86\\tcitalopram\\n', 'T5\\tAdverse_event 31 36\\tafter\\n', 'T12\\tCombination 64 72\\taddition\\n', 'E1\\tAdverse_event:T5 \\n', 'E2\\tCombination:T12 arg:T11 arg2:T9']\n",
            "['T3\\tSubject 5 13\\tone case\\n', 'T4\\tEffect 17 45\\tsevere symptomatic hepatitis\\n', 'T5\\tTreat-Disorder 98 111\\tonychomycosis\\n', 'T7\\tTreatment 62 93\\tpulse therapy with itraconazole\\n', 'T9\\tPopulation 5 8\\tone\\n', 'T10\\tDrug 81 93\\titraconazole\\n', 'T6\\tAdverse_event 46 55\\toccurring\\n', 'E1\\tAdverse_event:T6']\n",
            "['T4\\tSubject 24 84\\ta 50-year-old woman with advanced non-small cell lung cancer\\n', 'T7\\tEffect 99 117\\tstatus epilepticus\\n', 'T8\\tTreatment 142 180\\tcisplatin and gemcitabine chemotherapy\\n', 'T9\\tAge 26 37\\t50-year-old\\n', 'T10\\tGender 38 43\\twoman\\n', 'T5\\tDrug 142 151\\tcisplatin\\n', 'T13\\tDrug 156 167\\tgemcitabine\\n', 'T14\\tTreat-Disorder 73 84\\tlung cancer\\n', 'T15\\tRoute 168 180\\tchemotherapy\\n', 'T6\\tAdverse_event 89 98\\tdeveloped\\n', 'T12\\tCombination 152 155\\tand\\n', 'E1\\tAdverse_event:T6 \\n', 'E2\\tCombination:T12 arg:T5 arg2:T13']\n",
            "['T3\\tEffect 27 30\\tAVP\\n', 'T5\\tTreatment 75 85\\tinfliximab\\n', 'T7\\tTime_elapsed 31 42\\tthree weeks\\n', 'T8\\tDrug 75 85\\tinfliximab\\n', \"T9\\tTreat-Disorder 107 122\\tCrohn's disease\\n\", 'T10\\tSeverity_cue 20 26\\tsevere\\n', 'T4\\tAdverse_event 43 52\\tfollowing\\n', 'E1\\tAdverse_event:T4 \\n', 'A1\\tSeverity E1 High']\n",
            "['T5\\tTreatment 33 44\\tzafirlukast\\n', 'T6\\tEffect 89 159\\timpaired clearance of  S-warfarin and enhanced anti-thrombotic effects\\n', 'T8\\tSpeculation_cue 48 58\\tconsistent\\n', 'T9\\tDrug 33 44\\tzafirlukast\\n', 'T7\\tPotential_therapeutic_event 81 88\\tshowing\\n', 'E1\\tPotential_therapeutic_event:T7']\n",
            "[\"T3\\tEffect 15 33\\tPeyronie's disease\\n\", 'T6\\tDrug 51 61\\tcolchicine\\n', 'T7\\tFreq 41 50\\tlong-term\\n', 'T4\\tTreatment 41 71\\tlong-term colchicine treatment\\n', 'T5\\tAdverse_event 34 40\\tduring\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 118 190\\ta 29-year Nigerian female patient with generalized tonic-elonic seizures\\n', 'T4\\tEffect 14 52\\tsyndrome of inappropriate antidiuresis\\n', 'T5\\tTreatment 86 99\\tcarbamazepine\\n', 'T8\\tAge 120 127\\t29-year\\n', 'T9\\tRace 128 136\\tNigerian\\n', 'T10\\tGender 137 143\\tfemale\\n', 'T6\\tDrug 86 99\\tcarbamazepine\\n', 'T12\\tTime_elapsed 58 70\\tmuch earlier\\n', 'T13\\tTreat-Disorder 157 190\\tgeneralized tonic-elonic seizures\\n', 'T7\\tAdverse_event 71 82\\tside-effect\\n', 'E1\\tAdverse_event:T7']\n",
            "['T4\\tTreatment 91 133\\tanticalcineurinic drug (CyA or tacrolimus)\\n', 'T5\\tEffect 15 19\\tRSDS\\n', 'T8\\tDrug 115 118\\tCyA\\n', 'T9\\tDrug 122 132\\ttacrolimus\\n', 'T7\\tAdverse_event 34 61\\tosteoarticular complication\\n', 'E1\\tAdverse_event:T7']\n",
            "['T6\\tTreatment 48 58\\traloxifene\\n', 'T7\\tEffect 82 114\\tmalignant mixed mesodermal tumor\\n', 'T8\\tDrug 48 58\\traloxifene\\n', 'T9\\tSpeculation_cue 18 21\\tmay\\n', 'T5\\tAdverse_event 28 39\\tassociation\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T5\\tSubject 0 100\\tTwo children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis\\n', 'T6\\tEffect 126 158\\tseizures and transient blindness\\n', 'T8\\tTreatment 184 231\\ti.v. pulse methylprednisolone (IVPMP) treatment\\n', 'T9\\tPopulation 0 3\\tTwo\\n', 'T10\\tTreat-Disorder 21 50\\tidiopathic nephrotic syndrome\\n', 'T11\\tTreat-Disorder 62 101\\tendo-extracapillary glomerulonephritis,\\n', 'T12\\tDrug 195 213\\tmethylprednisolone\\n', 'T13\\tSeverity_cue 139 148\\ttransient\\n', 'T7\\tAdverse_event 178 183\\tafter\\n', 'E1\\tAdverse_event:T7 \\n', 'A1\\tSeverity E1 Low\\n', 'T1\\tRoute 184 194\\ti.v. pulse\\n']\n",
            "['T6\\tTreatment 37 86\\tlong-term therapy with the addition of citalopram\\n', 'T7\\tEffect 0 15\\tAdverse effects\\n', 'T9\\tDrug 19 30\\tpropafenone\\n', 'T10\\tTime_elapsed 37 46\\tlong-term\\n', 'T11\\tDrug 76 86\\tcitalopram\\n', 'T5\\tAdverse_event 31 36\\tafter\\n', 'T12\\tCombination 64 72\\taddition\\n', 'E1\\tAdverse_event:T5 \\n', 'E2\\tCombination:T12 arg:T11 arg2:T9']\n",
            "['T3\\tSubject 5 13\\tone case\\n', 'T4\\tEffect 17 45\\tsevere symptomatic hepatitis\\n', 'T5\\tTreat-Disorder 98 111\\tonychomycosis\\n', 'T7\\tTreatment 62 93\\tpulse therapy with itraconazole\\n', 'T9\\tPopulation 5 8\\tone\\n', 'T10\\tDrug 81 93\\titraconazole\\n', 'T6\\tAdverse_event 46 55\\toccurring\\n', 'E1\\tAdverse_event:T6']\n",
            "['T4\\tSubject 24 84\\ta 50-year-old woman with advanced non-small cell lung cancer\\n', 'T7\\tEffect 99 117\\tstatus epilepticus\\n', 'T8\\tTreatment 142 180\\tcisplatin and gemcitabine chemotherapy\\n', 'T9\\tAge 26 37\\t50-year-old\\n', 'T10\\tGender 38 43\\twoman\\n', 'T5\\tDrug 142 151\\tcisplatin\\n', 'T13\\tDrug 156 167\\tgemcitabine\\n', 'T14\\tTreat-Disorder 73 84\\tlung cancer\\n', 'T15\\tRoute 168 180\\tchemotherapy\\n', 'T6\\tAdverse_event 89 98\\tdeveloped\\n', 'T12\\tCombination 152 155\\tand\\n', 'E1\\tAdverse_event:T6 \\n', 'E2\\tCombination:T12 arg:T5 arg2:T13']\n",
            "['T3\\tEffect 27 30\\tAVP\\n', 'T5\\tTreatment 75 85\\tinfliximab\\n', 'T7\\tTime_elapsed 31 42\\tthree weeks\\n', 'T8\\tDrug 75 85\\tinfliximab\\n', \"T9\\tTreat-Disorder 107 122\\tCrohn's disease\\n\", 'T10\\tSeverity_cue 20 26\\tsevere\\n', 'T4\\tAdverse_event 43 52\\tfollowing\\n', 'E1\\tAdverse_event:T4 \\n', 'A1\\tSeverity E1 High']\n",
            "['T5\\tTreatment 33 44\\tzafirlukast\\n', 'T6\\tEffect 89 159\\timpaired clearance of  S-warfarin and enhanced anti-thrombotic effects\\n', 'T8\\tSpeculation_cue 48 58\\tconsistent\\n', 'T9\\tDrug 33 44\\tzafirlukast\\n', 'T7\\tPotential_therapeutic_event 81 88\\tshowing\\n', 'E1\\tPotential_therapeutic_event:T7']\n",
            "[\"T3\\tEffect 15 33\\tPeyronie's disease\\n\", 'T6\\tDrug 51 61\\tcolchicine\\n', 'T7\\tFreq 41 50\\tlong-term\\n', 'T4\\tTreatment 41 71\\tlong-term colchicine treatment\\n', 'T5\\tAdverse_event 34 40\\tduring\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 118 190\\ta 29-year Nigerian female patient with generalized tonic-elonic seizures\\n', 'T4\\tEffect 14 52\\tsyndrome of inappropriate antidiuresis\\n', 'T5\\tTreatment 86 99\\tcarbamazepine\\n', 'T8\\tAge 120 127\\t29-year\\n', 'T9\\tRace 128 136\\tNigerian\\n', 'T10\\tGender 137 143\\tfemale\\n', 'T6\\tDrug 86 99\\tcarbamazepine\\n', 'T12\\tTime_elapsed 58 70\\tmuch earlier\\n', 'T13\\tTreat-Disorder 157 190\\tgeneralized tonic-elonic seizures\\n', 'T7\\tAdverse_event 71 82\\tside-effect\\n', 'E1\\tAdverse_event:T7']\n",
            "['T4\\tTreatment 91 133\\tanticalcineurinic drug (CyA or tacrolimus)\\n', 'T5\\tEffect 15 19\\tRSDS\\n', 'T8\\tDrug 115 118\\tCyA\\n', 'T9\\tDrug 122 132\\ttacrolimus\\n', 'T7\\tAdverse_event 34 61\\tosteoarticular complication\\n', 'E1\\tAdverse_event:T7']\n",
            "['T6\\tTreatment 48 58\\traloxifene\\n', 'T7\\tEffect 82 114\\tmalignant mixed mesodermal tumor\\n', 'T8\\tDrug 48 58\\traloxifene\\n', 'T9\\tSpeculation_cue 18 21\\tmay\\n', 'T5\\tAdverse_event 28 39\\tassociation\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T5\\tSubject 0 100\\tTwo children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis\\n', 'T6\\tEffect 126 158\\tseizures and transient blindness\\n', 'T8\\tTreatment 184 231\\ti.v. pulse methylprednisolone (IVPMP) treatment\\n', 'T9\\tPopulation 0 3\\tTwo\\n', 'T10\\tTreat-Disorder 21 50\\tidiopathic nephrotic syndrome\\n', 'T11\\tTreat-Disorder 62 101\\tendo-extracapillary glomerulonephritis,\\n', 'T12\\tDrug 195 213\\tmethylprednisolone\\n', 'T13\\tSeverity_cue 139 148\\ttransient\\n', 'T7\\tAdverse_event 178 183\\tafter\\n', 'E1\\tAdverse_event:T7 \\n', 'A1\\tSeverity E1 Low\\n', 'T1\\tRoute 184 194\\ti.v. pulse\\n']\n",
            "['T6\\tTreatment 37 86\\tlong-term therapy with the addition of citalopram\\n', 'T7\\tEffect 0 15\\tAdverse effects\\n', 'T9\\tDrug 19 30\\tpropafenone\\n', 'T10\\tTime_elapsed 37 46\\tlong-term\\n', 'T11\\tDrug 76 86\\tcitalopram\\n', 'T5\\tAdverse_event 31 36\\tafter\\n', 'T12\\tCombination 64 72\\taddition\\n', 'E1\\tAdverse_event:T5 \\n', 'E2\\tCombination:T12 arg:T11 arg2:T9']\n",
            "['T3\\tSubject 5 13\\tone case\\n', 'T4\\tEffect 17 45\\tsevere symptomatic hepatitis\\n', 'T5\\tTreat-Disorder 98 111\\tonychomycosis\\n', 'T7\\tTreatment 62 93\\tpulse therapy with itraconazole\\n', 'T9\\tPopulation 5 8\\tone\\n', 'T10\\tDrug 81 93\\titraconazole\\n', 'T6\\tAdverse_event 46 55\\toccurring\\n', 'E1\\tAdverse_event:T6']\n",
            "['T4\\tSubject 24 84\\ta 50-year-old woman with advanced non-small cell lung cancer\\n', 'T7\\tEffect 99 117\\tstatus epilepticus\\n', 'T8\\tTreatment 142 180\\tcisplatin and gemcitabine chemotherapy\\n', 'T9\\tAge 26 37\\t50-year-old\\n', 'T10\\tGender 38 43\\twoman\\n', 'T5\\tDrug 142 151\\tcisplatin\\n', 'T13\\tDrug 156 167\\tgemcitabine\\n', 'T14\\tTreat-Disorder 73 84\\tlung cancer\\n', 'T15\\tRoute 168 180\\tchemotherapy\\n', 'T6\\tAdverse_event 89 98\\tdeveloped\\n', 'T12\\tCombination 152 155\\tand\\n', 'E1\\tAdverse_event:T6 \\n', 'E2\\tCombination:T12 arg:T5 arg2:T13']\n",
            "['T3\\tEffect 27 30\\tAVP\\n', 'T5\\tTreatment 75 85\\tinfliximab\\n', 'T7\\tTime_elapsed 31 42\\tthree weeks\\n', 'T8\\tDrug 75 85\\tinfliximab\\n', \"T9\\tTreat-Disorder 107 122\\tCrohn's disease\\n\", 'T10\\tSeverity_cue 20 26\\tsevere\\n', 'T4\\tAdverse_event 43 52\\tfollowing\\n', 'E1\\tAdverse_event:T4 \\n', 'A1\\tSeverity E1 High']\n",
            "['T5\\tTreatment 33 44\\tzafirlukast\\n', 'T6\\tEffect 89 159\\timpaired clearance of  S-warfarin and enhanced anti-thrombotic effects\\n', 'T8\\tSpeculation_cue 48 58\\tconsistent\\n', 'T9\\tDrug 33 44\\tzafirlukast\\n', 'T7\\tPotential_therapeutic_event 81 88\\tshowing\\n', 'E1\\tPotential_therapeutic_event:T7']\n",
            "[\"T3\\tEffect 15 33\\tPeyronie's disease\\n\", 'T6\\tDrug 51 61\\tcolchicine\\n', 'T7\\tFreq 41 50\\tlong-term\\n', 'T4\\tTreatment 41 71\\tlong-term colchicine treatment\\n', 'T5\\tAdverse_event 34 40\\tduring\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 118 190\\ta 29-year Nigerian female patient with generalized tonic-elonic seizures\\n', 'T4\\tEffect 14 52\\tsyndrome of inappropriate antidiuresis\\n', 'T5\\tTreatment 86 99\\tcarbamazepine\\n', 'T8\\tAge 120 127\\t29-year\\n', 'T9\\tRace 128 136\\tNigerian\\n', 'T10\\tGender 137 143\\tfemale\\n', 'T6\\tDrug 86 99\\tcarbamazepine\\n', 'T12\\tTime_elapsed 58 70\\tmuch earlier\\n', 'T13\\tTreat-Disorder 157 190\\tgeneralized tonic-elonic seizures\\n', 'T7\\tAdverse_event 71 82\\tside-effect\\n', 'E1\\tAdverse_event:T7']\n",
            "['T4\\tTreatment 91 133\\tanticalcineurinic drug (CyA or tacrolimus)\\n', 'T5\\tEffect 15 19\\tRSDS\\n', 'T8\\tDrug 115 118\\tCyA\\n', 'T9\\tDrug 122 132\\ttacrolimus\\n', 'T7\\tAdverse_event 34 61\\tosteoarticular complication\\n', 'E1\\tAdverse_event:T7']\n",
            "['T6\\tTreatment 48 58\\traloxifene\\n', 'T7\\tEffect 82 114\\tmalignant mixed mesodermal tumor\\n', 'T8\\tDrug 48 58\\traloxifene\\n', 'T9\\tSpeculation_cue 18 21\\tmay\\n', 'T5\\tAdverse_event 28 39\\tassociation\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T5\\tSubject 0 100\\tTwo children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis\\n', 'T6\\tEffect 126 158\\tseizures and transient blindness\\n', 'T8\\tTreatment 184 231\\ti.v. pulse methylprednisolone (IVPMP) treatment\\n', 'T9\\tPopulation 0 3\\tTwo\\n', 'T10\\tTreat-Disorder 21 50\\tidiopathic nephrotic syndrome\\n', 'T11\\tTreat-Disorder 62 101\\tendo-extracapillary glomerulonephritis,\\n', 'T12\\tDrug 195 213\\tmethylprednisolone\\n', 'T13\\tSeverity_cue 139 148\\ttransient\\n', 'T7\\tAdverse_event 178 183\\tafter\\n', 'E1\\tAdverse_event:T7 \\n', 'A1\\tSeverity E1 Low\\n', 'T1\\tRoute 184 194\\ti.v. pulse\\n']\n",
            "['T6\\tTreatment 37 86\\tlong-term therapy with the addition of citalopram\\n', 'T7\\tEffect 0 15\\tAdverse effects\\n', 'T9\\tDrug 19 30\\tpropafenone\\n', 'T10\\tTime_elapsed 37 46\\tlong-term\\n', 'T11\\tDrug 76 86\\tcitalopram\\n', 'T5\\tAdverse_event 31 36\\tafter\\n', 'T12\\tCombination 64 72\\taddition\\n', 'E1\\tAdverse_event:T5 \\n', 'E2\\tCombination:T12 arg:T11 arg2:T9']\n",
            "['T3\\tSubject 5 13\\tone case\\n', 'T4\\tEffect 17 45\\tsevere symptomatic hepatitis\\n', 'T5\\tTreat-Disorder 98 111\\tonychomycosis\\n', 'T7\\tTreatment 62 93\\tpulse therapy with itraconazole\\n', 'T9\\tPopulation 5 8\\tone\\n', 'T10\\tDrug 81 93\\titraconazole\\n', 'T6\\tAdverse_event 46 55\\toccurring\\n', 'E1\\tAdverse_event:T6']\n",
            "['T4\\tSubject 24 84\\ta 50-year-old woman with advanced non-small cell lung cancer\\n', 'T7\\tEffect 99 117\\tstatus epilepticus\\n', 'T8\\tTreatment 142 180\\tcisplatin and gemcitabine chemotherapy\\n', 'T9\\tAge 26 37\\t50-year-old\\n', 'T10\\tGender 38 43\\twoman\\n', 'T5\\tDrug 142 151\\tcisplatin\\n', 'T13\\tDrug 156 167\\tgemcitabine\\n', 'T14\\tTreat-Disorder 73 84\\tlung cancer\\n', 'T15\\tRoute 168 180\\tchemotherapy\\n', 'T6\\tAdverse_event 89 98\\tdeveloped\\n', 'T12\\tCombination 152 155\\tand\\n', 'E1\\tAdverse_event:T6 \\n', 'E2\\tCombination:T12 arg:T5 arg2:T13']\n",
            "['T3\\tEffect 27 30\\tAVP\\n', 'T5\\tTreatment 75 85\\tinfliximab\\n', 'T7\\tTime_elapsed 31 42\\tthree weeks\\n', 'T8\\tDrug 75 85\\tinfliximab\\n', \"T9\\tTreat-Disorder 107 122\\tCrohn's disease\\n\", 'T10\\tSeverity_cue 20 26\\tsevere\\n', 'T4\\tAdverse_event 43 52\\tfollowing\\n', 'E1\\tAdverse_event:T4 \\n', 'A1\\tSeverity E1 High']\n",
            "['T5\\tTreatment 33 44\\tzafirlukast\\n', 'T6\\tEffect 89 159\\timpaired clearance of  S-warfarin and enhanced anti-thrombotic effects\\n', 'T8\\tSpeculation_cue 48 58\\tconsistent\\n', 'T9\\tDrug 33 44\\tzafirlukast\\n', 'T7\\tPotential_therapeutic_event 81 88\\tshowing\\n', 'E1\\tPotential_therapeutic_event:T7']\n",
            "[\"T3\\tEffect 15 33\\tPeyronie's disease\\n\", 'T6\\tDrug 51 61\\tcolchicine\\n', 'T7\\tFreq 41 50\\tlong-term\\n', 'T4\\tTreatment 41 71\\tlong-term colchicine treatment\\n', 'T5\\tAdverse_event 34 40\\tduring\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 118 190\\ta 29-year Nigerian female patient with generalized tonic-elonic seizures\\n', 'T4\\tEffect 14 52\\tsyndrome of inappropriate antidiuresis\\n', 'T5\\tTreatment 86 99\\tcarbamazepine\\n', 'T8\\tAge 120 127\\t29-year\\n', 'T9\\tRace 128 136\\tNigerian\\n', 'T10\\tGender 137 143\\tfemale\\n', 'T6\\tDrug 86 99\\tcarbamazepine\\n', 'T12\\tTime_elapsed 58 70\\tmuch earlier\\n', 'T13\\tTreat-Disorder 157 190\\tgeneralized tonic-elonic seizures\\n', 'T7\\tAdverse_event 71 82\\tside-effect\\n', 'E1\\tAdverse_event:T7']\n",
            "['T4\\tTreatment 91 133\\tanticalcineurinic drug (CyA or tacrolimus)\\n', 'T5\\tEffect 15 19\\tRSDS\\n', 'T8\\tDrug 115 118\\tCyA\\n', 'T9\\tDrug 122 132\\ttacrolimus\\n', 'T7\\tAdverse_event 34 61\\tosteoarticular complication\\n', 'E1\\tAdverse_event:T7']\n",
            "['T6\\tTreatment 48 58\\traloxifene\\n', 'T7\\tEffect 82 114\\tmalignant mixed mesodermal tumor\\n', 'T8\\tDrug 48 58\\traloxifene\\n', 'T9\\tSpeculation_cue 18 21\\tmay\\n', 'T5\\tAdverse_event 28 39\\tassociation\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T5\\tSubject 0 100\\tTwo children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis\\n', 'T6\\tEffect 126 158\\tseizures and transient blindness\\n', 'T8\\tTreatment 184 231\\ti.v. pulse methylprednisolone (IVPMP) treatment\\n', 'T9\\tPopulation 0 3\\tTwo\\n', 'T10\\tTreat-Disorder 21 50\\tidiopathic nephrotic syndrome\\n', 'T11\\tTreat-Disorder 62 101\\tendo-extracapillary glomerulonephritis,\\n', 'T12\\tDrug 195 213\\tmethylprednisolone\\n', 'T13\\tSeverity_cue 139 148\\ttransient\\n', 'T7\\tAdverse_event 178 183\\tafter\\n', 'E1\\tAdverse_event:T7 \\n', 'A1\\tSeverity E1 Low\\n', 'T1\\tRoute 184 194\\ti.v. pulse\\n']\n",
            "['T6\\tTreatment 37 86\\tlong-term therapy with the addition of citalopram\\n', 'T7\\tEffect 0 15\\tAdverse effects\\n', 'T9\\tDrug 19 30\\tpropafenone\\n', 'T10\\tTime_elapsed 37 46\\tlong-term\\n', 'T11\\tDrug 76 86\\tcitalopram\\n', 'T5\\tAdverse_event 31 36\\tafter\\n', 'T12\\tCombination 64 72\\taddition\\n', 'E1\\tAdverse_event:T5 \\n', 'E2\\tCombination:T12 arg:T11 arg2:T9']\n",
            "['T3\\tSubject 5 13\\tone case\\n', 'T4\\tEffect 17 45\\tsevere symptomatic hepatitis\\n', 'T5\\tTreat-Disorder 98 111\\tonychomycosis\\n', 'T7\\tTreatment 62 93\\tpulse therapy with itraconazole\\n', 'T9\\tPopulation 5 8\\tone\\n', 'T10\\tDrug 81 93\\titraconazole\\n', 'T6\\tAdverse_event 46 55\\toccurring\\n', 'E1\\tAdverse_event:T6']\n",
            "['T4\\tSubject 24 84\\ta 50-year-old woman with advanced non-small cell lung cancer\\n', 'T7\\tEffect 99 117\\tstatus epilepticus\\n', 'T8\\tTreatment 142 180\\tcisplatin and gemcitabine chemotherapy\\n', 'T9\\tAge 26 37\\t50-year-old\\n', 'T10\\tGender 38 43\\twoman\\n', 'T5\\tDrug 142 151\\tcisplatin\\n', 'T13\\tDrug 156 167\\tgemcitabine\\n', 'T14\\tTreat-Disorder 73 84\\tlung cancer\\n', 'T15\\tRoute 168 180\\tchemotherapy\\n', 'T6\\tAdverse_event 89 98\\tdeveloped\\n', 'T12\\tCombination 152 155\\tand\\n', 'E1\\tAdverse_event:T6 \\n', 'E2\\tCombination:T12 arg:T5 arg2:T13']\n",
            "['T3\\tEffect 27 30\\tAVP\\n', 'T5\\tTreatment 75 85\\tinfliximab\\n', 'T7\\tTime_elapsed 31 42\\tthree weeks\\n', 'T8\\tDrug 75 85\\tinfliximab\\n', \"T9\\tTreat-Disorder 107 122\\tCrohn's disease\\n\", 'T10\\tSeverity_cue 20 26\\tsevere\\n', 'T4\\tAdverse_event 43 52\\tfollowing\\n', 'E1\\tAdverse_event:T4 \\n', 'A1\\tSeverity E1 High']\n",
            "['T5\\tTreatment 33 44\\tzafirlukast\\n', 'T6\\tEffect 89 159\\timpaired clearance of  S-warfarin and enhanced anti-thrombotic effects\\n', 'T8\\tSpeculation_cue 48 58\\tconsistent\\n', 'T9\\tDrug 33 44\\tzafirlukast\\n', 'T7\\tPotential_therapeutic_event 81 88\\tshowing\\n', 'E1\\tPotential_therapeutic_event:T7']\n",
            "[\"T3\\tEffect 15 33\\tPeyronie's disease\\n\", 'T6\\tDrug 51 61\\tcolchicine\\n', 'T7\\tFreq 41 50\\tlong-term\\n', 'T4\\tTreatment 41 71\\tlong-term colchicine treatment\\n', 'T5\\tAdverse_event 34 40\\tduring\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 118 190\\ta 29-year Nigerian female patient with generalized tonic-elonic seizures\\n', 'T4\\tEffect 14 52\\tsyndrome of inappropriate antidiuresis\\n', 'T5\\tTreatment 86 99\\tcarbamazepine\\n', 'T8\\tAge 120 127\\t29-year\\n', 'T9\\tRace 128 136\\tNigerian\\n', 'T10\\tGender 137 143\\tfemale\\n', 'T6\\tDrug 86 99\\tcarbamazepine\\n', 'T12\\tTime_elapsed 58 70\\tmuch earlier\\n', 'T13\\tTreat-Disorder 157 190\\tgeneralized tonic-elonic seizures\\n', 'T7\\tAdverse_event 71 82\\tside-effect\\n', 'E1\\tAdverse_event:T7']\n",
            "['T4\\tTreatment 91 133\\tanticalcineurinic drug (CyA or tacrolimus)\\n', 'T5\\tEffect 15 19\\tRSDS\\n', 'T8\\tDrug 115 118\\tCyA\\n', 'T9\\tDrug 122 132\\ttacrolimus\\n', 'T7\\tAdverse_event 34 61\\tosteoarticular complication\\n', 'E1\\tAdverse_event:T7']\n",
            "['T6\\tTreatment 48 58\\traloxifene\\n', 'T7\\tEffect 82 114\\tmalignant mixed mesodermal tumor\\n', 'T8\\tDrug 48 58\\traloxifene\\n', 'T9\\tSpeculation_cue 18 21\\tmay\\n', 'T5\\tAdverse_event 28 39\\tassociation\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T5\\tSubject 0 100\\tTwo children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis\\n', 'T6\\tEffect 126 158\\tseizures and transient blindness\\n', 'T8\\tTreatment 184 231\\ti.v. pulse methylprednisolone (IVPMP) treatment\\n', 'T9\\tPopulation 0 3\\tTwo\\n', 'T10\\tTreat-Disorder 21 50\\tidiopathic nephrotic syndrome\\n', 'T11\\tTreat-Disorder 62 101\\tendo-extracapillary glomerulonephritis,\\n', 'T12\\tDrug 195 213\\tmethylprednisolone\\n', 'T13\\tSeverity_cue 139 148\\ttransient\\n', 'T7\\tAdverse_event 178 183\\tafter\\n', 'E1\\tAdverse_event:T7 \\n', 'A1\\tSeverity E1 Low\\n', 'T1\\tRoute 184 194\\ti.v. pulse\\n']\n",
            "['T6\\tTreatment 37 86\\tlong-term therapy with the addition of citalopram\\n', 'T7\\tEffect 0 15\\tAdverse effects\\n', 'T9\\tDrug 19 30\\tpropafenone\\n', 'T10\\tTime_elapsed 37 46\\tlong-term\\n', 'T11\\tDrug 76 86\\tcitalopram\\n', 'T5\\tAdverse_event 31 36\\tafter\\n', 'T12\\tCombination 64 72\\taddition\\n', 'E1\\tAdverse_event:T5 \\n', 'E2\\tCombination:T12 arg:T11 arg2:T9']\n",
            "['T3\\tSubject 5 13\\tone case\\n', 'T4\\tEffect 17 45\\tsevere symptomatic hepatitis\\n', 'T5\\tTreat-Disorder 98 111\\tonychomycosis\\n', 'T7\\tTreatment 62 93\\tpulse therapy with itraconazole\\n', 'T9\\tPopulation 5 8\\tone\\n', 'T10\\tDrug 81 93\\titraconazole\\n', 'T6\\tAdverse_event 46 55\\toccurring\\n', 'E1\\tAdverse_event:T6']\n",
            "['T4\\tSubject 24 84\\ta 50-year-old woman with advanced non-small cell lung cancer\\n', 'T7\\tEffect 99 117\\tstatus epilepticus\\n', 'T8\\tTreatment 142 180\\tcisplatin and gemcitabine chemotherapy\\n', 'T9\\tAge 26 37\\t50-year-old\\n', 'T10\\tGender 38 43\\twoman\\n', 'T5\\tDrug 142 151\\tcisplatin\\n', 'T13\\tDrug 156 167\\tgemcitabine\\n', 'T14\\tTreat-Disorder 73 84\\tlung cancer\\n', 'T15\\tRoute 168 180\\tchemotherapy\\n', 'T6\\tAdverse_event 89 98\\tdeveloped\\n', 'T12\\tCombination 152 155\\tand\\n', 'E1\\tAdverse_event:T6 \\n', 'E2\\tCombination:T12 arg:T5 arg2:T13']\n",
            "['T3\\tEffect 27 30\\tAVP\\n', 'T5\\tTreatment 75 85\\tinfliximab\\n', 'T7\\tTime_elapsed 31 42\\tthree weeks\\n', 'T8\\tDrug 75 85\\tinfliximab\\n', \"T9\\tTreat-Disorder 107 122\\tCrohn's disease\\n\", 'T10\\tSeverity_cue 20 26\\tsevere\\n', 'T4\\tAdverse_event 43 52\\tfollowing\\n', 'E1\\tAdverse_event:T4 \\n', 'A1\\tSeverity E1 High']\n",
            "['T5\\tTreatment 33 44\\tzafirlukast\\n', 'T6\\tEffect 89 159\\timpaired clearance of  S-warfarin and enhanced anti-thrombotic effects\\n', 'T8\\tSpeculation_cue 48 58\\tconsistent\\n', 'T9\\tDrug 33 44\\tzafirlukast\\n', 'T7\\tPotential_therapeutic_event 81 88\\tshowing\\n', 'E1\\tPotential_therapeutic_event:T7']\n",
            "[\"T3\\tEffect 15 33\\tPeyronie's disease\\n\", 'T6\\tDrug 51 61\\tcolchicine\\n', 'T7\\tFreq 41 50\\tlong-term\\n', 'T4\\tTreatment 41 71\\tlong-term colchicine treatment\\n', 'T5\\tAdverse_event 34 40\\tduring\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 118 190\\ta 29-year Nigerian female patient with generalized tonic-elonic seizures\\n', 'T4\\tEffect 14 52\\tsyndrome of inappropriate antidiuresis\\n', 'T5\\tTreatment 86 99\\tcarbamazepine\\n', 'T8\\tAge 120 127\\t29-year\\n', 'T9\\tRace 128 136\\tNigerian\\n', 'T10\\tGender 137 143\\tfemale\\n', 'T6\\tDrug 86 99\\tcarbamazepine\\n', 'T12\\tTime_elapsed 58 70\\tmuch earlier\\n', 'T13\\tTreat-Disorder 157 190\\tgeneralized tonic-elonic seizures\\n', 'T7\\tAdverse_event 71 82\\tside-effect\\n', 'E1\\tAdverse_event:T7']\n",
            "['T4\\tTreatment 91 133\\tanticalcineurinic drug (CyA or tacrolimus)\\n', 'T5\\tEffect 15 19\\tRSDS\\n', 'T8\\tDrug 115 118\\tCyA\\n', 'T9\\tDrug 122 132\\ttacrolimus\\n', 'T7\\tAdverse_event 34 61\\tosteoarticular complication\\n', 'E1\\tAdverse_event:T7']\n",
            "['T6\\tTreatment 48 58\\traloxifene\\n', 'T7\\tEffect 82 114\\tmalignant mixed mesodermal tumor\\n', 'T8\\tDrug 48 58\\traloxifene\\n', 'T9\\tSpeculation_cue 18 21\\tmay\\n', 'T5\\tAdverse_event 28 39\\tassociation\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T5\\tSubject 0 100\\tTwo children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis\\n', 'T6\\tEffect 126 158\\tseizures and transient blindness\\n', 'T8\\tTreatment 184 231\\ti.v. pulse methylprednisolone (IVPMP) treatment\\n', 'T9\\tPopulation 0 3\\tTwo\\n', 'T10\\tTreat-Disorder 21 50\\tidiopathic nephrotic syndrome\\n', 'T11\\tTreat-Disorder 62 101\\tendo-extracapillary glomerulonephritis,\\n', 'T12\\tDrug 195 213\\tmethylprednisolone\\n', 'T13\\tSeverity_cue 139 148\\ttransient\\n', 'T7\\tAdverse_event 178 183\\tafter\\n', 'E1\\tAdverse_event:T7 \\n', 'A1\\tSeverity E1 Low\\n', 'T1\\tRoute 184 194\\ti.v. pulse\\n']\n",
            "['T6\\tTreatment 37 86\\tlong-term therapy with the addition of citalopram\\n', 'T7\\tEffect 0 15\\tAdverse effects\\n', 'T9\\tDrug 19 30\\tpropafenone\\n', 'T10\\tTime_elapsed 37 46\\tlong-term\\n', 'T11\\tDrug 76 86\\tcitalopram\\n', 'T5\\tAdverse_event 31 36\\tafter\\n', 'T12\\tCombination 64 72\\taddition\\n', 'E1\\tAdverse_event:T5 \\n', 'E2\\tCombination:T12 arg:T11 arg2:T9']\n",
            "['T3\\tSubject 5 13\\tone case\\n', 'T4\\tEffect 17 45\\tsevere symptomatic hepatitis\\n', 'T5\\tTreat-Disorder 98 111\\tonychomycosis\\n', 'T7\\tTreatment 62 93\\tpulse therapy with itraconazole\\n', 'T9\\tPopulation 5 8\\tone\\n', 'T10\\tDrug 81 93\\titraconazole\\n', 'T6\\tAdverse_event 46 55\\toccurring\\n', 'E1\\tAdverse_event:T6']\n",
            "['T4\\tSubject 24 84\\ta 50-year-old woman with advanced non-small cell lung cancer\\n', 'T7\\tEffect 99 117\\tstatus epilepticus\\n', 'T8\\tTreatment 142 180\\tcisplatin and gemcitabine chemotherapy\\n', 'T9\\tAge 26 37\\t50-year-old\\n', 'T10\\tGender 38 43\\twoman\\n', 'T5\\tDrug 142 151\\tcisplatin\\n', 'T13\\tDrug 156 167\\tgemcitabine\\n', 'T14\\tTreat-Disorder 73 84\\tlung cancer\\n', 'T15\\tRoute 168 180\\tchemotherapy\\n', 'T6\\tAdverse_event 89 98\\tdeveloped\\n', 'T12\\tCombination 152 155\\tand\\n', 'E1\\tAdverse_event:T6 \\n', 'E2\\tCombination:T12 arg:T5 arg2:T13']\n",
            "['T3\\tEffect 27 30\\tAVP\\n', 'T5\\tTreatment 75 85\\tinfliximab\\n', 'T7\\tTime_elapsed 31 42\\tthree weeks\\n', 'T8\\tDrug 75 85\\tinfliximab\\n', \"T9\\tTreat-Disorder 107 122\\tCrohn's disease\\n\", 'T10\\tSeverity_cue 20 26\\tsevere\\n', 'T4\\tAdverse_event 43 52\\tfollowing\\n', 'E1\\tAdverse_event:T4 \\n', 'A1\\tSeverity E1 High']\n",
            "['T5\\tTreatment 33 44\\tzafirlukast\\n', 'T6\\tEffect 89 159\\timpaired clearance of  S-warfarin and enhanced anti-thrombotic effects\\n', 'T8\\tSpeculation_cue 48 58\\tconsistent\\n', 'T9\\tDrug 33 44\\tzafirlukast\\n', 'T7\\tPotential_therapeutic_event 81 88\\tshowing\\n', 'E1\\tPotential_therapeutic_event:T7']\n",
            "[\"T3\\tEffect 15 33\\tPeyronie's disease\\n\", 'T6\\tDrug 51 61\\tcolchicine\\n', 'T7\\tFreq 41 50\\tlong-term\\n', 'T4\\tTreatment 41 71\\tlong-term colchicine treatment\\n', 'T5\\tAdverse_event 34 40\\tduring\\n', 'E1\\tAdverse_event:T5']\n",
            "['T3\\tSubject 118 190\\ta 29-year Nigerian female patient with generalized tonic-elonic seizures\\n', 'T4\\tEffect 14 52\\tsyndrome of inappropriate antidiuresis\\n', 'T5\\tTreatment 86 99\\tcarbamazepine\\n', 'T8\\tAge 120 127\\t29-year\\n', 'T9\\tRace 128 136\\tNigerian\\n', 'T10\\tGender 137 143\\tfemale\\n', 'T6\\tDrug 86 99\\tcarbamazepine\\n', 'T12\\tTime_elapsed 58 70\\tmuch earlier\\n', 'T13\\tTreat-Disorder 157 190\\tgeneralized tonic-elonic seizures\\n', 'T7\\tAdverse_event 71 82\\tside-effect\\n', 'E1\\tAdverse_event:T7']\n",
            "['T4\\tTreatment 91 133\\tanticalcineurinic drug (CyA or tacrolimus)\\n', 'T5\\tEffect 15 19\\tRSDS\\n', 'T8\\tDrug 115 118\\tCyA\\n', 'T9\\tDrug 122 132\\ttacrolimus\\n', 'T7\\tAdverse_event 34 61\\tosteoarticular complication\\n', 'E1\\tAdverse_event:T7']\n",
            "['T6\\tTreatment 48 58\\traloxifene\\n', 'T7\\tEffect 82 114\\tmalignant mixed mesodermal tumor\\n', 'T8\\tDrug 48 58\\traloxifene\\n', 'T9\\tSpeculation_cue 18 21\\tmay\\n', 'T5\\tAdverse_event 28 39\\tassociation\\n', 'E1\\tAdverse_event:T5 \\n', 'A1\\tSpeculated E1']\n",
            "['T5\\tSubject 0 100\\tTwo children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis\\n', 'T6\\tEffect 126 158\\tseizures and transient blindness\\n', 'T8\\tTreatment 184 231\\ti.v. pulse methylprednisolone (IVPMP) treatment\\n', 'T9\\tPopulation 0 3\\tTwo\\n', 'T10\\tTreat-Disorder 21 50\\tidiopathic nephrotic syndrome\\n', 'T11\\tTreat-Disorder 62 101\\tendo-extracapillary glomerulonephritis,\\n', 'T12\\tDrug 195 213\\tmethylprednisolone\\n', 'T13\\tSeverity_cue 139 148\\ttransient\\n', 'T7\\tAdverse_event 178 183\\tafter\\n', 'E1\\tAdverse_event:T7 \\n', 'A1\\tSeverity E1 Low\\n', 'T1\\tRoute 184 194\\ti.v. pulse\\n']\n",
            "['T6\\tTreatment 37 86\\tlong-term therapy with the addition of citalopram\\n', 'T7\\tEffect 0 15\\tAdverse effects\\n', 'T9\\tDrug 19 30\\tpropafenone\\n', 'T10\\tTime_elapsed 37 46\\tlong-term\\n', 'T11\\tDrug 76 86\\tcitalopram\\n', 'T5\\tAdverse_event 31 36\\tafter\\n', 'T12\\tCombination 64 72\\taddition\\n', 'E1\\tAdverse_event:T5 \\n', 'E2\\tCombination:T12 arg:T11 arg2:T9']\n",
            "['T3\\tSubject 5 13\\tone case\\n', 'T4\\tEffect 17 45\\tsevere symptomatic hepatitis\\n', 'T5\\tTreat-Disorder 98 111\\tonychomycosis\\n', 'T7\\tTreatment 62 93\\tpulse therapy with itraconazole\\n', 'T9\\tPopulation 5 8\\tone\\n', 'T10\\tDrug 81 93\\titraconazole\\n', 'T6\\tAdverse_event 46 55\\toccurring\\n', 'E1\\tAdverse_event:T6']\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "**Load the Parsed File Data and Merge the Text Data**"
      ],
      "metadata": {
        "id": "gmPZhEwPuyMX"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "train_txt_dict=pkl_load_dict('/content/drive/MyDrive/PHEE/output/train_txt.pickle')\n",
        "dev_txt_dict=pkl_load_dict('/content/drive/MyDrive/PHEE/output/dev_txt.pickle')\n",
        "test_txt_dict=pkl_load_dict('/content/drive/MyDrive/PHEE/output/test_txt.pickle')"
      ],
      "metadata": {
        "id": "i6nK_TLn6Le4"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "train_dev_dict=Merge(train_txt_dict, dev_txt_dict)\n",
        "text_dict=Merge(train_dev_dict, test_txt_dict)\n",
        "df=pd.DataFrame.from_dict(text_dict,orient='index',columns=['Text'])\n",
        "df.reset_index(inplace=True)"
      ],
      "metadata": {
        "id": "xVS0Kk79-nCg"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "**Create Dataframe of Raw Data**"
      ],
      "metadata": {
        "id": "CJRXAujXu9Tg"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df_creation(df,Merge,'/content/drive/MyDrive/PHEE/output/data_df.pkl')"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "qcyWpVhN-Mzb",
        "outputId": "8ecc370c-4c3e-47f6-9076-3ec742c2d182"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "The shape of the final data set is: (4832, 19)\n"
          ]
        }
      ]
    }
  ]
}